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ABSTRACT 
Cockayne Syndrome (CS) is a rare autosomal recessive disorder characterised by 
neurodegeneration, dwarfism and at least three of the following; hearing loss, dental caries, 
pigmentary retinopathy, characteristic facial appearance and photosensitivity. Cells from 
CS patients fail to recover RNA synthesis after irradiation and exhibit a loss of 
transcription-coupled repair, with overall genome repair being unaffected. There are two 
genetic complementation groups of CS alone, A and B, with the majority of patients 
belonging to group B. The genes defective in each of the complementation groups have 
been cloned, the CSA gene in 1995 and CSB in 1990. 
For the purposes of this study the CSB gene was sequenced in patients from 
complementation group B, in an attempt to identify the causative mutations. The analysis 
of thirteen patients from different backgrounds has revealed a wide variety of mutations in 
the CSB gene. A considerable number of the mutations found in CS-B patients resulted in 
severely truncated products. Several patients possessed two alleles affected in this way 
and it is unlikely that any functional protein is produced, confirming that CSB is a non- 
essential gene. The mutations identified did not reveal any regions within the gene that 
could be termed as hotspots. There was, however a tendency for the mutations to be 
located towards the 3' two thirds of the gene, indicated by the clustering of the mutations 
in this region. The severity of the mutation does not however correlate with the site or type 
of mutation. 
Clustering of the mutations towards the 3' end and the high levels of conservation in the 
central part of the gene prompted a study into the functional significance of the N- and C- 
terminal ends of the protein. Also, the presence of a highly acidic region of amino acids 
and a stretch of glycine residues led to a study of the effects of removing and replacing 
these regions. Removal of the glycine domain results in non-functional protein with 
respect to cell survival after UV irradiation, whereas the removal of seven glutamic acid 
residues from the acidic rich region, does not appear to have a particularly dramatic effect. 
Deletion of the C-terminal 25 amino acids of CSB totally destroys the repair ability of the 
gene. In contrast, cDNAs deleted at the N-terminus are able to at least, partially retain 
repair activity. 
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AIMS 
This project is intended to provide insight into the function of the CSB protein and expand 
knowledge of Cockayne syndrome and how its characteristic symptoms arise. Such 
information will also contribute to the field of DNA repair, particularly when linked to 
transcription, thereby increasing knowledge of how mammals respond to DNA damage. 
CHAPTER 1 GENERAL INTRODUCTION 
1.1 Nucleotide excision repair 
In order to maintain the genetic integrity of the genome, a number of mechanisms have 
evolved to effect repair of damage in DNA occurring both spontaneously and 
environmentally. One of the most significant and widely studied sources of environmental 
DNA damage is UV light, which causes lesions such as cyclobutane pyrimidine dimers and 
pyrimidine-pyrimidone (6-4) photoproducts. The major pathway involved in the repair of 
UV damage is nucleotide excision repair (NER) (Friedberg et al., 1995). 
Generally, NER consists of five steps : 
a) damage recognition, 
b) incision of the damaged strand on both sides of the lesion, 
c) excision of the lesion-containing oligonucleotide, 
d) synthesis of a new strand, 
e) ligation. 
1.1.1 Nucleotide excision repair in E. soli 
In total, six gene products are required for NER in E. coli and these proteins alone can be 
used to reconstitute the reaction in vitro on naked DNA (reviewed in Friedberg et al., 
1995). The mechanism of the reaction is outlined in figure 1.1 (Hoeijmakers, 1993). 
The first step in the reaction is dimerisation of the UvrA gene product. UvrA is a DNA- 
dependent ATPase, and the hydrolysis of ATP is required for the dimerisation reaction and 
also increases the specificity of dimer binding to damaged DNA. The dimer once formed 
recruits a single molecule of UvrB, also in an ATP dependent manner. This complex has 
I 
been demonstrated as having a weak 5' to 3' helicase activity. It is thought that this 
activity may allow the complex to translocate along the DNA and scan for lesions. 
When a lesion is encountered in the DNA, UvrB becomes bound at this site and the UvrA 
dimer is dissociated. The binding of UvrB is thought to result in a conformational change 
in the DNA helix, which is recognised and allows binding by UvrC. 
The position of the 3' incision is variable but generally occurs four or five phosphodiester 
bonds from the lesion. In contrast the 5' incision always occurs eight bonds from the 
damage site. ATP is required for the incisions but is not hydrolysed. This suggests that it 
binds and causes a conformational change which allows the incisions to occur, effected by 
UvrC 5' and UvrB 3' to the damage. 
The next few stages of NER are catalysed by the concerted actions of UvrD (DNA helicase 
II) and DNA polymerase I. It is suggested that, firstly, UvrD releases UvrC and the lesion 
containing oligonucleotide. DNA polymerase I binds the exposed 3' OH group and then 
displaces UvrB during synthesis of the new strand. The nicks remaining after repair 
synthesis are sealed by DNA ligase. 
1.1.2 Nucleotide excision repair in eukaryotes 
NER in eukaryotic cells follows the same basic steps observed in E. coli, but a far greater 
number of gene products are involved in the reaction. Much of the information gained on 
the mechanism of NER in humans has been provided by the study of mutant cell lines. In 
recent years NER has been reconstituted in vitro with purified proteins both for the yeast 
and human systems (Aboussekhra et al., 1995; Guzder et al., 1995). This has provided 
great insight into the proteins necessary for the reaction and identified accessory roles for 
others. 
The reaction is highly conserved between S. cerevisiae and mammals with many proteins 
showing not only functional homology, but also great similarity at the amino acid level. 
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Figure 1.1 Diagrammatic representation of the E. coli nucleotide excision repair 
mechanism (Hoeijmakers, 1993). 
Human Protein Yeast Protein Comments 
XPA Rad14 Binds damaged and single-stranded DNA 
RPA Rpa Three subunits, single-stranded binding 
protein, binds XPA 
XPC/hHR23A, B Rad4/Rad23 Binds damaged and single-stranded DNA 
Not required for all excision repair 
substrates 
TFIIH TFIIH Six to nine subunits including helicases 
XPB and XPD 
XPG Rad2 3' DNA endonuclease 
XPF/ERCC 1 Rad 1 /Rad 10 5' DNA endonuclease 
PCNA PCNA Stimulates DNA synthesis by polymerases 
Sands 
L DNA Polymerases S and c Po18 and Pole Synthesises new DNA 
DNA Ligase I77 Lig I Seals nicks 
Table 1.1 A summary of the human proteins and their S. cerevisiae counterparts which are involved in NER, and the functions that they are likely to carry out in the reaction. 
Table 1.1 outlines the essential factors required for NER in mammalian cells and their 
yeast counterparts. 
1.1.3 Nucleotide excision repair disorders 
Three major disorders are associated with defects in nucleotide excision repair, xeroderma 
pigmentosum, Cockayne syndrome, and trichothiodystrophy. 
1.1.3.1 Xeroderma pigmentosum 
Xeroderma pigmentosum (XP) is a rare autosomal recessive disorder, with the most 
characteristic and easily identifiable symptoms being hyperpigmentation and sun- 
sensitivity (Kraemer and Slor, 1984). XP patients are in particular associated with a 
greatly elevated risk of skin cancers. In rare cases of XP these features can be 
accompanied by the clinical features of CS. Cells derived from XP patients demonstrate an 
increased sensitivity to killing after treatment with DNA damaging agents and in particular 
UV irradiation (Arlett and Lehmann, 1979). In addition to the increased killing, cells also 
demonstrate an increased mutation frequency in response to damage. 
XP was first identified as a NER disorder in 1968 when Cleaver showed that patients with 
XP were unable to carry out NER after UV irradiation (Cleaver, 1968). Cellular diagnosis 
of XP patients is carried out by measuring the incorporation of 3H-thymidine into UV 
irradiated non-S phase cells by autoradiography, or into non-dividing cells by scintillation 
counting. These assays measure the levels of repair synthesis or unscheduled DNA 
synthesis (UDS). UDS experiments on XP cells demonstrated a large variability between 
different XP cell lines (Bootsma et al., 1970) and subsequently seven complementation 
groups, A to G were identified (Cleaver and Kraemer, 1989). The corresponding genes 
have all been cloned and their products participate in the different steps of NER. A further 
complementation group of XP has also been identified, termed XP variant, in which there 
is no defect in NER (Cleaver, 1972). XP variant cells have been shown to be defective in 
3 
post-replication repair (Lehmann et al., 1975) although no gene has as yet been identified 
in this group. 
1.1.3.2 Cockayne Syndrome 
Cockayne syndrome (CS) is a rare autosomal recessive disorder characterised by 
neurodegeneration and dwarfism as well as at least three of the following; hearing loss, 
dental caries, pigmentary retinopathy, characteristic facial appearance and photosensitivity 
(reviewed in Nance and Berry, 1992). Cells from CS patients exhibit a loss of 
transcription-coupled repair (see below), with overall genome repair being unaffected. The 
cellular and molecular characteristics of CS will be discussed in more detail later. 
1.1.3.3 Trichothiodystrophy 
Trichothiodystrophy is a rare autosomal recessive disorder characterised by sulphur- 
deficient brittle hair, ichthyosis, and mental and physical retardation (Pollitt et al., 1968). 
Patients also have distinctive facies with protruding ears and a receding chin. Some 
patients with TTD are photosensitive and cells derived from these patients are defective in 
NER (Stefanini et al., 1986), whereas those TTD patients without photosensitivity have no 
NER defect (Stefanini et al., 1987). 
TTD has three complementation groups, two of which are the same as the XP 
complementation groups XP-B and XP-D, with the mutations occurring in the same genes, 
(discussed in greater detail below). The third group termed TTD-A consists of a single 
patient. The repair defect in cells derived from this patient can be corrected by fusion with 
cells from all NER complementation groups (Stefanini et al., 1993). 
1.1.4 Genes involved in NER 
1.1.4.1 XPA/RPA 
XP-A patients exhibit one of the severest forms of XP suffering from elevated skin cancer 
levels and progressive mental retardation. Cells derived from patients in the XP-A 
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Figure 1.2 Picture representation of' the mechanism Of mall malian NFR (adapted from 
Lehmann, 1995). 
complementation group show no gene or strand specific repair (Evans et al., 1993) and are 
totally deficient in the incision step of NER (Reardon et al., 1993). Mutation studies have 
shown some Japanese patients to have reduced levels of mRNA and 16 from 21 patients 
studied possess the same mutation (Tanaka et al., 1990). In general, the mutations 
identified tend to correlate well with the clinical features observed (Satokata et al., 1990; 
Satokata et al., 1992; Satokata et al., 1992). Purified recombinant XPA has been shown to 
correct the repair defect in extracts from XP-A cells (Park and Sancar, 1993; Robins et al., 
1991) clearly demonstrating the defect in these cells. 
Damage recognition can occur through the combined actions of XPA and the single- 
stranded binding protein RPA (Robins et al., 1991) (see Figure 1.2). Individually both 
preferentially bind single-stranded or damaged DNA, but have a greater affinity as a 
complex (Burns et al., 1996; He et al., 1995). The same is true for the yeast homologues 
Rad14 and Rpa (Guzder et al., 1993). It is also interesting that XPA and Rad14 generally 
bind to (6-4) photoproducts rather than pyrimidine dimers in UV irradiated DNA (Guzder 
et al., 1993; Jones and Wood, 1993) suggesting that these lesions are likely to repaired 
more efficiently by NER. Also, (6-4) photoproducts do not distort the DNA double helix 
to the same extent as dimers, indicating that XPA does not recognise this type of damage 
through structural changes in the DNA. 
Replication protein A (RPA) is a heterotrimeric complex consisting of three polypeptides 
of 70,32 and 14 kDa. It has been shown to be involved in replication (Fairman and 
Stillman, 1988; Wold and Kelly, 1988), probably during the initiation and elongation 
stages. RPA has also been shown to be necessary for NER, since depleted extracts are 
deficient in incision (Shivji et al., 1992). Also, mutants with deletions in XPA that are 
unable to bind RPA are defective in NER (Li et al., 1995). These and other data have 
demonstrated that the XPA-RPA interaction is necessary for damage processing (Li et al., 
1995) and incision (Mu et al., 1995). 
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XPA is known to interact with damaged DNA, RPA, TFIIH and ERCC 1, and the sites of 
these interactions have been extensively studied. The XPA protein consists of 273 amino 
acids and has a molecular weight of 31 kDa. There are three consensus motifs within the 
gene, two zinc finger motifs and a nuclear localisation signal (Miyamoto et al., 1992; 
Tanaka et at., 1990). It has been shown that the amino acids from met98 to phe219 are 
necessary and sufficient for binding to damaged DNA (Kuraoka et al., 1996). In particular, 
mutation of cys108 to a serine residue abolishes the DNA binding activity of XPA 
(Asahina et at., 1994; Miyamoto et at., 1992). Binding to ERCC1 occurs via a region 
containing a cluster of seven glutamic acid residues (Nagai et at., 1995) and interaction 
with TFIIH is through the C-terminal 48 amino acids (Park et al., 1995). Expression of 
mutant cDNAs missing either the glutamic acid cluster or the C-terminal 48aas in XP-A 
cells, results in only marginal recovery of the UV resistant phenotype (Li et at., 1995; 
Miyamoto et al., 1992). Neither of these regions of the protein is required for DNA 
binding activity, but interaction with ERCC1 is stimulatory (Nagai et at., 1995). 
As mentioned earlier, XPA is able to recognise damage when in a tight complex with RPA 
and is able to bind to two of the three subunits of RPA. Residues 153 to 176 are required 
for binding to the RPA 70 kDa subunit and the first 58 residues bind to the RPA 34 kDa 
subunit (Li et at., 1995). However, it appears that only the interaction with the RPA 70 
kDa subunit is significant, as deletion of residues 153-176 of XPA abolishes NER activity 
and there is no effect from deletion of amino acids 1-58 (Li et al., 1995). It is also 
interesting that the essential region for interaction with RPA is also necessary for binding 
to damaged DNA. 
More specifically, RPA has been shown in vitro to suppress the non-specific endonuclease 
activity of XPF-ERCC 1 whilst promoting its specific junction cutting activity (see below) 
(Matsunaga et al., 1996). Recently it has also been reported that although RPA may not be 
required for XPF-ERCC I activity (see below), it specifically blocks incision of the strand 
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to which it is bound whilst stimulating cleavage of the other strand (de Laat et al., 1998). 
A similar activity has been suggested for RPA on XPG incision of an open 30 nucleotide 
bubble substrate (Matsunaga et al., 1996), although this is not universally agreed (Evans et 
al., 1997). 
Several groups have proposed similar models for the role of RPA in NER. It has been 
suggested that RPA together with XPA is able to recognise damaged DNA, with RPA able 
to stabilise the unwound DNA around the lesion. Furthermore it is postulated that RPA 
plays a role in the recruitment of the nucleases, and the release of the excised 
oligonucleotide and repair proteins. This model is supported by data indicating that RPA 
can bind XPG (He et al., 1995) and stimulate the activity of the DNA polymerases a and S 
(Coverley et al., 1991). It is also interesting that the predicted length of the repair patch 
(26-27nt) correlates well with the size of the RPA binding site of 30nt (Kim et al., 1992) 
suggesting that RPA may be located across the repair patch, either protecting the site from 
non-specific nucleases, or stabilising the structure. 
Knockout mice for XPA have been generated which are completely defective in NER (de 
Vries et al., 1995; Nakane et al., 1995) confirming the requirement for this protein in 
repair. The mice are hypersensitive to UVB and chemical carcinogens resulting in skin and 
eye tumours (de Vries et al., 1995; Nakane et al., 1995). Nakane et. al. reported that the 
mice are fertile and demonstrate no physical abnormalities or pathological alterations. 
Particularly relevant for comparison with the XP-A patients is the lack of any 
neurodegeneration or gliosis in mice studied up to the age of 18 months (Nakane et al., 
1995) whereas patients have neurological abnormalitites. However mice of over 13 days 
have been reported as having growth retardation and liver defects such as reduced size, 
anaemia and disturbed haematopoeisis (de Vries et al., 1995). The XPA knockout mice 
demonstrate some of the symptoms exhibited by XP-A patients and show the same repair 
defects and UV sensitivity, thereby providing a good model system. 
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1.1.4.2 XPC/HHR23A&B 
The XPC gene product and associated proteins also have some involvement in damage 
recognition in UV irradiated DNA. Five XP-C patients have been studied to determine the 
site of the causative mutation (Li et al., 1993). Most of the mutations found in XPC were 
frameshifts and therefore totally inactivating, demonstrating that XPC is not essential for 
viability. 
Much of the work on human XPC has been carried out using mutant human cell lines. XP- 
C cells are unable to carry out the repair of damaged DNA in transcriptionally inactive 
regions of the genome, but are able to repair damage on the transcribed strand of active 
genes (Venema et al., 1991; Venema et al., 1990). This observation explains the residual 
repair that can be seen in XP-C mutant cells. Using an in vitro DNA repair 
complementation assay, Masutani et. al. purified XPC and found that it co-purifies with a 
protein that is the homologue of yeast Rad23 (Masutani et al., 1994). In addition to this 
protein termed hHR23B a second homologue of Rad23 exists, called hHR23A which is 
also able to complex with XPC, although this is barely detectable (Sugasawa et al., 1996). 
XPC alone is able to bind DNA with a preference for single-stranded DNA (Masutani et 
al., 1994) or damaged DNA (Reardon et al., 1996). However, when XPC is complexed 
with either hHR23A or hHR23B its repair activity is stimulated. Generally XPC is found 
in a complex with hHR23B, although the reason for such a preference is not clear since 
either Rad23 homologue can produce stimulation of repair. Reconstitution experiments 
(Aboussekhra et al., 1995; Bessho et al., 1997) have demonstrated that the XPC complex is 
necessary for NER. This has led to a widely accepted model that XPC/hHR23 is required 
for the formation or stabilisation of the damage recognition-incision complex. This is 
further supported by data that showed hHR23 stimulates repair activity at an early stage of 
the reaction either at or prior to incision (Evans et al., 1997; Sugasawa et al., 1997). There 
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is also recent direct evidence that XPC is involved in damage recognition (Sugasawa et. al., 
unpublished observations). 
The homologue of XPC in yeast, Rad4 forms a complex with Rad23 that has been shown 
to be essential for reconstitution of S. cerevisiae NCR (Guzder et al., 1995). Rad4 is not 
essential for viability, and Rad23 cells show only moderate UV sensitivity. However, 
Rad23 cells demonstrate no repair of CPDs or (6-4) photoproducts up to 4 hours after UV 
irradiation (Verhalte et al., 1996). The reason for the moderate UV sensitivity is unclear, 
since it is not consistent with the repair characteristics of the cells. 
1.1.4.3 XPG 
Cells from XP-G patients demonstrate low levels of excision activity (Reardon et al., 1993) 
and in vivo experiments have shown a severe lack of repair (Cleaver and Kraemer, 1989). 
Recombinant XPG protein is able to correct the defective NER in human cell extracts from 
XP-G patients (O'Donovan and Wood, 1993), demonstrating that this protein activity is 
absent in these cells. 
The product of the XPG gene and its S. cerevisiae homologue Rad2 are structure-specific 
endonucleases (Habraken et al., 1995; O'Donovan et al., 1994) which are able to cleave at 
junctions between ssDNA and dsDNA where the free single-stranded tail is 5' to the 
double-stranded DNA. It has also been demonstrated in vitro that purified recombinant 
XPG protein can cleave an artificial bubble structure with an opening of at least 5bp (Evans 
et al., 1997). This group also showed that the cutting could occur on either strand of the 
structure, but the single-strand/double-strand junction had to have 5' to 3' polarity. These 
yeast and human proteins are also members of the DnaselV/FEN-1 gene family, many of 
which are involved in replication (reviewed in Lieber, 1997). FEN1 is a nuclease which is 
able to cleave at branched DNA structures and in particular is required for the processing 
of Okazaki fragments. The FEN1 family of proteins have three regions of homology 
termed N, I and C. Most family members have only a short gap of 18 amino acids between 
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regions N and I, illustrated in Figure 1.3, whereas the NI? R proteins tend to have a gap of 
over 640 residues. 
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Figure 1.3 The FEN1 family of proteins illustrating the N, I and C regions of homology 
(Lieber, 1997). 
This may be due to the fact that the NER members do not require a free 5' end for nuclease 
activity, suggesting there may be structural reasons for the larger separation of these 
regions. Also, it is interesting that the N and I spacer regions of Rad2 can be removed and 
result in a nuclease capable of flap cleavage, supporting the idea that the larger spacer 
region is significant for the cleavage of NER substrates. In summary, this group of 
proteins are nucleases and all tend to produce nicks at branched DNA structures, providing 
further evidence for the involvement of XPG in the 3' incision of NER. Consistent with 
these findings, cells deficient in XPG are unable to make the 3' incision in an artificial 
substrate containing a single cisplatin lesion, and subsequently are defective in repair 
synthesis and excision of the damaged oligonucleotide (O'Donovan et al., 1994). 
1.1.4.4 ERCC 1-XPF 
Cells from most patients in XP complementation group F are moderately UV sensitive 
(Cleaver and Kraemer, 1989) and extracts from these cells are defective in excision 
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nuclease activity (Reardon et at., 1993). When treated with UV, XP-F cells are able to 
repair 10-15% of damage shortly after irradiation, increasing to 60% after longer 
incubation (Cleaver and Kraemer, 1989). 
The proteins XPF and ERCC 1 form a tight complex, formation of which is intrinsic to the 
stability of both proteins. Mutations occurring in the middle of ERCCI result in an 
unstable protein, probably due to the loss of the XPF interaction (Sijbers et al., 1996). As 
with XPG, the ERCCI-XPF complex and its yeast counterpart Radl-RadlO is able to 
cleave at single-strand/double-strand junctions. The polarity of the junction cleaved is the 
opposite of that observed for XPG suggesting that ERCC1-XPF is responsible for the 
second incision in NER, 5' of the damage site (Matsunaga et al., 1995) (see figure 1.2). 
A great deal of work has been carried out on the RadI and Rad10 proteins, the S. cerevisiae 
homologues of XPF and ERCC1. This has provided insight into the mechanism of action 
of the human complex in NER and its involvement in other pathways. Deletion mutants of 
Radl and Rad10 are very UV sensitive and exhibit no damage-specific DNA incision. The 
Radl-RadlO complex also functions in the mitotic recombination pathway implicating 
ERCC1-XPF in recombination. This might explain the sensitivity of ERCCI and XPF 
mutants to crosslinking agents, as resulting lesions require mitotic recombination for their 
repair (Schiestl and Prakash, 1990). 
Knockout mice have been generated for ERCCI and have been shown to have disturbed 
growth, a reduced lifespan and abnormalities of liver nuclei (McWhir et al., 1993). Weeda 
et. al. have also produced mice null for ERCCI, and mice carrying a seven amino acid C- 
terminal truncation that results in a transcript reduced to approximately 15% of that seen in 
normal mice (Weeda et al., 1997). The symptoms displayed by ERCCI mice are very 
severe compared to those exhibited by XPA knockout mice, since both mutations result in 
totally defective NER. XPA mice are viable, develop normally and have a normal lifespan 
(de Vries et al., 1995; Nakane et at., 1995). This suggests an additional function for 
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ERCCI, as alluded to above, probably in the repair of genotoxic lesions such as crosslinks, 
via the mitotic recombination pathway. 
The location and coupling of incisions in NER has been extensively studied. Generally, 
the 3' incision mediated by XPG occurs first, since uncoupled 3' incisions are found more 
commonly than uncoupled 5' incisions (Mu et al., 1996; O'Donovan et al., 1994; Sijbers et 
al., 1996). In some cases and with certain types of lesion, it has been demonstrated that the 
3' incision can occur in the absence of ERCC1-XPF (Mu et al., 1996), whereas, for other 
damages such as cisplatin, absence of the complex results in the complete loss of incision 
activity (Moggs et al., 1996). Interestingly, in the yeast system it has been shown that the 
Rad 1-Rad 10 complex is indispensable for incision with the reconstituted system (Guzder et 
al., 1995). 
The location of the sites of incision correlates well with that of E. coli, with the 3' incision 
occurring closer to the lesion. It has been shown that the 3' nick occurs between two and 
nine phosphodiester bonds from the site of damage. The second site of incision generally 
occurs sixteen to twenty-five bonds 5' of the damage, releasing an oligonucleotide of 
around twenty-six to twenty-seven nucleotides in length (Moggs et al., 1996). The precise 
location of the incisions is dependent on the nature of the lesion, but the length of the 
displaced oligonucleotide appears to be relatively consistent in all cases. 
1.1.4.5 TFIIH 
TFIIH is a multi-subunit complex containing between six and nine subunits depending on 
the preparation and was first identified as one of the RNA polymerase II general 
transcription factors. TFIIH was identified as being involved in repair through the 
discovery that the proteins encoded by the genes XPD and XPB, defective in patients with 
the repair disorder xeroderma pigmentosum, were part of the complex (Drapkin et al., 
1994; Schaeffer et al., 1994; Schaeffer et al., 1993). TFIIH was subsequently shown to 
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complement the repair defects in cells from XP patients in complementation groups B and 
D (Mu et al., 1995; Schaeffer et al., 1994; Schaeffer et al., 1993). Although the intact 
complex is required for the NER reaction to occur, it is the activities associated with the 
XPB and XPD proteins that are thought to be necessary to effect repair. These two 
proteins are ATP-dependent DNA helicases with XPB and XPD demonstrating 3' to 5' and 
5' to 3' polarity respectively (Drapkin et al., 1994; Schaeffer et al., 1993). 
Patients from XP complementation groups B and D show some similarities and the 
proteins XPB and XPD are helicases and part of the TFIIH complex (Drapkin et al., 1994; 
Schaeffer et al., 1994; Schaeffer et al., 1993). Both complementation groups contain 
patients with symptoms of TTD, and XP with CS, and to date no patient from 
complementation group B has exhibited the clinical features of XP alone (Broughton et al., 
1994; Vermeulen et al., 1994; Weeda et al., 1990). At the cellular level XP-B cells have a 
weak excision signal and XP-D cells fail to excise dimers at a detectable level as measured 
in an in vitro excision assay (Reardon et al., 1993), demonstrating a likely requirement for 
both proteins for active NER in vivo. 
There are only four patients from three families assigned to the XP-B group and three of 
these patients have features of XP with CS. The repair defect in two siblings can be 
corrected by microinjection of XPB cDNA (Vermeulen et al., 1993). The repair defect in 
XP-B cells can also be alleviated by microinjection of the TFIIH complex (van Vuuren et 
at., 1994). Mutational analysis of the XPB gene has shown that the helicase domains are 
essential for the repair function and that the protein is nuclear, independent of its own 
nuclear localisation signal (Ma et at., 1994). 
Many patients have been assigned to the XP-D complementation group. Mutations in the 
XPD gene inactivate its ability to correct the UV sensitive phenotype of XP-D cells 
(Frederick et al., 1994) and can result in either XP, XP with CS or TTD (Broughton et at., 
1994; Broughton et al., 1995; Takayama et at., 1996; Takayama et al., 1995). XPD is an 
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essential gene and studies on the S. pombe and S. cerevislae yeast homologs rad15 and 
RAD3 have been used to study mutations. By identifying the totally inactivating 
mutations, Taylor et. al. were then able to identify mutations characteristic to either of the 
disease phenotypes XP, XP/CS or TTD (Taylor et al., 1997). The S. cerevisiae homologue 
Rad3 has been used to investigate the significance of the XPD helicase activity (Guzder et 
al., 1995). The data from both yeast systems suggests that the XPD helicase activity is 
required for NER but is not essential for transcription, and they are consistent with the idea 
that TTD is a transcription disorder. 
1.1.4.6 TTD-A 
The repair defect in TTD-A cells can be corrected by microinjection of the RNA 
polymerase II general transcription factor TFIIH (Vermeulen et al., 1994) (see below), 
suggesting that the gene mutated in these cells is a component of this complex. However, 
the major genes which form TFIIH have been cloned and none has been shown to correct 
the repair defect of TTD-A (Marinoni et al., 1997; Vermeulen et al., 1994). 
1.1.4.7 XPE 
In 1988 it was reported that an XP-E cell line lacked a factor which could bind DNA (Chu 
and Chang, 1988; Patterson and Chu, 1989). However, further work has shown that only 
three from twelve XP-E patients studied are defective in this DNA binding activity 
(Keeney et al., 1994). The DNA binding protein is a heterodimer of proteins of molecular 
weights 127 kDa and 48 kDa (Keeney et at., 1992). Investigation into the genes encoding 
these proteins has shown that mutations found to date are only seen in the smaller p48 
subunit (Nichols et at., 1996). 
1.1.5 Repair synthesis 
The repair synthesis step of NER in mammalian cells has been much less studied than the 
incision step, but it is known that the post-incision repair synthesis reaction requires a 
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minimum of four proteins; PCNA, RFC, DNA ligase I and DNA polymerase S or c. 
Reconstitution of the NER reaction has shown these proteins to be involved, with pol c the 
polymerase in this case (Aboussekhra et al., 1995). It is thought that RFC loads PCNA 
onto a repair-type template for synthesis by either DNA pol S or c (Podust et al., 1994). 
There is considerable evidence for the involvement of PCNA in repair synthesis, both in 
vitro (Nichols and Sancar, 1992; Shivji et al., 1992) and in vivo (Celis and Madsen, 1986). 
Depletion of PCNA from human cell extracts results in a complete lack of repair synthesis 
(Shivji et al., 1992). 
There is a single patient, 46BR that possesses a mutation in the DNA ligase I gene and 
shows a defect in the joining of Okazaki fragments during DNA replication. This patient is 
also hypersensitive to DNA damaging agents including UV, suggesting that, along with the 
reconstitution data, ligase I is responsible for sealing the nick to the newly synthesised 
oligonucleotide (Barnes et al., 1992). The excised oligonucleotide is released 
independently of repair synthesis and both the excised oligo and the gapped DNA are 
complexed with proteins (Mu et al., 1996), although the exact proteins bound is not clear. 
It has also been shown that the kinetics of the incision and repair synthesis reactions are 
similar, hinting that these two steps are likely to be tightly coupled (Moggs et al., 1996). 
1.2 Basal Transcription by RNA Polymcrase II 
There is a clear link between nucleotide excision repair and transcription, through the 
transcription/repair factor TFIIH, as discussed above in a repair context. This section will 
explain the basics of transcription initiation and explain in some detail the role that TFIIH 
fulfils in this process. For reviews on transcription initiation (see Buratowski, 1994; 
Maldonado et al., 1996; Nikolov and Burley, 1997; Ranish and Hahn, 1996; Stargell and 
Struhl, 1996; Tjian and Maniatis, 1994; Zawel et al., 1995). 
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Transcription in human cells is a complex process with many associated factors as well as 
those which are directly involved in initiation. As generally understood, TFIID binds to 
the TATA-box of the promoter where the two together act as a binding site for TFIIB 
which can recruit RNA polymerase II (RNAPII) and TFIIF. This complex is kinetically 
stable and is able to recruit TFIIE and TFIIH, creating an ATP-dependent open complex, 
thereby allowing transcription to initiate. 
The minimal transcription initiation complex consists of TFIID, TFIIA, TFIIB, TFIIF and 
RNA pol II. TFIID is a complex comprising the TATA-box binding protein (TBP) and 
combinations of associated factors (TAFs) of which there are eight known (reviewed in 
(Tansey and Herr, 1997)). TBP alone is sufficient for binding to the TATA-box, but 
binding to other core promoter elements is dependent on the TAFs. TBP itself has a saddle 
shape structure of which the inner surface interacts with the minor groove of the TATA- 
box causing a distortion in the DNA (Nikolov and Burley, 1997). 
TFIIA binds the promoter-TFIID complex, but is not required for promoters where 
transcription is driven by TBP alone. TFIIA is thought to work by establishing and 
maintaining the complex under physiological conditions by counteracting repressors of 
transcription. 
TFIIB has two domains and binds the TBP-DNA complex where it is then able to recruit 
RNA polymerase II. The protein is able to interact in vitro with RNAPII, TFIIF and the 
TBP-DNA complex. RNAPII is recruited at this stage, followed by TFIIF via interactions 
with RNAPII and TFIIB. TFIIF unlike the other initiation factors is also thought to be 
involved in the elongation stages of transcription. 
The complete initiation complex consists of the factors described above along with TFIIE 
and TFIIH. However, it is possible for transcription to be initiated in vitro in the absence 
of these two factors. TFIIE is a tetramer containing two subunits of each of the products of 
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two genes. TFIIE is required for the recruitment of TFIIH and appears to have a regulatory 
role in the enzymatic functions of this complex. 
There are two theories about the mechanism of basal transcription, whether the 
transcription factors and associated proteins exist as a complex, termed the holoenzyme, or 
are recruited in a step-wise fashion, as described above. A holoenzyme was first described 
in yeast and required the addition of TBP and TFIIE for transcriptional activity (Koleske 
and Young, 1994). However, the RNAPII holoenzyme described by Ossipow et. al., 1995 
from human cell extracts contains both these factors. Since holoenzymes have been 
isolated from human and yeast cells as an intact complex, it seems likely that they do exist 
at some stage during transcription. As to whether such large complexes are consistently 
present in the cell remains a matter for some debate. 
In addition to the basal transcription factors described above, several proteins have been 
identified as associating with the RNAPII holoenzyme. Such factors include the group 
known as suppressors of RNA polymerase B (SRBs) which were first identified in yeast 
(reviewed in (Koleske and Young, 1995)). This group of proteins is thought to be involved 
in stabilising interactions between RNAPII and the general transcription factors and may 
also confer responsiveness to co-activators (Koleske and Young, 1994). The human 
equivalents of SRBs have been identified both by analysis of the constituents of a purified 
RNAPII complex (Maldonado et al., 1996) and by immunoprecipitation with anti-SRB 
antibodies, which also bring down RNAPII (Chao et al., 1996). 
1.2.1 TFIIH 
As previously discussed, the general transcription factor TFIIH is involved in both 
transcription and NER. TFIIH is a multi-subunit complex and consists of nine 
polypeptides; XPB, XPD, Cdk7/M015, cyclin H, MAT!, p34, p44, p52 and p62 (reviewed 
in Hoeijmakers et al., 1996). No precise functions have as yet been assigned to the p34, 
p44, p52 and p62 subunits, however all except p62 have been shown to contain consensus 
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sequences. Zinc finger motifs often occurring in DNA binding proteins are present in p34 
and p44 and p52 has WD-repeats which are thought to have a structural role possibly in 
protein: protein interactions, indicating possible roles for these proteins. The subunits XPB 
and XPD as explained above are helicases that work with opposite polarity and are likely 
to be involved in open complex formation, allowing the transcription and repair machinery 
access. The final three subunits are involved in the kinase activity associated with TFIIH. 
The C-terminal domain of the large subunit of RNA polymerase II (RNAPII-CTD) is the 
target of phosphorylation by TFIIH (Serizawa et al., 1995). This activity is conferred by 
the cyclin-dependent activating kinase (CAK), which consists of the TFIIH subunits 
Cdk7/MO15 and cyclin H (Makela et al., 1994). CAK can exist either in complex with 
TFIIH or in a smaller complex (Adamczewski et at., 1996; Shiekhattar et al., 1995). In 
vitro studies have demonstrated that CAK can either function alone, or as part of TFIIH to 
phosphorylate RNAPII-CTD, TFIIE, TFIIF, TBP and the cell cycle regulators cdc2 and 
cdk2 (Okhuma and Roeder, 1994; Serizawa et al., 1995; Shiekhattar et at., 1995). 
Phosphorylation of the RNAPII-CTD is an important event, since its phosphorylation state 
shows a distinct correlation with the transcriptional status of the enzyme. Un- 
phosphorylated RNAPII is required for initiation (Akoulitchev et al., 1995) and resides in 
complexes that are ready to initiate. However, the RNAPII that exists during elongation is 
highly phosphorylated (Cadena and Dahmus, 1987; O'Brien et at., 1994). 
In vitro studies have shown CAK activity associated with TFIIH to have a specificity for 
RNAPII-CTD, whereas, free or recombinant CAK demonstrates a preference for cdk2 and 
cdc2 (Rossignol et al., 1997; Yankulov and Bentley, 1997). Shiekhattar et. al. have also 
reported specificity by showing that although both complexes are able to phosphorylate 
RNAPII-CTD, only TFIIH can carry out the reaction when RNAPII is part of the pre- 
initiation complex (Shiekhattar et al., 1995). 
18 
MAT1, another TFIIH subunit is also involved in the kinase activity associated with this 
transcription factor and its substrate specificity. MAT1 strongly associates with cyclin 11 
and cdk7, but is not essential for CAK assembly or kinase activity (Adamczewski et at., 
1996). MAT! does, however have a stimulatory effect on kinase activity (Adamczewski et 
al., 1996) and alters the substrate specificity of CAK from cdk2 to RNAPII-CTD 
(Yankulov and Bentley, 1997). In addition to MAT1, TFIIE is also able to stimulate the 
RNAPII-CTD phosphorylation by TFIIH (Lu et al., 1992). This is conferred by p56, one 
of two TFIIE subunits (Okhuma and Roeder, 1994) which is reported to occur in an 
oligomeric form for this purpose, distinct from the transcriptionally active heterodimer 
(Serizawa et at., 1994). It can be postulated from the above data that phosphorylation of 
RNAPII-CTD performs a regulatory role in transcription and possibly traps or stabilises 
RNAPII in the elongation complex. 
TFIIH provides a link between the cellular processes of transcription, NER and cell cycle 
regulation. It is likely that the CAK activity which phosphorylates cdc2 and cdk2 in vivo is 
separate from that of TFIIH, since free CAK rather than TFIIH has the greatest affinity for 
these substrates. Also, it has been demonstrated that TFIIH kinase activity remains 
constant during the cell cycle (Adamczewski et al., 1996). 
The link with NER is somewhat clearer, with mutations in the TFIIH subunits XPB and 
XPD resulting in the DNA repair disorders XP, TTD and XP with CS. In addition to this, 
Roy et. al. have shown that M015/cdk7 depleted extracts could not function in an in vitro 
repair assay (Roy et al., 1994). This is likely to be a result of destabilisation or inactivation 
of the whole TFIIH complex, rather than the lack of kinase activity. It is also important to 
consider the observations of Adamczewski et. al., 1996 who reported that TFIIH kinase 
activity is reduced after UV irradiation. This again may be a secondary response rather 
than a direct effect from the kinase, but DNA damage clearly affects the activity. This may 
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be through recruitment of TFIIH to the damage site for repair, during which the kinase 
activity is unnecessary. 
1.3 Transcription-coupled repair 
Transcription and repair are linked through the basal transcription and NER factor TFIIH. 
A previous link had been established when it was shown that transcription inhibited by UV 
irradiation recovered faster than could be accounted for by the rate of damage removal 
from the genome (Mayne and Lehmann, 1982). This suggested another more rapid 
mechanism of repair was responsible for recovery from inhibition of transcription. Such a 
mechanism was demonstrated by Hanawalt and co-workers in 1985, who reported a five- 
fold faster repair of UV induced pyrimidine dimers in the transcriptionally active DHFR 
gene in CHO cells when compared with the genome overall (Bohr et al., 1985). A similar 
phenomenon was reported in mouse 3T3 cells with the active c-abl gene, which was 
repaired much faster than the inactive c-mos gene (Madhani et al., 1986). 
More detailed information on "transcription-coupled repair" (TCR) was provided by 
Mellon et. al. who showed that preferential repair was due to faster removal of CPDs from 
the transcribed strand. The non-transcribed strand was repaired at the same rate as the rest 
of the genome (Mellon et al., 1987). There are two cellular factors, chromatin structure 
and transcription, which may influence or control transcription-coupled repair. 
It has been proposed that repair of the transcribed strand is initiated by a stalled RNAPII, 
blocked at a lesion (Hanawalt et al., 1994). Also, treatment with the RNA polymerase 
inhibitor a-amanitin abolishes selective repair of the transcribed strand (Leadon and 
Lawrence, 1991), demonstrating a requirement for active transcription in TCR. However, 
the rate of TCR does not correlate with that of transcription (Bedoyan et al., 1992; Venema 
et al., 1992) or with the transcription-blocking efficiency of the lesion (McGregor et al., 
1995). Therefore, a further process must be functioning to effect preferential repair. 
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It has been reported that the compactness of the local chromatin structure around a lesion 
influences the rate of its repair (Smerdon and Thoma, 1990). Additionally, cells treated 
with sodium butyrate, causing relaxation of nucleosomal structure, show enhanced excision 
repair (Ramanathan and Smerdon, 1989). Such data implies that transcription-coupled 
repair is not a selective mechanism, but occurs purely as a result of increased accessibility 
of the repair machinery to the damaged DNA. However, the existence of transcription- 
coupled repair in the lac operon of E. coli (Mellon and Hanawalt, 1989) casts doubt on this 
theory, since E. coli does not possess a stable nucleosome structure. Therefore, it is 
unlikely that an open chromatin structure around sites of damage directly results in TCR, 
although it clearly influences the general rate of repair. 
1.3.1 Transcription-coupled repair in E. coli 
Preferential repair in E. coli was first noted by study of the lac operon in vivo under induced 
and un-induced conditions, that is, with active and inactive transcription respectively. 
Mellon and Hanawalt reported that when the lac operon was induced, the transcribed 
strand was repaired faster than the complementary strand (Mellon and Hanawalt, 1989). 
The existence of such strand-specific repair was not entirely new, since the phenomenon of 
mutation frequency decline (MFD) had alluded to such a process many years earlier. 
Mutation frequency decline can be explained such that after UV irradiation, cells are able 
to rapidly decrease the frequency of revertant mutations in tRNA genes, without loss of 
viability (reviewed in Witkin, 1994). Bockrath and Palmer reported that the revertant 
phenotype occurred via UV induced mutations in the transcribed strand of tRNA genes. 
Cells mutant for MFD, mfd-1 are unable to prevent these mutations, and are therefore 
predicted to have a defect in transcription-coupled repair (Bockrath and Palmer, 1977). 
The mfd-1 mutant cells have since been shown to possess a defect in TCR both in vitro 
(Selby et al., 1991) and in vivo (Kunala and Brash, 1995). Furthermore, a partial MFD 
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phenotype could be restored in mfd-1 cells by inhibiting transcription with rifampicin, 
demonstrating a requirement for active transcription in this process (Li and Bockrath, 
1995). 
The transcription-coupled repair reaction in E. coil could not be reconstituted with known 
repair proteins (Selby and Sancar, 1990), suggesting that the presence of a stalled RNA 
polymerase molecule was not sufficient to induce preferential repair. More detailed studies 
have shown that pyrimidine dimers in the non-template strand have no effect on 
transcription, with no stalling of RNAP. However, dimers occurring in the template strand 
block RNAP elongation and cause stable ternary complexes (Selby and Sancar, 1990). 
Therefore, although a stalled RNAP molecule is not the direct signal for repair, its presence 
appears to be essential for TCR to occur. In vivo studies on the actively transcribed genes 
uvrC (Selby and Sancar, 1995), lacl and lacZ (Kunala and Brash, 1995) have shown that 
TCR occurs only with an elongating RNAP complex. This indicates that there may be an 
inhibition of preferential repair when RNAP is bound to the initiation site. Therefore, a 
"transcription-repair coupling factor"(TRCF) is presumed to exist to allow repair proteins 
to recognise RNAP stalled at a lesion, rather than within the initiation complex. 
The transcription-repair coupling factor is identical to the MFD gene product, and the TCR 
defect observed in mfd-1 cells can be corrected by addition of purified TRCF (Selby and 
Sancar, 1993; Selby et al., 1991). TRCF is an abundant protein of 130 kDa that shares 
homology with UvrB at its N-terminus as well as a C-terminal potential leucine zipper and 
seven recG-like helicase motifs (Selby and Sancar, 1993). As yet no helicase activity has 
been demonstrated for TRCF (Selby and Sancar, 1995), although it does have a weak 
ATPase activity that is not stimulated by DNA or stalled RNAP (Selby and Sancar, 1993). 
The UvrB-like domain may facilitate binding to UvrA (Selby and Sancar, 1993) and 
provide a means for recruitment of the repair proteins to the lesion. 
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Using a defined reconstituted system, Selby and Sancar demonstrated that transcription 
preferentially inhibited repair of the transcribed strand. Such inhibition could be overcome 
by addition of TRCF. Not only was the inhibition prevented but, repair of the transcribed 
strand was stimulated by TRCF without any effect on repair of the non-transcribed strand 
(Selby and Sancar, 1993). TRCF is able to bind DNA at initiation and elongating RNAP 
complexes in an ATP-dependent manner (Selby and Sancar, 1995), but TCR only occurs 
with an elongating RNAP complex (Kunala and Brash, 1995; Selby and Sancar, 1995). 
Therefore, it is not the binding of TRCF to the stalled complex, but its ability to displace it 
from the site of the lesion, which facilitates the repair. On this pretext, TRCF has no effect 
on an initiation complex but is able to release RNAP in an ATP-dependent manner from an 
elongation complex stalled at a lesion without affecting initiation complexes. The 
mechanism of displacement is, however distinct from that of the rho-dependent termination 
of transcription (Pavco and Steege, 1990; Selby and Sancar, 1995) discounting any 
involvement of this process in TCR. Displacement of stalled RNAP by TRCF is not 
specific to complexes stalled at DNA damage, since the same process occurs when 
elongation is blocked by a tightly bound protein (Pavco and Steege, 1990). 
A model can be proposed for the mechanism of transcription-coupled repair in E. coli. 
TRCF binds at a stalled RNAP complex and displaces the polymerase and the truncated 
transcript. The ability of TRCF to bind UvrA targets this protein to the damage site, 
allowing recruitment of UvrB and the rest of the repair enzymes. 
Unfortunately, Selby and Sancar were unable to detect targeting of (A)BC exinuclease to 
the lesion in their reconstituted system (Selby and Sancar, 1993). However, binding of 
TRCF to UvrA is significant, since addition of excess UvrA inhibits TCR, presumably by 
binding to TRCF away from the DNA and preventing its action on stalled RNAP 
complexes (Selby and Sancar, 1995). 
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1.3.2 Transcription-coupled repair in S. cerevisiae 
The first evidence for preferential repair in yeast was provided by study of the mating type 
loci MATa and HMLa The two loci have identical sequences, but in yeast a-cells the 
MATa locus is actively transcribed, whilst the HMLa locus is silenced by the Sir proteins. 
Terleth et. al., 1989 reported that MATa is repaired at two and a half times the rate of 
HMLa. However, mutation of the upstream activating sequence of MATa did not 
eliminate the preferential repair, despite the lack of active transcription. This preferential 
repair was absent in a strain mutant for Sir3, one of the proteins responsible for silencing of 
HMLa (Terleth et al., 1989). This was due to an increase in the repair of HMLa rather than 
a reduction for MATa, suggesting that the local chromatin structure was responsible for the 
differences in repair rates. 
Authentic "transcription-coupled repair" or transcription-dependent repair has subsequently 
been demonstrated in URA3, RPB2 and GAL7, where there is a distinct requirement for 
active transcription. The GAL7 gene is inducible, thereby allowing a direct comparison of 
repair within a gene under conditions of active and inactive transcription. When induced, 
the transcribed strand is repaired two to three times faster than the non-transcribed strand 
or the overall genome. In contrast, there is no preferential or strand-specific repair 
observed when GAL7 is uninduced, with both strands repaired at the same rate as the rest 
of the genome (Leadon and Lawrence, 1992). A similar observation was made in the 
actively transcribed RPB2 gene, the TCR of which was shown to be dependent on 
transcription. Strand-specific repair could be observed when the gene was actively 
transcribed either within the genome or episomally on a plasmid (Sweder and Hanawalt, 
1992). 
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1.3.2.1 Yeast TCR mutants 
The gene RAD26 was identified through its homology with the human CSB gene that is 
defective in patients with Cockayne syndrome. Cells derived from these patients lack 
transcription-coupled repair (van Gool et al., 1994). Deletion mutants of rad26 are viable 
and grow normally demonstrating that the protein does not have an essential function 
(Verhage et al., 1996). The cells also do not show any sensitivity to UV, cisplatin or 7- 
irradiation, although they do exhibit a delay in recovery of growth after UV treatment (van 
Gool et al., 1994). rad26 mutants are almost completely deficient in the preferential repair 
of the transcribed strand of RPB2 (van Gool et al., 1994), being repaired at virtually the 
same rate as the non-transcribed strand. Unlike E. coli mfd-1 there is no evidence of 
inhibition of repair in the transcribed strand by a stalled RNA polymerase II molecule. 
Purified Rad26, like MFD is an ATPase, but the enzymatic activity is far more active and 
has a strict DNA dependence (Guzder et al., 1996). 
The yeast homologue of the second Cockayne syndrome gene, CSA has also been cloned 
and has been called RAD28 (Bhatia et al., 1996). In contrast to rad26 deletion strains, 
rad28 deficient cells are able to carry out transcription-coupled repair at the same rate as 
wild-type cells (Bhatia et al., 1996). As seen in rad26, rad28 shows no increased 
sensitivity to killing by UV, y or MMS (Bhatia et al., 1996), thus indicating that Rad28 is 
not required for strand-specific repair of UV induced damage, contrary to the case for CSA 
in human cells (see below). 
1.3.2.2 Double mutants 
Double mutants have been created for the TCR genes rad26 and rad28 with the global 
genome repair genes rad7 and rad16 which are essential for the repair of non-transcribed 
regions of the genome (Bang et al., 1992; Verhage et al., 1994). Double mutants of rad28 
with either rad7 or rad16 show only a slightly enhanced UV sensitivity compared to rad28 
alone (Bhatia et al., 1996). This illustrates that even in a global repair deficient 
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background, Rad28 does not contribute to UV sensitivity. Such evidence suggests that 
either RAD28 is not the true functional homologue of CSA, or that this gene has no 
function in yeast. 
rad26 deletion strains are impaired for transcription-coupled repair, but are not UV 
sensitive compared to wild-type (van Gool et al., 1994). However, double mutants of 
rad26 and rad7 or rad16 are more UV sensitive than either deletion strain alone, but are 
still less sensitive than mutants which are completely defective in NER (Verhage et al., 
1996). 
Analysis of strand-specific repair of the RPB2 locus in rad7rad26 or radl6rad26 double 
mutants showed that there was no repair of the non-transcribed strand and little repair in 
the transcribed strand. Repair of the transcribed strand in double mutants was less reduced 
compared to a rad26 alone background, indicating that RAD7 and RAD16 contribute to the 
repair of the transcribed strand in TCR-defective circumstances (Verhage et al., 1996). 
Such residual repair of the transcribed strand was also seen in GAL7 when induced, but not 
when repressed indicating a dependency on transcription. Therefore, in yeast some 
transcription-coupled repair can occur independently of Rad26 function. Furthermore, at 
an induced GAL7 locus, disruption of RAD26 has very little effect on TCR unless it is 
combined with disruption of RAD7 or RAD16 (Verhage et al., 1996). Therefore in this 
situation a coupling factor does not appear to be required, possibly because induced GAL7 
is very heavily transcribed (St. John et al., 1981). This is very similar to the situation in the 
IPTG induced lacZ gene in E. coli, where transcription-coupled repair still occurs in a mfd 
mutant (Kunala and Brash, 1995). 
The above information indicates that although Rad26 is involved in TCR, it is not essential 
for all transcribed strand repair. This may be specific to the yeast system, either as a result 
of redundancy or because a more efficient global genome repair system in yeast reduces the 
dependency on such a process. 
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Definition of true transcription-coupled repair suggests that the phenomenon depends on 
active transcription, thus separating the mechanism from the preferential repair observed 
through differences in local chromatin structure. A total dependence on RNAPII 
transcription can be shown by the absence of TCR in temperature sensitive RNAPII 
mutants at the restrictive temperature (Leadon and Lawrence, 1992; Sweder and Hanawalt, 
1992). There is however clearly a link between TCR and chromatin structure, since active 
transcription will result in a relaxed nucleosome structure in that region. 
Recent experiments have involved the study of TCR, the influence of a stalled transcription 
complex and the recovery from this state. Reagan and Friedberg have developed an assay 
whereby they could measure the kinetics of recovery of RNA synthesis by analysis of 
templates carrying at least one RNAPII blocking lesion. This reflects the capacity of cell 
lines to remove lesions from the transcribed strand of the GAL10 and RNR3 genes (Reagan 
and Friedberg, 1997). The recovery of RNA synthesis in NER mutants directly reflected 
their repair status, with the NER defective radl and rad2 mutant cells showing no recovery 
of RNA synthesis. Also, rad26 null cells showed a delay in recovery reflecting the ability 
of global genome repair to repair these lesions, albeit at a slower rate. Interestingly the 
GGR mutants rad7 and radl6 demonstrated a slightly more rapid recovery than wild-type 
cells, illustrating the lack of involvement of GGR in transcription-coupled repair. 
Transcription at the CYCI promoter in vitro with RNAPII is inhibited by addition of 
damaged plasmid to the extracts. This inhibition is strictly dependent on NER (You et al., 
1998), and requires the RAD26 gene product. Alleviation of transcription inhibition can 
occur by addition of TFIIH, with a requirement for the kinase subunits. These data 
interlink Rad26, TFIIH and stalling of RNA polymerase, suggesting a possible role of 
Rad26 in this early stage prior to repair. 
Further data on the site and timing of action of Rad26 has been reported by Tjisterman et. 
al., 1997. This group have shown that Rad26 is not required for the repair of lesions on the 
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transcribed strand within 50bp of the transcription initiation site (Tijsterman et al., 1997). 
This 50bp distance also corresponds to the region where TFIIH dissociates from the 
transcription complex. Therefore it has been suggested that since TFIHH is already 
associated with the transcription machinery within the first 50bp of mRNA synthesis, there 
is no requirement for a coupling factor (Tijsterman et al., 1997). 
1.3.3 Mammalian transcription-coupled repair and Cockayne syndrome 
Cockayne syndrome (CS) is a rare autosomal recessive disorder which demonstrates 
biochemical and genetic heterogeneity. Nance and Berry carried out a comprehensive 
study of 140 CS patients (Nance and Berry, 1992) demonstrating the clear diagnostic 
criteria of poor growth, neurological abnormalities and photosensitivity. Other common 
features of CS include sensorineural hearing loss, cataracts, pigmentary retinopathy and 
dental caries. A mean age of death of 12Y4 years was reported, although more recently two 
siblings of 42 and 55 years of age have been reported with particularly mild clinical 
symptoms, but characteristic cellular features (Miyauchi et at., 1994). Unlike patients with 
xeroderma pigmentosum, no cases of cancer have been reported in classical CS patients 
and they also have no disposition to infectious complications. 
At the cellular level, fibroblasts derived from CS patients are hypersensitive to UV 
irradiation (Mayne et al., 1982) and fail to recover RNA synthesis after irradiation (Mayne 
and Lehmann, 1982). This cellular characteristic has been used as a tool for diagnosis of 
patients and a test for complementation. Complementation analysis has shown there to be 
two complementation groups of CS alone, A and B, with the majority of patients belonging 
to group B (Lehmann, 1982; Stefanini et al., 1996; Tanaka et at., 1981). With reference to 
complementation, no obvious clinical, cellular or racial distinctions can be made between 
individuals in the two groups (Stefanini et al., 1996). 
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Cockayne syndrome cells are defective in the repair of transcriptionally active DNA when 
compared to normal cells (Venema et at., 1990). Study of the two active loci ADA and 
DHFR and the inactive locus 754 has demonstrated the transcription-coupled repair defect. 
In cells derived from either complementation group there is virtually no removal of 
cyclobutane pyrimidine dimers from either ADA or DHFR four hours after irradiation. 
After 24 hrs, the extent and rate of repair is the same in all three loci, that is the same level 
as for the 754 locus in normal cells (Venema et at., 1990). Interestingly, CS cells also have 
reduced levels of repair of ribosomal RNA genes which are normally transcribed by RNA 
polymerase I (Christians and Hanawalt, 1994). This suggests that the CS gene products are 
required for transcription-coupled repair in a much wider context than just by association 
with RNA polymerase II. 
Neither CSA or CSB protein is essential for viability or basal transcription, however they 
are required for transcription-coupled repair and recovery of RNA synthesis after UV in 
vivo (van Gool et at., 1997). Analysis of the repair of different DNA adducts has been used 
to determine the dependence on and influence of transcription. Repair of the NA-AAF 
induced N-(deoxyguanosin-8-yl)-2-aminofluorene (dG-C8-AF) adduct was studied in the 
active ADA gene, and its repair was shown to occur at similar rates in both normal and CS 
cell lines without strand specificity (van Oosterwijk et al., 1996). Therefore repair of this 
lesion is not influenced by transcription-coupled repair. Nevertheless CS cells are three 
times as sensitive to the toxic effects of NA-AAF and RNA synthesis fails to recover after 
NA-AAF treatment (van Oosterwijk et at., 1996). Similarly, McGregor et. al. have 
attempted to correlate the rate of repair in the HPRT gene with the transcription blocking 
effect of the adducts 1-nitrosopyrene (1-NOP), N-acetoxy-2-acetylaminofluorene (NA- 
AAF) and benzo(a)pyrene diol epoxide (BPDE). BPDE blocks transcription four times 
more efficiently than either 1-NOP or NA-AAF. However, the TCR of 1-NOP adducts is 
twice as fast as that of BPDE lesions, with repair of NA-AAF lesions slower again and not 
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strand-specific (McGregor et al., 1995). Therefore, the extent to which DNA lesions block 
transcription has no bearing on the occurrence or rate of transcription-coupled repair. 
Donahue et. al. studied the effects of the NA-AAF induced adducts N-2-aminofluorene 
(AF) and N-2-acetylaminofluorene (AAF) in an in vitro transcription assay. AF adducts 
are not preferentially repaired and when present on the transcribed strand they result in a 
weak RNAPII pause site that can be bypassed. In contrast, AAF lesions are helix 
distorting and create an absolute block to elongation when situated on the transcribed 
strand. Interestingly, either lesion occurring on the non-transcribed strand results in 
enhanced arrest at nearby sequence-specific pause sites (Donahue et al., 1996). All the 
above data show that the transcription blocking lesions are also those that are subject to 
transcription-coupled repair and although there is no direct rate correlation, there is a clear 
link. It is possible that a stalled RNA polymerase molecule may be involved in the 
targeting of repair machinery to transcriptionally active DNA, albeit indirectly. 
The CSA and CSB gene products are not only required for TCR of UV damage, but also 
oxidative damage (e. g. thymine glycols). Cockayne syndrome cells from either 
complementation group are defective in the repair of ionizing radiation and oxidative 
damage from the transcribed strand (Cooper et al., 1997; Leadon and Cooper, 1993). Cells 
derived from patients with XP-G combined with CS are defective in TCR of thymine 
glycols (Cooper et al., 1997). This demonstrates a correllation between the presence of CS 
symptoms and the lack of TCR of oxidative and ionising radiation-induced damage. The 
XPG function required for this TCR role is distinct from its incision role in NER, since 
cells from XP-G patients with XP alone and totally NER deficient XP-A cells are 
proficient in this repair. Cooper et. al. have suggested that since XPG has been implicated 
in the assembly of a pre-incision complex in NER, it may be involved in a similar process 
in BER, the major pathway for the removal of oxidative damage (Cooper et al., 1997). 
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1.3.3.1 CSA 
The CSA gene was cloned by functional complementation of a CS-A cell line with a cDNA 
library and confirmed by identification of mutations in the gene in CS-A patients. The 
gene encodes a 44 kDa protein which is a member of the WD-repeat family of proteins 
(Henning et al., 1995). WD-repeats are highly conserved repeating units that are 
frequently regulatory and occur in many proteins involved in processes such as cell 
division, gene transcription, transmembrane signalling and mRNA modification (for 
review see Neer et al., 1994). The CSA gene is able to complement the UV sensitive defect 
of cells from rodent complementation group 8 and hence is identical to ERCC8 (Itoh et al., 
1996). Recombinant CSA protein has been shown in one report to interact in vitro with 
CSB and the TFIIH subunit p44 (Henning et al., 1995). Another group however found 
CSA and CSB were associated with different high molecular weight complexes (van Gool 
et al., 1997). 
1.3.3.2 CSB 
The ERCC6 gene was cloned by functional complementation of the UV sensitive hamster 
mutant UV61 from rodent complementation group 6 (Troelstra et al., 1990). This gene is 
able to correct the UV sensitivity and RNA synthesis defect of CS-B cells, and mutations 
were identified in a CS-B patient. This confirmed that ERCC6 was the CSB gene. The 
gene is located on chromosome 10g11-q21 and encodes a 1493 amino acid protein with a 
predicted molecular weight of 168 kDa (Troelstra et al., 1992). Figure 1.4 is a 
diagrammatic representation of the CSB gene showing putative functional domains. Of 
particular note are the seven consecutive domains that are characteristic of members of the 
SWI/SNF family of putative helicases and ATPases. 
Figure 1.5 shows the SNF2 superfamily of proteins with examples, particularly the SNF2- 
like family of NTP-binding proteins. Other members of the family are involved a wide 
variety of cellular processes, for example MOT! in transcriptional repression (Davis et al., 
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Figure 1.5 The SWUSNF family of proteins (Pazin and Kadonaga, 1997) 
1992), RADS4 in recombination repair (Emery et at., 1991), lodestar in chromosome 
segregation (Girdham and Glover, 1991), CSB in transcription-coupled repair (Troelstra et 
al., 1992) and RAD16 in global genome repair (Schild et at., 1992). 
However, as yet no member of the gene family, including CSB has been shown to possess 
any distinct helicase activity. 
The CSB protein possesses a strong DNA-dependent ATPase activity (Selby and Sancar, 
1997; van Gool et al., 1997) which can be stimulated by single-stranded DNA or to a 
greater extent by double-stranded DNA. CSB has been shown to associate with CSA 
(Henning et at., 1995), XPG (Iyer et al., 1996), XPA, XPB and the p34 subunit of TFIIE 
(Selby and Sancar, 1997) in experiments using either in vitro translated proteins, or GST 
pull-down assays. However, no such interactions were found when NER and transcription 
proficient cell-free extracts were used to determine possible interactions (van Gool et al., 
1997). The only significant interaction found in these experiments was a proportion of 
approximately 10-15% of RNA pol II that bound tightly to CSB (van Gool et al., 1997). 
Tantin et. al. have also shown CSB to interact with RNA pol II and more specifically with 
molecules engaged in ternary complexes containing DNA and nascent RNA. Furthermore, 
ATP hydrolysis, presumably through CSB is required for stable formation of this complex 
(Tantin et at., 1997). Gel filtration experiments have shown both CSA and CSB to be part 
of large complexes. However, the complexes in which these proteins reside are of different 
sizes suggesting that they do not act together in a single complex (van Gool et at., 1997). 
1.3.3.3 SWI/SNF complexes 
The S. cerevisiae SWI2/SNF2 protein is part of a large complex of approximately 2 Mda, 
comprising at least ten subunits including SWI1, SWI3, SNFS and SNF6 (Cairns et at., 
1994; Peterson et at., 1994). SWI2/SNF2 is a positive regulator of transcription and shows 
in vitro DNA-dependent ATPase activity (Laurent et at., 1993). A link with chromatin 
structure was first noted due to mutations in core histories being able to suppress mutations 
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in the genes encoding the SWI/SNF complex (Iiirchhorn et al., 1992; Kruger et al., 1995). 
Furthermore, in vitro DNasel protection assays have shown that SWI/SNF can disrupt pre- 
assembled nucleosomes in an ATP-dependent manner (Owen-Hughes et al., 1996). The 
ATPase and nucleosome remodelling activity can be stimulated by single-stranded, 
double-stranded or nucleosomal DNA (Laurent et al., 1993). 
A further nucleosome remodelling complex called RSC has been shown to exist in yeast. 
Many of the subunits are homologous to the subunits of SWI/SNF, including STH1 the 
ATPase homologue of SWI2/SNF2 that is consequently a member of the SNF2 gene 
family (Cairns et at., 1996). The RSC complex, in contrast to SWI/SNF contains subunits 
that are essential for mitotic growth, and as such it is likely to perform a function distinct 
from that of SWI/SNF. 
Similar complexes also exist in humans, Drosophila and mouse with the SWI2/SNF2 
homologues within these complexes being the most extensively studied. The Drosophila 
complex NURF is different from other chromatin remodelling complexes in the fact that its 
ATPase subunit ISWI is stimulated preferentially by nucleosomal DNA and not at all by 
free DNA. It has also been shown to be able to assist gene activation on chromaitn 
templates at an early stage in transcription initiation (Mizuguchi et al., 1997). Therefore 
the Drosophila complex NURF performs a specific role in relaxing the chromatin structure 
at promoters allowing transcription to occur. 
Human cells possess several SNF2 homologues with the genes hbrm and BRG1 being part 
of high molecular weight complexes that are able to disrupt nucleosomes in vitro (Kwon et 
al., 1994). The DNA repair protein CSB, as mentioned earlier is also a member of the 
SNF2 family and as such is a DNA-dependent ATPase (van Gool et al., 1997). The protein 
resides within a high molecular weight complex of at least 700 kDa. This may suggest a 
possible chromatin remodelling function, but as yet none of the other subuits have been 
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identified and the action of the complex has not yet been tested for its effect on 
nucleosomal structure. 
1.3.3.4 CSB knockout mice 
Knockout mice have been created for CSB, by mimicking the stop mutation at K337 found 
in the CS-B patient CS IAN (Troelstra et al., 1992). The mice generated with this mutation 
are viable and appear normal (van der Horst et al., 1997). Closer examination revealed the 
CS characteristics of UV sensitivity, inactive transcription-coupled repair, normal global 
genome repair and defective recovery of RNA synthesis after UV. However, the 
prominent clinical features of CS patients of growth failure and neurological dysfunction 
are exhibited only mildly in the mice. Interestingly, the mice also showed an increased 
susceptibility to skin cancer with multiple tumours appearing at 23 weeks in response to 
UV, compared with single tumours in wild-type mice at 27 weeks (van der Horst et al., 
1997). 
The theory presented for this significant difference between the human and mouse situation 
is that the TCR of CPDs helps to prevent carcinogenesis. Therefore the greater efficiency 
of GGR in humans is able to compensate for a defect in TCR better than in mice, and 
therefore humans do not present with skin cancer (van der Horst et al., 1997). Also, the 
life-span of humans is considerably longer than that of mice, although patients rarely live 
beyond their teens. Therefore, it is possible that if patients lived to a greater age they may 
demonstrate an increased incidence of skin cancer. 
1.3.3.5 CSB and transcription 
Cockayne syndrome cells fail to recover RNA synthesis after UV irradiation, but as 
described previously this does not always correlate with a defect in transcription-coupled 
repair (van Oosterwijk et al., 1996). Global genome repair in CS cells functions normally, 
therefore the majority of lesions will be repaired albeit more slowly. However, the 
phenotype in CS patients is very severe even in comparison to XP-A patients who are 
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defective in all NER. Therefore, many groups have predicted a transcription defect in 
these cells, since the repair defect cannot account for the severity of the clinical phenotype 
of the patients. 
Extracts from Cockayne Syndrome cells from both complementation groups have been 
shown to have reduced levels of RNAPII transcription in vitro (Dianov et al., 1997). 
Balajee et. al. studied levels of transcription in vivo in intact and permeabilised CS-B cells. 
Intact CS-B fibroblasts and lymphoblasts showed a 50% reduction in uridine pulse 
labelling and therefore transcription when compared with both normal and XP-A cells. 
This reduction in transcription could be complemented by transfection of the CSB gene. 
Transcription in permeabilised cells was analysed in chromatin which was isolated under 
physiological conditions. The level recorded in CS-B cells was about 50% of that in 
normal chromatin. In this case transcription can be restored to normal levels by addition of 
normal cell extracts (Balajee et al., 1997). These data demonstrate a link between the CSA 
and CSB gene products and transcription, even in the absence of damage (discussed in 
greater detail in chapter 7). 
Further evidence linking the stimulation of repair to transcriptional arrest was 
demonstrated by Wang et. al. with the use of triplex forming oligonucleotides. Specific 
oligonucleotides can be used to block transcription initiation and elongation through their 
ability to bind in the major groove of duplex DNA at polypurine-polypyrimidine sequences 
(Beal and Dervan, 1991). When mammalian cells are treated with triplex-forming oligos, 
mutations can be specifically induced in an SV40 vector contained within the cells. Such 
triplex-induced mutagenic activity cannot be detected in CS-B or XP-A cells suggesting a 
requirement for TCR in this process. Furthermore, the oligos that induced mutagenic 
activity in normal cells also inhibited transcription and stimulated repair (Wang et al., 
1996). Again a process or assay that results in transcriptional arrest requires active repair 
and the CSB protein. 
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The CSB protein has also been shown to enhance RNAPII elongation of an artificial 
undamaged template by a factor of three (Selby and Sancar, 1997). A template containing 
a T-T cyclobutane dimer results in a strong block to transcription, and addition of CSB to 
this template induces the addition of a single nucleotide to the nascent transcript. This 
suggests that CSB is able to recognise either the damage or the stalled polymerase and 
either induces the addition of the nucleotide as a signal for repair, or for the restart of 
transcription. 
Selby and Sancar have also looked at the effects of CSB and TFIIS on a blocked RNA 
polymerase molecule. TFIIS can stimulate the backward movement of RNAPII and 
transcriptional read-through, possibly by allowing access of the repair machinery to a 
lesion site (Aso et al., 1995; Reines et al., 1996). This backward movement also involves 
the digestion of the nascent transcript by a blocked polymerase. This has led to the theory 
that TFIIS may be involved in TCR by acting together with CSA and CSB in signalling 
damage and recruiting repair machinery, through association with a stalled polymerase. 
Addition of CSB to a stalled polymerase can counteract the TFIIS-induced transcript 
shortening (Selby and Sancar, 1997). Therefore, it is unlikely that TFIIS works with CSB 
as a TRCF, since they appear to work at odds with respect to the nascent transcript. Also, 
disruption of yeast TFIIS in S. cerevisiae had no overt effect on TCR (Verhage et al., 1997), 
demonstrating that any involvement this molecule may have in TCR is not essential for the 
pathway, at least in yeast. 
Mu and Sancar have developed an in vitro model system using purified human excision 
repair factors and defined substrates. They have attempted to mimic NER with a DNA 
duplex substrate carrying a T-T dimer, and TCR with a transcription-like bubble that 
terminates at a cylobutane thymine dimer. The dimer is removed three times faster from 
the bubble substrate than from duplex DNA. The faster repair from the bubble substrate is 
independent of the XPC protein (Mu and Sancar, 1997) which is now thought to be 
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required for the recognition of damage during NI: R. Therefore the lack of requirement for 
XPC in TCR suggests that damage recognition in this reaction occurs by a separate 
mechanism, possibly through a stalled polymerase molecule or CSB. 
1.3.3.6 RNA polymerase II ubiquitination 
Recent experiments by Bregman and co-workers have suggested a link between the CS 
genes and ubiquitination of RNA polymerase II. After UV or cisplatin treatment, a fraction 
of the large subunit of RNAPII was ubiquitinated, but this process did not occur in CS-A or 
CS-B cells. Ubiquitination could be restored by introduction of the CS cDNA constructs 
(Bregman et at., 1996). 
In normal cells UV is able to induce a transient reduction in the levels of the large subunit 
of RNAPII, presumably as a consequence of ubiquitination. Normal levels of RNAPII 
return after 16-24 hours through new protein synthesis (Ratner et at., 1998). In contrast to 
the lack of ubiquitination and degradation of RNA pol II in CS cells, repair deficient XP 
cells show a sustained reduction in RNAPII large subunit, indicating an inability to induce 
new protein synthesis. UV-induced reduction of RNAPII large subunit can be inhibited in 
both normal and repair-deficient cells by proteasome inhibitors, demonstrating that the 
ubiquitination is a signal for degradation (Ratner et al., 1998). 
Ubiquitination also appears to be linked to the phosphorylation state of the RNAP C- 
terminal domain (CTD), which as described earlier is highly phosphorylated in elongating 
RNAPII complexes. In all cells, a ubiquitinated RNAPII large subunit has a 
hyperphosphorylated CTD, but the portion of RNAPII whose levels were most quickly 
reduced were relatively hypophosphorylated. However, the ubiquitinated residues do not 
map to the CTD (Ratner et al., 1998), showing that phosphorylation is not a signal for 
ubiquitination and vice-versa. Although ubiquitination is not triggered by phosphorylation, 
the phosphorylation state of RNAPII-CTD is a good indicator of the transcriptional status 
of the polymerase. 
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It has been suggested that stalled RNAPII complexes backtrack to allow repair of the 
blocking lesion, then the RNA synthesis restarts. The above data contradicts this theory, 
suggesting that RNAPII stalled at a lesion is targeted for degradation through 
ubiquitination. Therefore rather than transcription continuing after repair, it is likely that 
the transcript is aborted. This is in agreement with the reaction in E. coli, whereby a stalled 
RNAP is displaced by TRCF (Pavco and Steege, 1990). Lack of ubiquitination in CS cells 
is consistent with the idea that CSA and CSB act in a similar fashion as TRCF, removing 
stalled RNA polymerase molecules. Therefore CSA and CSB might be involved in the 
targeting of ubiquitin conjugating enzymes to stalled RNAPII molecules, leading to their 
subsequent removal and degradation. 
1.3.3.7 Transcription-coupled repair -a link with mismatch repair 
The mismatch repair pathway is responsible for the correction of single base mismatches 
and small insertions or deletions that can occur during replication (for review see Friedberg 
et al., 1995). Patients defective in mismatch repair are associated with the hereditary form 
of colon cancer HNPCC (hereditary non-polyposis colon carcinoma). 
In E. coli the major proteins involved in this process are MutH, MutS and MutL, and 
recently it has been suggested that these proteins are also involved in transcription-coupled 
repair. This theory arose from the observation that residual MFD seen in transcription- 
inhibited mfd-1 cells was of a very similar level to that occurring in the mismatch repair 
mutants mutS and mutL (Li and Bockrath, 1995). Also, levels of TCR in the lacl gene 
were very similar in both mfd-1 and mismatch repair deficient cells (Mellon and Champe, 
1996). However, Selby and Sancar could not detect a TCR defect in mutL or mutS cells 
and were able to reconstitute TCR in vitro without the addition of these proteins (Selby and 
Sancar, 1993). 
Reduced transcription-coupled repair is also seen in mismatch deficient human cells such 
as tumour cell lines and HNPCC-derived lymphoblastoid cell lines (Mellon et al., 1996). 
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More specifically, defects in the AlutS and AiulL homologucs k IS112 or 1hA11.111 result in 
reduced TCR of UV damage without affecting the levels of ovcrnll gcnomc repair (Lcadon 
and Avrutskaya, 1997). The same however, is not true in the yeast Sceralslrtr, with 
normal TCR observed in cells defective for , 115111, AILIII, PAISI or AI511J. Additionally, 
no effect can be seen through mutation of , 115112 in either a global gcnomc (AkIU7) or 
transcription-coupled (ARAD26) repair deficient background (Swcdcr ct aL, 1996). 
The only circumstances in yeast where mismatch repair deficiency effects transcription- 
coupled repair is in the removal of oxidative damage. AISII2 deficient yeast arc unable to 
remove thymine glycols from the transcribed strand of the RP112 gene (Lcadon and 
Avrutskaya, 1998). The same defect is observed in double mutants of the MutL 
homologues AIL111 and PAISI, but not with mutation of either alone (Lcadon and 
Avrutskaya, 1998). Transcription-coupled repair of thymine glycols in human cells does 
not have the same requirement as TCR of UV damage, with respect to the involvement of 
mismatch repair proteins. Cells defective for h. t1S112 arc unable to remove oxidative 
damage from the transcribed strand of active genes, whereas repair of such regions is 
unaffected by mutation of hAIL111(Mellon ct al., 1996). 
The above data suggest that the involvement of mismatch repair in transcription-coupled 
repair is not evolutionarily conserved. 
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CHAPTER 2 MATERIALS AND METHODS 
2.1 Cell Culture Techniques 
2.1.1 Primary human fibroblasts 
Primary human fibroblasts were cultured in Eagle's MEM (Gibco BRL) supplemented 
with 12.8 ml 7.5% sodium bicarbonate (Gibco BRL), 4.5 ml each of 200mM L-glutamine 
(Gibco BRL) and 10000 U/ml penicillin/ 10000 pg/ml streptomycin (Gibco BRL), and 15% 
foetal calf serum. Cultures were grown under 5% C02. 
2.1.2 CHO cells 
CHO cells were cultured in Eagle's MEM supplemented with 12.8 ml sodium bicarbonate, 
4.5 ml each L-glutamine, penicillin/streptomycin and 100X non-essential amino acids 
(Gibco BRL) and 10% foetal calf serum. Cultures were grown under 5% C02. 
2.1.3 Sub-culturing and harvesting 
Cells were trypsinised and spun down through 5 ml of medium. The pellet was 
resuspended in an appropriate volume and counted on a haemocytometer. Large flasks for 
growth of fibroblasts were re-seeded with a minimum of 106 cells. CHO cells were grown 
up from the cells remaining after trypsinisation. 
2.1.4 Transfection 
UV61 CHOs were plated on 10 cm dishes at a density of 5x105 cells per dish and were 
grown for two days. On the second day, 3 ml of fresh medium was added to the cells. 
Forty microlitres of 10 mg/ml polybrene was added and washed over the cells followed by 
5 µg of the DNA to be transfected. The dishes were incubated at 37°C for 6 hr. Following 
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incubation, the cells were treated with 20% DMSO in serum-free medium for 4 min. The 
cells were then washed three times in serum-free medium and returned to standard culture 
medium overnight. The medium was changed the following day. Two days post- 
transfection the cells were trypsinised and each culture seeded back into three new 10 cm 
dishes and selection was applied using 1 mg/ml G418. The cells were cultured, refreshing 
the selection medium every 4-5 days until colonies formed, typically after around 15 days. 
Colonies were isolated using cloning rings, adding trypsin to the colony within the ring. 
The detached colony was transferred to a bijou containing 1 ml of medium and split 
between a small flask and a single well in a six-well plate. 
2.1.5 Freezing 
Trypsinised cells were suspended in 10% DMSO in standard culture medium and frozen at 
a density of 2x106/ ml. 
2.1.6 UV survival-Method I 
Cells were plated at densities of 102,2x102,4x102 and 8x102 per 6 cm dish corresponding 
to increasing doses. Four dishes were prepared at each density and left overnight to attach. 
The dishes were irradiated with UV-C at 0,3,6 and 9 J/m2 at a rate of 0.5 J/m2/sec and the 
medium replaced. After 7 days of colony growth, the cells were fixed, stained and the 
number of colonies counted. 
2.1.7 UV survival-Method II 
Cells were plated at 105 per 6 cm dish, plating one dish for each dose and were left 
overnight to attach. The dishes were irradiated as for method I with 0,3,6 and 9 J/m2, then 
trypsinised and counted. The cells were plated at the densities indicated in method I, 
preparing four dishes for each dose. After 7 days of growth, colonies were counted and 
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survival expressed as a percentage of un"irradiated colony numbers after correction for 
plating efficiency. 
2.1.8 RNA synthesis after UV-C irradiation 
Ten 3 cm dishes were prepared for each cell line, plating 10' cells per dish. Each 
experiment contained control cell lines of wild-type and mutant for transcription-coupled 
repair as well as the cells of interest. The control cells in this case were the CSB hamster 
mutant line UV61 and the parental line AA8. After overnight incubation, the dishes were 
irradiated at doses of 0,3,6,9 and 12 J/m2 with duplicate dishes for each dose. The cells 
were allowed to recover for 7 hr and then pulse labeled for 30 min in 2 ml of medium 
containing 5 jCi/ml specific activity 3H-uridine. The medium was removed, the cells 
washed with PBS and lysed with 0.5 ml of 2% SDS. The cells were scraped off the dishes 
with silicon rubber and 100 pl duplicate samples per dish were each spotted onto 3 cm 
3MM filter strips. The filters were treated in 5% trichloroacetic acid for 5-10 min, then 
washed twice in IMS and allowed to air dry. Incorporation of 3H was measured by 
scintillation counting and post-irradiation RNA synthesis expressed as a percentage of 
levels in un-irradiated cells. 
2.2 Molecular Methods 
2.2.1 Total RNA extraction 
Human skin fibroblasts were harvested from a confluent large flask containing between 
5x106 and 10' cells. The monolayer was trypsinised and spun down through 5 ml medium. 
The pellet was resuspended in a small volume of PBS and transferred to an eppendorf. 
500 pl of Solution D (4M guanidinium thiocyanate, 25mM sodium citrate, 0.5% sarcosyl; 
O. 1M 2-mercaptoethanol), 50 µl of 2M sodium acetate and 500 pl of phenol: chloroform 
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(50: 50) were added sequentially, mixing after each addition. The solution was spun at 
15,000 rpm for 5 min then the upper aqueous phase transferred to a fresh tube. The RNA 
was precipitated with 500 gl of isopropanol, spinning for 10 min at 15,000 rpm. The pellet 
was washed with 70% ethanol and resuspended in 50 µl filter sterile double distilled water. 
The RNA was used directly for cDNA synthesis or stored in ethanol at -80°C. 
2.2.2 cDNA synthesis 
cDNA synthesis was carried out in three sections using the antisense PCR primers for 
fragments II (EC 176 25-mer), IV (E6-2) and VI (EC 179 no. 6) (see Table 2.1 and Appendix 
I). Primers were at a concentration of 25 ng/µl and 2 µl of this solution was mixed with 
8 pl of RNA. The reaction was heated to 80°C for 10 min, then put on ice briefly and 
mixed with 4 pl first strand synthesis buffer (250mM Tris-HC1 pH8.3,375mM KCI, 
15mM MgC12), 2 µl 10mM dNTPs (Gibco BRL), 2 pl 0.1 M DTT and 1 µ1 MMuLV 
Reverse Transcriptase (IOU/µl, Pharmacia). The reaction was incubated at 37°C for 2 hr 
then made up to a volume of 40 µl ready for PCR. 
2.2.3 PCR 
The gene was amplified in six pieces, using the cDNAs, primers and cycling conditions 
outlined in Table 2.1. Each reaction was carried out in a 50pl volume comprising of 5 µl 
Px10 buffer (100mM Tris-HCl pH9,500mM KCI, 15mM MgCl21 0.1% gelatin), 2.5 µl 
2.5mM dNTP mix, 1 pl of each primer at 20 pmol/pl, 1 pl of 0.5 U/µl Red Hot Polymerase 
(Advanced Biotechnologies), 5 pl cDNA and SDW. Reactions were overlaid with 50 Pl 
mineral oil before amplification. PCR products were visualised on a 0.8% agarose gel. 
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Fragment cDNA 5' primer 3' primer Cycling conditions 
primer 
I II F1 R1 94°C 5min x1 cycle 
(1134 bp) (EC 179 no. 1) (EC 179 no. 2) 94°C I min 
65°C 1.5min x 40 cycles 
72°C 3min 
II II F2 R2 94°C 5min xI cycle 
(889 bp) (EC17625-mer) (EC176 25-mer) 94°C lmin 
63°C 1.5min x 40 cycles 
72°C 3min 
III IV F3 R3 94°C 5min x1 cycle 
(671 bp) (E6-5) (E6-6) 94°C I min 
67°C 1.5min x 40 cycles 
72°C 3min 
IV IV F4 R4 94°C 5min x1 cycle 
(1146 bp) (E6-1) (E6-2) 941C I min 
67°C 1.5min x 40 cycles 
72°C 3min 
V VI F5 R5 94°C 5min xI cycle 
(1482 bp, (E6-3, E6-9) (E6-4, E6-10) 94°C lmin 
960 bp) 65°C 1.5min x 40 cycles 
72°C 3min 
VI VI F6 R6 94°C 5min x1 cycle 
(928 bp) (EC 179 no. 5) (EC 179 no. 6) 94°C 1 min 
60°C 1.5min x 40 cycles 
72°C 3min 
Table 2.1 The cDNAs, PCR primers and amplification conditions used for the PCR 
amplification of CSB cDNA in six fragments. 
2.2.4 Re-amplification 
The first round PCR product was run on a 2% low melting point agarose gel and the 
desired band excised from the gel. The agarose was diluted with 200-500 gl TE depending 
on the amount of DNA and melted at 65°C for use as a template in further rounds of 
amplification. Second round amplifications were carried out as before, replacing the sense 
primer with a nested biotin-tagged primer. The oligonucleotides were synthesised with an 
amino-linker on the 5' end and removed from the column with 10% ammonia at 55°C 
overnight. The solution was run through a NAP 10 column and the oligonucleotide eluted 
44 
in 1 ml TE. For addition of the biotin, half of the oligonuclcotidc stock was precipitated 
and resuspended in O. 1M HEPES. This was mixed with biotinyl succinimide overnight at 
room temp and purified on a NAP 10 column. 
2.2.5 Selection of oligonuclcotidcs 
Oligonucleotides were obtained from Rotterdam for amplification of the full length open 
reading frame of the CSB gene, giving amplification in six fragments. Some of the primer 
pairs gave good or adequate products, others however gave no amplification irrespective of 
the conditions employed during cycling (see chapter 3). Replacement primers were 
designed to cover the regions that did not amplify with the original sets. The primers were 
designed as 24-mers on the Oligo 5.0 computer program which is able to screen chosen 
sequences for mis-priming, primer dimers and hairpins. It is also possible to predict 
melting temperatures and annealing temperatures, although cycling conditions need to be 
checked fully as is discussed in the section below. In total, new oligonucleotides were 
designed for fragments III, IV and V. 
2.2.6 Strand separation 
The second round PCR products were diluted with TE and mixed with 50 µl streptavidin- 
coated magnetic beads for 1-2 hr. The beads had been washed twice with 2x Bind and 
Wash buffer (10mM Tris-HCI pH7.5,1mM EDTA, 2M NaCl). The beads were then 
washed twice with Triton Wash Solution (TWS-0.17% Triton X-100,500mM NaCl, 
10mM Tris-HC1 pH7.5,1mM EDTA pH8) and resuspended in 32 µl TE. The DNA was 
denatured by addition of 8 µl of 2M NaOH/4mM EDTA with 5 min incubation at room 
temp. At this stage the biotinylated sense strand remains attached to the magnetic beads 
and the other strand is in the supernatant. The supernatant was in on an agarose gel to 
assess the amount of ssDNA in the supernatant, giving an estimate of the ssDNA still on 
45 
the beads and therefore the binding efficiency. The beads were again washed twice with 
TWS and once with TE, followed by resuspension in SDW ready for sequencing. 
2.2.7 Sequencing 
Dynabead bound ssDNA and ssDNA plasmid preps were subjected to sequencing carried 
out according to the Sequenase version 2.0 kit (Amersham). Reactions were run on 
denaturing polyacrylamide gels for approximately two hours at a constant power of 60W, 
dried and exposed to autoradiographic film overnight. 
2.2.8 DNA purification 
DNA was purified according to the Glassmax DNA Isolation Matrix kit (Gibco BRL) 
following gel purification. 
2.2.9 Standard techniques 
Ligations, minipreps, ssDNA preparation, restriction digests and transformations were 
carried out by standard procedures as described by Sambrook et. al. 1989. 
2.2.10 Maxipreps 
Two procedures were used for the large scale preparation of plasmid DNA. A 200 ml 
overnight culture was harvested by spinning at 5,000 rpm for 5 min. The pellet was 
resuspended in 10 ml Solution I (50mM glucose, 25mM Tris-HC1 pH8,10mM EDTA), 
followed by sequential addition of 20 ml Solution II (0.2M NaOH, 1% SDS) and 10 ml 
Solution III (60% 5M KCI, 11.5% acetic acid). The solution was incubated on ice for 30 
min then spun down at 10,000 rpm for 10 min. The supernatant was filtered through gauze 
into 100 ml of ethanol and the DNA spun down (10,000 rpm, 10 min). 
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2.2.10.1 Method I 
The DNA was resuspended in 5 ml 5xTE and mixed with 6g Caesium chloride and 500 µl 
of 1 mg/ml ethidium bromide. This was spun at 48,000 rpm for at least 17 hr and the 
plasmid band removed. The ethidium bromide was removed by iso-amyl alcohol 
extraction and the DNA ethanol precipitated. The pellet was resuspended in 500 pl TE and 
the concentration determined using the Pharmacia Genequant. 
2.2.10.2 Method II 
The DNA was resuspended in 400 µl of TE and treated with 4 µl of 1 mg/ml boiled RNase 
for 15 min at 37°C. The solution was precipitated with 200 pl of 2.5M NaCI/20% 
polyethylene glycol on ice for 15 min and spun down at 15,000 rpm for 10 min. The pellet 
was resuspended in 400 µl of TE and extracted with phenol twice followed by two 
chloroform/iso-amyl alcohol (24: 1) extractions. The DNA was ethanol precipitated and 
resuspended in 1 ml TE and the concentration determined as for method I. 
2.2.11 Site-directed mutagenesis I 
The plasmids pcBlsSE6 (WT CSB within pBluescript, from C. Troelstra) and pCI-WT (WT 
CSB within pCI-neo, Promega) were transformed into the ung-, dut- strain CJ236 to 
produce uracil containing ssDNA. The mutagenesis primers were designed to carry the 
change in the middle of a 26-mer in the case of single base changes. For greater 
differences or deletions, oligonucleotides of up to 40 nt were synthesised. 
Mutagenesis primers were phosphorylated by mixing 2 µl of 10 ng/µl primer with 20 µ15x 
Ligation buffer with ATP (Gibco BRL) and 5U Polynucleotide kinase (Pharmacia) in a 
total volume of 100 µl. The mixture was incubated at 37°C for one hour. For the primer 
annealing reaction, 10 µl of phosphorylated primer was mixed with 100 ng ssDNA and 
2 µl 10 x annealing buffer (200mM Tris-HCI pH7.5,20mM MgC129 500mM NaCl) and 
heated to 65°C for 3 min followed by 10 min at 37°C. For synthesis and ligation of the 
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complementary strand, 2 pl 10 x synthesis buffer (175mM Tris-HC1 pH7.5,37.5mM 
MgC12,21.5mM DTT, 8mM ATP, 4mMdNTP), 1 pl BRL ligase (1 U/µl) and 1 pl T7 
DNA polymerase were added and the reaction incubated at 37°C for 2 hr. Half of the 
reaction mix was transformed into competent DHSaF', where uracil containing DNA will 
be degraded and only the newly synthesised mutant DNA will result in ampicillin resistant 
colonies. Individual colonies were picked and checked for presence of the mutation either 
by restriction analysis or sequencing. All constructs were sequenced through the entire 
CSB open reading frame to check for polymerase errors. 
2.2.12 Site-directed mutagenesis II 
Site-directed mutagenesis reactions were also carried out using the Stratagene Quikchange 
mutagenesis kit. Primers carrying the desired mutation were designed complementary to 
both strands of the DNA. In general 2S µg of double stranded pCI-WT plasmid was mixed 
with 125 ng of each primer, 2 µl 10 x buffer, 1.5mM dNTPs and 2 units of Pfu polymerase. 
The mixture was overlayed with 25 µl of mineral oil and a PCR like reaction was carried 
out annealing at 55°C for 1 min and extension for 20 min at 65°C (2 min per kb of 
plasmid). After amplification, 1 unit of DpnI restriction enzyme was added and the 
reactions incubated at 37°C for 1 hour. Between 1 and 10 µl of the reaction was 
transformed into the supercompetent E. coli cells XL-1 blue (Stratagene). 
2.3 Biochemical Techniques 
2.3.1 Whole cell extracts I 
CHO cell lines were grown to confluency on 10 cm dishes, trypsinised and washed three 
times with ice cold PBS. The cell pellet was finally resuspended in 300 µl ice cold PBS, 
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vortexed for three short bursts of 10 sec, then sonicated twice for 30 sec, placing onto ice 
between each burst. 
2.3.2 Whole cell extracts II 
Cell pellets were washed three times in PBS then resuspended in 200 µl of buffer (50mM 
NaF, 20mM HEPES pH7.8,450mM NaCl, 25% glycerol, 0.2mM EDTA, 0.5mM DTT and 
protease inhibitor cocktail, Boehringer). The cell suspension was then subjected to snap 
freezing on dry ice/ethanol, followed by rapid thawing at 30°C. The cycle of freeze 
thawing was repeated twice more. Cell debris was spun down for 5 min at 12,000 rpm at 
4°C. The supernatant was aliquoted into 10 pl samples and snap frozen immediately on 
dry ice/ethanol. 
2.3.3 Cell fractionation I 
Cell fractions were prepared as described by Krude et. al. 1997. Cells were grown to near 
confluence on 10 cm dishes and washed once with PBS. They were then washed with ice 
cold hypotonic buffer (20mM potassium-HEPES, 5mM potassium acetate, 0.5mM MgC12, 
0.5mM DTT), then replaced with 10 ml of the same buffer and allowed to swell for 10 min 
at 4°C. After swelling all excess buffer was removed and the cells scraped off into the 
residual liquid. The suspension was transferred into a dounce homogeniser and the cells 
disrupted with 25-50 strokes. The suspension was transferred to an eppendorf and the 
nuclei spun down at 4,000 rpm for 5 min at 4°C. The supernatant containing the 
cytoplasmic extract was transferred to a fresh tube. The pelleted nuclei were washed three 
times with PBS and finally resuspended in 100 µl of hypotonic buffer with 0.4M NaCl. 
The nuclei were incubated on ice for 90 min and nuclear material pelleted at 13,000 rpm 
for 30 min at 4°C. The supernatant contains the nuclear extract and the pellet nuclear 
debris. 
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2.3.4 Cell fractionation II 
Cell fractions were prepared as described by Rathmell and Chu, 1994. Cell pellets were 
washed several times in PBS, once in wash buffer (10mM HEPES pH7.5,10mM KCI, 
0.5mM DTT), and finally in 40 µl wash buffer with 4 µl 10% NP-40. Cells were lysed in 
this buffer at 4°C with mixing for 10-20 min, checking for lysis periodically. Nuclei were 
pelleted at 13,000 rpm for 2 min at 4°C and the resulting supernatant is the cytoplasmic 
fraction. The nuclei were then resuspended in 40 pl high salt buffer (20mM HEPES 
pH7.5,500mM NaCl, 0.2mM EDTA, 0.5mM PMSF, 0.5mM DTT, 1.5mM MgC12,20% 
glycerol) and extracted for 15 min on ice. Nuclear debris was pelleted at 13,000 rpm for 10 
min at 4°C, with the supernatant being the nuclear extract. 
2.3.5 SDS PAGE 
Proteins were run on 8% denaturing polyacrylamide gels with 0.1% SDS in lx running 
buffer (25mM Tris, 0.19M glycine, 0.1% SDS). Gels were run using the Bio-Rad mini 
protean system until the 45 kDa marker reached the bottom of the gel. 
2.3.6 Western Blotting 
SDS-Page gels were transferred to a tank containing cold blotting buffer (3 g/lt Tris, 145 
g/lt glycine, 0.01% SDS) and soaked for 5-10 min. The proteins were transferred onto 
Nitrobind nitrocellulose transfer membrane (MSI) using the Bio-Rad MiniProtean wet 
blotting system, either overnight at 15 V or for 3 hr at 100 V. The blot was then blocked 
for at least 1 hr in PBS with 10% milk, 0.1% Tween. 
2.3.6.1 HA antibody 
Blocked blots were mixed with either the commercially obtained HA (BabCo) or HA 
purified from 12CA5 hybridoma cells at 1: 1000 dilution in PBS with 2% milk, 0.1% 
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Tween at room temperature for 1-2 hr. Blots were then washed three times for 10 min in 
the PBS-milk-Tween solution, then incubated with horseradish peroxidasc-conjugated 
mouse immunoglobulins (Dako) at 1: 2500 dilution in PBS-milk-Tween for I hr at room 
temperature. Blots were then washed a further 3x 10 min and finally with PBS-Tween to 
remove the milk. Proteins were visualised using the ECL detection system and 
autoradiography. 
2.3.6.2 CSB antibody 
Blocked blots were washed with PBS with 0.1% Tween to remove excess milk and 
transferred to a 15 ml tube containing 4 ml of polyclonal CSB antibody (van Gool et al., 
1997) diluted 1: 400 in PBS-Tween. The blot was incubated with the antibody at 4°C 
overnight with rolling. Blots were washed 3x 10 min in PBS-Tween then incubated for 
1'/z hr at 4°C with 1: 1000 dilution (PBS-Tween) of alkaline phosphatase conjugated rabbit 
immunoglobulins (BioSource International). After incubation with the secondary 
antibody, blots were again washed 3x 10 min in PBS-Tween, finally washing in AP buffer 
(100mM Tris pH9.5,100mM NaCl, 5mM MgC12) for 5 min. Proteins were visualised by 
adding 10 ml of AP buffer containing 111 µl nitroblue tetrazolium chloride (one tablet 
dissolved in 1 ml water, Sigma) and 11 µl bromo-chloro-indolyl-phosphate (one tablet 
dissolved in 500 µl DMF, Sigma). The reaction was stopped by removing the buffer and 
washing the filter with either water or TE. 
2.3.7 Purification of IIA antibody 
Supernatant from 12CA5 hybridoma cells was harvested and spun down to remove cell 
debris. Saturated ammonium sulphate solution was added to the supernatant to give a final 
concentration of around 50%. The precipitate was spun down at 10,000 rpm for 5 min and 
resuspended in ice cold PBS. The suspension was dialysed overnight into PBS with 
several changes of buffer. The solution was run through a1 ml HiTrap protein G column 
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(Pharmacia) and the antibody eluted with 1M glycine (p'12.5). Immediately after elution 
the antibody fractions were neutralised with IM Tris. Fractions were tested for protein 
content using the Bio-Rad protein assay and checked on a Coomassie stained SDS-PAGE 
gel for immunoglobulin bands. The peak fractions were pooled and dialysed again into 
PBS. 
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CHAPTER 3 PCR AND SEQUENCING CONDITIONS 
3.1 Introduction 
There are a number of different techniques available for the sequencing of cloned genes to 
identify mutations occurring in patients suffering from genetic syndromes. Analysis of 
such genes involves extracting RNA from cultured primary fibroblasts, performing RT- 
PCR and direct sequencing. At the start of this study, we were provided with a series of 
primers and conditions by C. Troelstra, Rotterdam, that she had used to amplify the CSB 
gene from human cells in six fragments of around 1kb. However, different thermal cyclers 
produce different conditions and variation in starting materials can result in sub-optimal 
conditions. In my hands, the conditions used by Troelstra were not suitable for the 
amplification of CSB. Some of the primer pairs gave good or adequate products, others 
however gave no amplification irrespective of the conditions employed during cycling. 
Replacement primers were designed to cover the regions that did not amplify with the 
original sets. The primers were designed as 24-mers on the Oligo 5.0 computer program 
that is able to screen chosen sequences for mis-priming, primer dimers and hairpins. It is 
also possible to predict melting temperatures and annealing temperatures, although cycling 
conditions need to be checked fully as discussed in the section below. In total, new oligos 
were designed for fragments III, IV and V. There were also several methods being 
employed in the laboratory for RNA extraction, cDNA synthesis and direct sequencing. 
To determine the most efficient way to screen Cockayne syndrome type B patients for 
mutations it was necessary to check all methods for suitability and optimise those selected. 
Ultimately I was able to amplify CSB using a similar strategy to that used by Troelstra 
et. al., 1992 through the six fragments and primers shown in figure 3.1. 
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Figure 3.1 The location of the PCR primers finally used to amplify the C5ß cDNA in six 
fragments. 
3.2 RNA extraction 
RNA extraction can be performed with two aims, to produce total RNA or poly(A) mRNA 
with the latter a more complex and time consuming procedure. The cDNA synthesis and 
PCR amplification methods should be sensitive enough for total RNA to be sufficient. 
Total RNA extraction has been carried out regularly in the laboratory using two 
procedures, cell lysis with non-ionic detergent and guanidinium thiocyanate extraction. 
3.2.1 Non-ionic detergent lysis 
This method involves lysing the cell pellet using the non-ionic detergent NP-40 and then 
spinning out the nuclei. The cytoplasmic supernatant contains the RNA, whereas the 
genomic DNA remains in the nuclear pellet. This method therefore allows both RNA and 
DNA preps to be performed on the same cell pellet. 
3.2.2 Guanidinium Thiocyanate 
This method uses the chemical guanidinium thiocyanate to break open both the cells and 
nuclei. It is also able to protect the RNA from degradation during the lysis procedure 
through inhibition of RNases. The released RNA is then purified by phenol extraction and 
precipitated which also removes guanidinium from the preparation. 
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3.2.3 Results and discussion 
Both methods of extraction produced around around 50 pg total RNA from approximately 
5x 106 primary fibroblasts. When run on either a formaldehyde or sterile standard agarose 
gel, the RNA was not degraded and the 28S and 18S ribosomal RNA bands were clearly 
visible at the 2: 1 ratio expected (Figure 3.2). It was also of sufficiently good quality to 
give cDNA that amplified reproducibly in a PCR reaction. Both methods of extraction 
were used during this project with equal success. 
3.3 cDNA synthesis 
The cDNA synthesis reaction, a standard procedure was carried out as outlined in chapter 
2. The variable part of the procedure was the type of priming method chosen, resulting in 
very different amplification targets. There are three main types of priming used for cDNA; 
random hexamers, oligo dT and gene specific primers. To test the efficiency of cDNA 
synthesis it was necessary to use PCR of a control hprt DNA fragment and of the desired 
gene. It is important to use the target gene to test the cDNA, as genes all have different 
compositions. For example, GC rich regions and palindromic sequences will result in 
secondary structure and therefore cause problems in elongation. 
3.3.1 Oligo dT 
Oligo dT primers anneal to the poly(A) tail of mRNA and extend upstream from the single 
priming site. This technique works very efficiently for the short hprt gene and the 3' end 
of CSB. However, the efficiency of synthesis decreases with length of extension either due 
to the RNA not being intact or the cDNA synthesis not reaching the full length of the RNA 
transcript. This makes amplification of the 5' regions particularly difficult with large genes 
such as the 4.7 kb CSB cDNA. 
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3.3.2 Random hexamers 
Random hexamers are 6 nt primers made up of random nucleotides which, because of their 
random nature are able to anneal at many different positions on the RNA. This method of 
priming is useful for long genes giving priming throughout the length of RNA, so that 
elongation along the full length of the transcript is not required. The main drawback with 
this method is that the primers consist of a wide variety of sequences and are able to anneal 
in a large number of places within the RNA. Therefore, the cDNA made from the target 
sequence will only make up a small proportion of the total cDNA synthesised. 
3.3.3 Specific priming 
This method involves the use of antisense primers specific for the gene of interest to prime 
the synthesis of cDNA. The number of primers needed depends on the size of the 
transcript and the efficiency of the elongation reaction. Generally, to be certain of high 
yield quality cDNA each reaction should not be expected to extend further than 2-3 
kilobases. 
3.3.4 Results and discussion 
The cDNAs were initially tested for amplification of a control fragment from the hprt gene 
and the fragment VI at the 3' end of CSB. Any cDNAs that gave products in each of the 
above test PCRs was checked for amplification of the rest of the CSB fragments. 
Random hexamer primed cDNAs failed to give products with either of the test fragments 
(Figure 3.3) and this procedure was not pursued. 
Oligo dT was the second primer tested for cDNA synthesis. All cDNAs primed this way 
amplified well with the control fragment and CSB fragment VI (Figure 3.3). However, the 
farther upstream in the CSB gene the PCR primer pairs are situated, the weaker the 
amplification and the more variable the product (Figure 3.4). The oligo dT primed cDNAs 
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tested also failed to give PCR products for fragments I and II at the 5' end of the gene. 
Figure 3.4 shows the bands produced for fragment II. The main drawback to using oligo 
dT primed cDNA for amplification of CSB result from the gene being 4.7 kb. With a large 
gene the size of CSB, the eDNA needs to extend a long way from a single primer. 
Therefore, the RNA needs to be of high quality and the cDNA synthesis procedure has to 
be very efficient. Sub-optimal synthesis will result in a high proportion of short cDNAs, 
thereby reducing the amount of target DNA produced from the 5' end. Consequently the 
amplification of this region will be very difficult. 
Gene specific primers were also tested for use in eDNA synthesis in an attempt to 
counteract the problems encountered with the oligo dT and random hexamer primers. The 
cDNA was synthesised in three overlapping pieces using the reverse primers for fragments 
II, IV and VI (see Figure 3.1). Amplification was carried out on the corresponding 
fragments and the fragment immediately upstream. With this method of synthesis it was 
not possible to check the quality of the cDNA by amplification of a control PCR fragment. 
Therefore the optimisation of cDNA synthesis and PCR had to be combined, which will be 
discussed further in section 3.4. 
There are two advantages to the use of gene specific primers for eDNA synthesis. Firstly, 
eDNA is generated only from the target gene eliminating a dilution effect from non- 
specific sequences, greatly reducing the chances of mispriming in PCR and inhibition of 
amplification from too much DNA in the reaction. Secondly, several primers along the 
gene can be used in synthesis, reducing the extent of elongation required in each reaction. 
In this case, for CSB, each primer was only expected to generate a maximum of 3kb of 
cDNA. 
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Figure 3.2 Formamide agarose gel of a standard total RNA preparation, demonstrating 
the relative positions of the 28S and 18S ribosomal RNA hands 
12 
Figure 3.3 Agarose gel showing the control hprt PCR product amplified from cl)NAs 
primed with oligo dT (lane 1) and random hexamers (lane 2). 
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Figure 3.4 Agarose gel showing amplification of the 5' end of ('Wß, demonstrating the 
weak signal obtained for fragment II (lanes 3 and 4). and the barely visible product for 
fragment I (lanes 1 and 2). Lane 5 shows amplification of the control hprt fragment. 
3.4 PCR 
PCR is a very powerful technique allowing generation of large quantities of DNA from a 
very small amount of starting material. It is however, highly dependent on the nature of its 
components and the conditions employed during the reaction. PCR is also a variable 
technique and two thermal cyclers will rarely give identical conditions even when set to the 
same program. The starting material can also have a great influence on the conditions 
required for efficient amplification. For example, if the target DNA is plasmid there is a 
much greater amount of target material in the sample compared to that present when 
amplifying from an equivalent amount of cDNA. A greater amount of starting material 
will make the amplification more flexible, allowing amplification at non-optimal 
conditions. It is therefore important when trying to amplify from a low abundance eDNA 
that conditions are optimised carefully. 
3.4.1 Optimisation of conditions 
Conditions were optimised using cDNAs synthesised by each of the above methods for the 
six fragments used in the amplification of CSB. Initially, primers obtained from Rotterdam 
were tested at the conditions suggested, then checked with a series of different annealing 
temperatures. Annealing temperatures of oligonucleotides can also be predicted from their 
composition by applying the following formula: 
4(G+C)+2(A+T)-5. 
Each primer pair was checked at three annealing temperatures between 60°C and 70°C. As 
described below three primer sets did not give reliable products and therefore new primers 
were designed for these regions. The new primers were also checked to find the optimal 
annealing conditions. 
58 
3.4.2 Results and discussion 
Most of the primer pairs gave products at one of the annealing temperatures tested. 
Fragment I however, gave unreliable PCR products unrelated to the quality of the cDNA, 
with the same cDNA unable to give reproducible amplification. One explanation for this 
erratic amplification could be a large amount of secondary structure, common in the 5' 
untranslated region of genes, preventing the primers from annealing to the target sequence. 
This problem was overcome by introducing a hot start step into the PCR. This involves 
heating the reaction to 94°C for 5 min before beginning the cycling reaction to eliminate 
secondary structure from the first round of PCR. Once this problem had been overcome, 
the amplification of this fragment could also be optimised. 
The six fragments could be amplified with a wide range of annealing temperature, using a 
standard amplification protocol as outlined in Table 3.1 below. 
Fragment Hot Start Denaturation Annealing Elongation No. of cycles 
I 94°C 5 min 94°C 1 min 65°C 1 min 72°C 2 min 35 
II 94°C 5 min 94°C 1 min 63°C 1 min 72°C 2 min 35 
III 94°C 5 min 94°C 1 min 67°C 1 min 72°C 2 min 35 
IV 94°C 5 min 94°C 1 min 67°C 1 min 72°C 2 min 35 
V 94°C 5 min 94°C 1 min 67°C 1 min 72°C 2 min 35 
VI 94°C 5 min 94°C 1 min 60°C 1 min 72°C 2 min 35 
Table 3.1 The PCR cycling conditions employed for the optimal amplification of the six 
fragments encompassing the whole ORF of the CSB cDNA. 
3.5 Sequencing 
Two approaches can be taken when sequencing PCR products, cloning and direct 
sequencing. The cloning procedure takes advantage of a property of the Taq Polymerase 
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which adds a single A nucleotide onto the 5' end of each strand of amplified DNA. The 
PCR products can therefore be cloned easily into a T-vector which has single T overhangs. 
The clones allow generation of ssDNA and production of large quantities of DNA. 
However, several clones from each PCR product must be sequenced to ensure that any 
changes identified are mutations rather than PCR errors. This method is particularly useful 
when studying patients that have compound heterozygous mutations or splice 
abnormalities. In such cases it is necessary to identify differences between alleles. 
Alternatively, the PCR product can be sequenced directly, preventing PCR errors being 
visible on the sequencing gel and being confused with mutations. Direct sequencing also 
allows simple distinction between heterozygous and homozygous mutation, where in the 
case of homozygous changes only the mutant band is observed. However, when looking at 
sequence with a heterozygous change, both the mutant and parental bands will be present at 
the same position. 
For the purposes of this study, cloning was used as a back-up procedure when direct 
sequencing failed to give sufficient information as to the nature of the mutation. Direct 
sequencing is a far more rapid and labour efficient way of sequencing PCR products. 
Therefore, it was decided to test two available techniques for direct sequencing for use in 
this project. 
3.5.1 Cycle sequencing 
Cycle sequencing is based on PCR and uses a modified Taq polymerase. The method 
works by incorporating radioactively labelled nucleotides into the DNA via a primer 
extension reaction then mixing with dideoxy terminators. 
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3.5.2 Strand separation 
The strand separation technique works by tagging one strand of the DNA by re-amplifying 
the first round PCR product using a biotin tagged nested primer. The DNA is bound onto 
streptavidin coated magnetic beads via the biotin and the two strands are separated by 
alkaline denaturation with the tagged strand held with a magnet. The resulting single- 
stranded DNA can be sequenced as usual using the Amersham Sequenase 2.0 kit as 
described in Chapter 2. 
3.5.3 Results and discussion 
The two sequencing methods were initially tested for sequencing of CSB fragment VI 
which results in a pure, high yield PCR product. Both methods produced good results with 
clear sequencing ladders and a minimal amount of cross-banding. From these results it 
was difficult to determine the method most suitable for sequencing CSB, with the strength 
of signal the only variation, being slightly stronger with the strand separation method. 
Therefore, the other CSB PCR fragments were tested with both methods. When 
sequencing fragment V, the strand separation method again gave good clear results. 
However, for cycle sequencing clear sequence was obtained for very few of the reactions, 
most resulting in considerable cross-banding or smearing. 
3.6 Conclusions 
Many different techniques were tested with the CSB gene to determine the best methods 
and conditions for the amplification and sequencing of the gene in CS patients. 
For RNA extraction both methods have been employed during the project, with the cell 
lysis procedure being preferred when genomic DNA is also required for analysis. For 
cDNA synthesis, both priming by oligo dT and specific primers gave amplification. 
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Because priming with the specific primers gave the more reliable results this method was 
used, despite it being necessary to make three cDNAs for each patient. 
Strand separation was the method of choice for direct sequencing, giving much clearer and 
therefore more reliable data. More recently a new sequencing method has been used in the 
laboratory (Amersham). It is able to eliminate the cross-banding seen particularly in cycle 
sequencing, due to the use of 33P-labelled ddNTP terminators. It is also more rapid and 
reliable than either of the sequencing methods described here, leading to the method being 
used routinely. 
The techniques discussed here have been used for the analysis of the CSB gene in 
Cockayne Syndrome patients. The results of these analyses are shown in chapter 4. 
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CHAPTER 4- MUTATIONS IN CSB 
4.1 Introduction 
Cockayne Syndrome (CS) cells are deficient in transcription coupled repair and fail to 
recover RNA synthesis after UV-C irradiation. Patients suffering from Cockayne 
Syndrome can therefore be diagnosed by testing for the ability of fibroblasts grown from a 
skin biopsy to recover RNA synthesis after irradiation. This is illustrated in Fig 4.1 which 
shows the recovery of RNA synthesis in normal and mutant cell lines at a range of UV 
doses. 
There are two complementation groups of CS, A and B with the majority of patients 
belonging to group B (Stefanini et al., 1996). The genes defective in each of the 
complementation groups have been cloned, the CSA gene in 1995 by Henning et al., 1995 
and CSB in 1990 by Troelstra et al., 1990. In this study the CSB gene was sequenced in 
patients from complementation group B, in an attempt to identify the causative mutations. 
It was hoped that such an analysis would identify regions of the gene essential for function 
and determine a link between the location of the mutation, the clinical severity and the 
nature of the CS symptoms. 
As described in Chapter 1, CSB is a member of the SWI/SNF superfamily of putative 
helicases and ATPases. All members of this family contain the consensus sequences of the 
seven helicase domains which are highly conserved between species. If such regions are 
important for function, it can be predicted that mutations falling within this area may 
inactivate the protein. 
Structural homologues of CSB have been found and sequenced in mouse and the yeast 
Saccharomyces cerevisiae. Mutations found in the cell lines studied can be compared with 
the mouse and yeast sequences to discover whether they fall within the conserved regions 
of the gene or change important residues. The nature of the amino acid change can also 
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give important clues as to whether the mutation is a polymorphism or an inactivating 
change. A large change in size, charge or hydrophilic/hydrophobic nature between the 
original residue and the substituted amino acid is likely to prove the most disruptive to the 
protein. 
4.2 Materials and Methods 
The techniques outlined in Chapter 3 were used for the sequencing of the CSB gene for 
patients with Cockayne Syndrome from complementation group B. In brief, the 
methodology consisted of total RNA extraction from primary fibroblast cell lines and 
cDNA was synthesised by reverse transcription primed in three fragments with the gene 
specific primers R2, R4 and R6 (see table 2.1). The cDNA was then subjected to PCR 
amplification under the conditions outlined in Table 3.1 and sequenced directly. The sense 
strand is biotin tagged and bound to streptavidin coated magnetic beads. The tagged strand 
can be separated from the complementary strand and sequenced using the Sequenase 
Version 2.0 kit (for more detail, see section 3.3). Mutations not resulting in deletions, 
frameshifts or terminations were created in a mammalian expression vector by site-directed 
mutagenesis and cloning. The subsequent mutant genes were transfected into the mutant 
hamster cell line UV61, which is in the CS-B complementation group, to check for the 
ability to correct the UV-C sensitive phenotype. Stably transfected clones were analysed 
for UV survival. 
In the case of CS1MA, a region of the genomic DNA was sequenced to check for 
mutations at the intron/exon boundaries. Genomic DNA was purified from the supernatant 
of the alkaline lysis RNA preparation (see chapter 2). The supernatant was treated with 
RNase (1 µg/ml final concentration) at 37'C for 2 hr, then proteinase K (1 gg/ml final 
concentration) at 65°C for 1 hr. The solution was extracted once each with equal volumes 
of phenol, phenol: chloroform/iso-amyl alcohol (50: 50) and ehloroform/iso-amyl alcohol 
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Figure 4.1 The incorporation of 3H-uridine into CS-B (. ) and wild-type (. ) cells 
demonstrating the levels of RNA synthesis 24 hr after UV irradiation (data courtesy of H. 
Fawcett). 
CS2BEI 
Figure 4.2 Diagrammatic representation of CSB illustrating the position and nature of 
mutations found in CS-B patients. The CSB protein is shown with the seven domains 
conserved in DNA helicases/ATPases(hatched boxes) and the putative nuclear-localisation 
signals(black boxes). Amino acid changes resulting from mutations are shown boxed with the 
change indicated by white lettering on black background, and the cell line designations are 
shown below. The subscripts 1 and 2 denote the different alleles. Mutations shown below the 
depicted protein result in protein truncations, whereas those above are single amino acid 
changes. 
(24: 1). Ethanol was added as 2'/2 volumes of the sample and the tube inverted twice to mix. 
The DNA was spooled from solution and resuspended in 500Etl sterile double distilled 
water overnight with shaking at 37'C. 
New primers were designed from intron sequence (C. Troelstra, Rotterdam) to allow 
amplification of the boundaries of introns 9 and 10 with exon 10 (see Appendix I for 
primer sequences). 
4.3 Results 
Thirteen patients were analysed that had previously been diagnosed as CS through failure 
to recover RNA synthesis after UV irradiation, and subsequently assigned to the CS-B 
group by somatic cell fusion and complementation assays (Lehmann, 1982; Stefanini et al., 
1996). The CSB cDNA was sequenced in each case and compared to the published 
sequence. Two of these patients were siblings presenting a very unusual pattern of 
mutations, which due to their complex and interesting nature will be discussed in a later 
chapter. 
In total, four types of mutations were found in the patients studied, as a result of either 
deletions or base substitutions. Two categories of deletion were observed in the CSB 
eDNA during this project. Two patients possess a deletion resulting from aberrant 
splicing, which has caused the exon to be removed, along with the flanking introns, 
possibly due to mutations at the splice junctions. Secondly, three patients carry single base 
deletions within a run of repeated nucleotides. This causes a frameshift downstream of the 
deletion, altering the amino acid sequence such that there is premature termination of the 
transcript and truncated protein is produced. 
Base substitutions can give rise to two types of mutation, amino acid substitutions and 
termination codons. In the case of the latter, the effect of replacing an amino acid with a 
stop codon results clearly in truncated protein. Amino acid substitutions are far more 
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Cell line' as changeb Racial Age` Age Of Pigment. Gait` Cataracts Caries Ref 
Group Onset Retino .° CS2TAN (88) YK T 5l7sto Turkish 9 1.5 n n 88 in Lehmann, 1993 #604 
CSIMA (34) LW Del 665-723 Caucasian 4 dead 0 ? 34 in [Lehmann, 1993 #604] 
CSIABR (107) RC + 25 866 Caucasian 6 0.2 y [Stefanini, 1996 #5959] 
+ 26 1203 
CSITAN (77) YA Arg735stop Turkish 8 1.5 n 77 in [Lehmann, 1993 #604 
25627 JM Arg735stop Caucasian 5 y y 
Ar 453sto 
CS2BE -1 1179 Caucasian 21 1 y y [Brumback, 1978 #1094] 
Del 665-723 
CS4BR (39) Arg670Trp Caucasian 24 3 y y y y 39 in [Lehmann, 1993 #604] 
Glnl84stop 
CS2BI (9) MS Arg670Trp Caucasian 16 0.7 y y 19 in [Lehmann, 1993 #604] 
Pro1042Leu 
CSIBE Arg670Trp Caucasian 11 1.5 y y; n [Brumback, 1978 #1094] 
-1 1179 
CS3TAN (98) MI I T 851A Turkish 1.7 0.3 n n n 98 in Lehmann, 1993 #6041 
CSI IAF (67) IN Val957G1y Israeli 7 2 y y 67 in [Lehmann, 1993 #604] 
Jewish 
'Bold: Patient with early onset form of disorder. bBold: Less severe mutation. For compound heterozygotes, this is assumed to be the more C-terminal of two truncating 
mutations, or a mis-sense mutation if one allele is a truncation and the other a mis-sense. `Age at biopsy. dpigmentary retinopathy. `Gait defects. y, yes; n, no. 
Table 4.1 The origin, clinical features and mutations of the patients studied in this chapter. 
complex, with the effect of the change not always obvious. It is therefore particularly 
important in these cases to determine whether the change is phenotypically significant. 
Initially, when mutations were found that resulted in amino acid substitutions, the entire 
gene was sequenced to check for the absence of any other changes. Subsequently, the 
cDNA was sequenced within the central fragments and not continued outside fragments II 
to V if putative inactivating mutations were found. 
All mutations found during this section of the project are shown in Figure 4.2. This figure 
is a diagrammatic representation of CSB showing the position of putative nuclear 
localisation signals and the seven helicase domains. The full sequence of the CSB cDNA 
is shown in Appendix III. 
4.3.1 CS2BE and CS1MA 
CS1MA is the offspring of unrelated parents of Western origin and was therefore not 
expected to carry a homozygous mutation. However, there was an unusually small PCR 
product on amplification of fragment 3 for CS1MA, which on direct sequencing showed 
that amino acids 665 to 723 were absent (Fig 4.3). The deletion spans exon 10 which 
comprises 174 nucleotides and is positioned within helicase/ATPase domain III. The 
deletion is likely to be the result of a splicing abnormality. In an attempt to find the origins 
of the probable aberrant splicing, the boundaries between exon 10 and introns 9 and 10 
were analysed in CS! MA, through PCR and sequencing of genomic DNA from these 
regions. The sequencing failed to show any mutations which may be responsible for the 
removal of exon 10 during splicing. The cause of this deletion remains unsolved. 
CS2BE originates from the USA and has the typical features of a CS patient as shown in 
Table 4.1. This patient is a compound heterozygote, carrying a different mutation in each 
allele of CSB. The first allele has a deletion of exon 10 as described above for CS 1 MA 
that was noticed by the presence of two distinct bands on amplification of PCR fragment 
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Figure 4.3 Sequence for patient CS 1 MA (panel a) and wild-type (panel h) around the 
boundary of exons 10 and 11, demonstrating the absence of exon 10 in CS 1 MA. 
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Figure 4.4 Sequence for patient CS2BF (panel a) and wild-type (panel h) around 
position 3614, showing the presence of both the wild-type and single T deleted alleles 
from the arrow upwards in a. 
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III from CS2BE. These two products are also apparent on the sequencing gel where 
CS2BE yielded two species. Of the two species present in the sequencing of fragment 3 in 
CS2BE, one is the full length wild type product and the other is the deleted product from 
CS1MA, both shown in Figure 4.3. 
The mutation present in the second allele of CS2BE is a deletion of a single T nucleotide at 
position 3614, initially observed on the direct sequencing of PCR fragment 5 (Figure 4.4). 
Downstream of the deletion, two sequences are apparent which on closer inspection reveal 
the deletion of aT from the middle of two runs of A's. The sequence of this allele is 
shifted by one base giving the shadowing effect seen in the panel a of Figure 4.4 when 
compared to the wild-type in the panel b. 
4.3.2 CSIABR 
CSIABR is a Caucasian patient from Australia with the severe early onset form of 
Cockayne Syndrome (see Table 4.1) and is the offspring of a consanguineous marriage. 
Unxpectedly, the patient possesses heterozygous mutations that are both insertions. The 
first of the insertions is the result of aberrant splicing with 25bp of intron 13 present 
between nucleotide 2677 and 2678, the 3' end of exon 13 (Figure 4.5). The first amino 
acid mutated is residue 866, with a stop codon occurring 10 amino acids downstream. 
The second mutation, also an insertion, consists of 26bp at nucleotide 3686 and is of 
unknown origin (Figure 4.6), with the first amino acid mutated being 1203. This mutation 
has also been seen in patient CS I OBR (Mallery et al., 1998). 
4.3.3 CS1TAN and CS2TAN 
The two Turkish patients CSITAN and CS2TAN are the offspring of consanguineous 
marriages and consequently both carry inactivating mutations in both alleles of the CSB 
gene. CSITAN possesses aC to T transition at nucleotide 2282 illustrated in Figure 4.7b 
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Figure 4.5 Sequence for CS I ABR (panel a) and wild-type (panel b) around the boundary 
of exons 13 and 14. Panel a shows the presence of both the wild-type sequence from panel b 
and the 25bp insertion from intron 13. The gels and sequence read in the 3' to 5' orientation. 
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Figure 4.6 Sequence for CSIABR (panel a) and wild-type (panel b) around position 3686. 
Panel a shows the presence of both the wild-type sequence shown in panel b and the 26bp 
insertion. The gels and sequence read in the 3' to 5' orientation. 
along with the wild-type sequence at this position for comparison. This nucleotide change 
results in the substitution of arginine 735 with an opal stop codon. A similar occurrence is 
observed in patient CS2TAN where the CSB gene carries aG to A transvcrsion at position 
1630 causing the change of Tryptophan 517 to a stop. This mutation is shown in Figure 
4.8 with an A present in the same position as the G in the wild-type sequence. In both of 
the above cases premature termination has occurred, which will result in the production of 
severely truncated and probably non-functional protein. 
4.3.4 25627 
The patient 25627 is the sibling of the sun-sensitive patient 11961 described by Arlett et. 
al., 1978 and assigned as CS group B by Lehmann, 1982. This patient has mutations in 
both alleles of CSB resulting in premature termination of the transcript, as discussed in the 
above section. However, in this case, the patient is a compound heterozygote with a 
different mutation in the allele originating from each parent. The first of the mutations is 
the C to T at nucleotide 2282, previously seen in patient CS 1 TAN. The direct sequencing 
of fragment III, in contrast to that of CSITAN (Figure 4.7a) shows the presence of two 
bands at position 2282, the wild- type C from one allele and the mutant T. The mutation in 
the second allele of 25627 is aC to T at nucleotide 1436 where again direct sequencing of 
the region reveals the presence of both the mutant and wild-type bases, demonstrating the 
heterozygous nature of the patient (Figure 4.9). Both mutations create opal stop codons 
replacing Arginine 735 as explained earlier and Arginine 453 in the case of C1436T. 
4.3.5 CS3TAN and CS1IAF 
Patient CS3TAN is a Turkish patient and CS 1IAF is of Israeli-Jewish origin. Both patients 
are the offspring of consanguineous marriages and consequently possess homozygous 
mutations. In contrast to the mutations discussed earlier, which all result in truncated 
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Figure 4.7 Sequence of patient 25627 and wild-type (panel a) showing the presence of 
bands in lanes I in both the T and C tracks around position 2282. Panel b shows the same 
C to T change this time homozygous, present in patient CS I TAN. 
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Figure 4.8 Sequence ot'wild-type (panel a) and patient C'S2'I'AN (panel b) around position 
1630 showing a homozygous G to A change in the patient. 
proteins, the base changes occurring in the CSI3 gene of patients CS3TAN and CS 1 IAF 
result in amino acid substitutions. CS3TAN has aT to A transition at nucleotide 2630 
located within PCR fragment IV, which on direct sequencing clearly shows the mutant 
base when compared to the wild-type sequence (Figure 4.10). This mutation results in a 
change at residue 851 from tryptophan to arginine. Trp851 is conserved between human, 
mouse and yeast (appendix II) at the edge of helicase domain IV and within a run of 37aa 
with 76% identity to S. cerevisiae Rad26. 
Figure 4.11 illustrates the mutation in CS 1IAF, aG nucleotide at nucleotide 2949 replaces 
T in wild-type cases. This results in a valine to glycine substitution at residue 957. As 
with the W851R mutation in CS3TAN residue 957 is highly conserved and is situated in a 
stretch of 79 as with a yeast: human identity level of 83%. 
4.3.6 CS1BE, CS4BR and CS2BI 
The three patients CS1BE, CS4BR and CS2BI are compound heterozygous for mutations 
in CSB, inheriting one affected allele from each parent. One particularly interesting point 
about these patients is that they share a common mutation despite their diverse origins. 
The common mutation is aC to T at nucleotide 2087, heterozygous in all three patients as 
shown by the example in Figure 4.12, with both aC and aT present in the same position. 
The nucleotide change results in the substitution of arginine 670 with a tryptophan residue. 
Arg670 is located within helicase/ATPase domain III and at the beginning of a stretch of 
34aa that are 92% identical when compared to the corresponding region in the S. cerevisiae 
homologue Rad26 (van Gool et al., 1994). 
The second alleles in each case carry different mutations. CS I BE has a deletion of a single 
A at 3615 from within a run of four identical nucleotides and is illustrated in Figure 4.13. 
This is manifest by the sequence of the mutant allele in this position being offset by one 
base relative to the WT sequence. The deletion of A at 3615 causes a frameshift at amino 
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Figure 4.9 Sequence of patient 25627 (lanes 1) and wild-type (lanes 11 and III) around 
position 1436, showing the presence ol'hoth nucleotides (' and T in the patient lane. 
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Figure 4.10 Sequence of'wild-type (panel a) and patient ('S3"I'AN (panel h) at position 
2630 showing an A in place of'Fin panel h. 
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Figure 4.11 Sequence of wild-type (panel a) and CSI IAF (panel h) around position 
2949 showing the nucleotide change from T to G in CS 11AF. 
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Figure 4.12 Sequence of wild-type (panel a), patient CSI BF- (panel b) and a homozygous 
mutant control (panel c) around position 2087. Panel h shows the presence of both the wild- 
type C and mutant T nucleotides at the same position. 
acid 1179 and ultimately premature termination at residue 1200 as seen previously in 
patient CS2BE. 
Interestingly, the two patients CS 1 BE and CS2BE have single nucleotide deletions at 
different positions which result in the same mutant protein. The mutation in the second 
allele of CS4BR also results in severely truncated protein. In this case, the cause of the 
truncation is aC to T point mutation at nucleotide 629 as demonstrated in Figure 4.14, 
where both the mutant and wild-type sequences at this point are shown. The change results 
in an opal stop codon at amino acid 184 leaving less than a quarter of the gene translated. 
Finally the second mutation in CS2BI, as with the first allele is an amino acid substitution 
mutation. This, as shown in Figure 4.15 is aT nucleotide at position 3204 instead of the 
wild-type C, with both bands being present on the sequencing gel in CS2BI. The mutation 
results in a proline to leucine change at aal042. This change is not situated at a 
particularly highly conserved site, but is within the putative nuclear localisation signal, 
which is likely to be functionally significant. 
The summary of all the mutations found in the CSB cDNA of Cockayne Syndrone patients 
studied is shown in Figure 4.2. This is a diagrammatic representation of the cDNA 
showing the position of the mutations relative to the putative functional domains. 
4.3.7 Polymorphisms 
Three silent polymorphisms have been observed in the CS-B patients studied in this 
chapter two of which do not result in amino acid changes. AG to C change at nucleotide 
214 has been seen in the two patients CS2TAN and CS3TAN, and is located at leucine 45. 
It is possible that other patients within this study possess this polymorphism as this region 
was not sequenced in all the patients. Interestingly, the polymorphism at leucine 45 is the 
same amino acid as that mutated to proline in patient CS2GO (see chapter 5). 
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Figure 4.13 Sequence of wild-type (lanes II) and CS213I (lanes I) around position 3615 
showing that lanes I possess both the wild-type and single A deleted alleles. 
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Figure 4.14 Sequence of wild-type (panel a) and CS4IR (panel b) around position 629 
showing both the wild-type C and the mutant "1' are present in the same position in panel b. 
ACGT 
ýý _ 
IS 
- 
a 
i 
_ý 
ACGT 
b 
Figure 4.15 Sequence of wild-type (panel a) and CS2131 (panel h) around position 3204 
showing both the wild-type C and the mutant T present at the same position in panel h. 
The second polymorphism detected was aC to T change located at nucleotide 2830 and the 
amino acid 917. This change has been checked in all patients here and has been seen in 
three patients, CS 1 TAN, CS 1 BE and CS2131. 
Finally, one polymorphism identified in CS-B patients results in an amino acid substitution 
of asparagine for glycine at residue 399 through aG to A change at nucleotide 1275. It was 
determined that this change was a polymorphism rather than an inactivating mutation for a 
number of reasons. The two patients, CSIIAF and CS4BR, who possess this change each 
have confirmed inactivating mutations. Also, the corresponding amino acid in the mouse 
CSB protein is also asparagine. 
It is also interesting to note one other feature of the CSB cDNA observed during this 
sequencing project. In all cases it was seen that a small proportion of the PCR fragment III 
products were missing exon 8 as determined by sequencing analysis. This is seen in the 
sequencing of all CS-B patients in this study, and in a cDNA sample wild-type for CSB. It 
is likely that the consistent deletion of exon 8 is the result of alternative splicing events. 
4.4 Functional Complementation 
As discussed above, many of the mutations found in CS-B patients result in substantial 
truncations, which almost certainly cause a total loss of function of CSB protein and are 
therefore null alleles. The mutations that fall into this category are the exon deletions, 
single base deletions and the resulting frameshifts and point mutations giving rise to stop 
codons. Point mutations that result in amino acid substitutions cannot with any certainty 
be said to result in non-functional protein. To be certain that amino acid changes found 
were inactivating mutations and not polymorphisms, they were tested for functional 
complementation in the hamster mutant cell line UV61. 
The mis-sense mutations found in Cockayne syndrome patients were introduced into the 
CSB cDNA in pBluescript (generously provided by A. van Gool, Rotterdam) either by 
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subcloning of fragments used in sequence analysis or by site-directed mutagenesis. All 
PCR and mutagenised products were sequenced in entirety to ensure there were no errors. 
The resulting mutant genes were transferred from pBluescript into either of the mammalian 
expression vectors, pCDNA3 as a BamUI fragment in the earlier experiments, or pCl-neo 
as a Xbal fragment in later experiments. 
The CSB cDNA was then transfected into the UV sensitive hamster cell line UV61 from 
the same complementation group as CS-B. Transfectants were selected by their ability to 
grow in medium containing the antibiotic G418. Resistance to G418 is conferred by the 
neo marker carried on the expression vector. Transfected cells were subsequently analysed 
both as a population and as single clones. The population was plated onto three 10cm 
dishes, two were irradiated with three doses of 4 Jm'2 with a one day recovery period 
between each dose and the third was mock irradiated. Several days after the final dose the 
un-irradiated cells formed a confluent monolayer in all experiments. Similarly, irradiated 
UV61 cells transfected with wild type CSB cDNA grew to confluence within a few days. 
In contrast, irradiated cultures from cells containing the mutant cDNAs R670W, W85IR, 
V957G and P1042L failed to show any significant cell growth. This is a strong indication 
that the mutations present result in a protein that is unable to correct the UV sensitive 
phenotype of UV61. Clones showing G418 resistance were picked and expanded for 
further analysis. These clones were checked for the presence of the CSB cDNA by PCR 
amplification from total genomic DNA using all six sets of primers. Two clones for each 
transfected cDNA that were shown to contain the full length cDNA were tested for UV 
survival. Survivals were carried out as a colony forming assay, using four different doses 
of 0,3,6 and 9 Jm 2. The level of survival is shown as the number of colonies on irradiated 
plates expressed as a percentage of those on un-irradiated dishes. 
Figure 4.16 shows the survival curves for the transfection of cDNAs expressed in 
pCDNA3. The wild-type gene when carried in this vector does not restore the survival 
71 
CU 
> 
.Z 
ý N 
ý 0 
0.1 
46 
Dose (Jm-2) 
8 10 
Figure 4.16 Graph illustrating the ability of CSB cDNAs with the mutations R670W (0), 
W851R (0) and V957G (") to correct the UV sensitivity of UV61. All three mutants fail 
to show any survival above that of untransfected UV61 (o).  = AA8, A= WT corrected. 
100 
> 
N 
ý 0 
Dose (Jm-2) 
Figure 4.17 Graph illustrating the inability of CSB cDNA carrying the mutation P1042L 
(") to correct the UV sensitivity of UV61. The mutant fails to show any UV resistance 
above that of untransfected UV61 cells (o).   = AA8, A= WT corrected. 
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levels up to AA8 parental levels. The aim of this study was to determine whether 
mutations inactivated the gene, therefore full correction by the wild-type gene was not 
essential for the purposes of this experiment. The mutants R670W, V957G and W851R 
were cloned into pCDNA3 for transfection and as illustrated in Figure 4.16, all fail to show 
any significant levels of UV resistance above that of the UV61 cells either untransfected or 
carrying empty vector. 
In contrast to the partial complementation seen with CSB carried on pCDNA3, when the 
gene was transfected on the alternative expression vector pCI-neo, it was able to restore 
UV resistance back to AA8 parental levels (Figure 4.17). The last of the mutations tested 
for ability to correct, P1042L failed to show any correction of the UV sensitive phenotype 
of UV61 (Figure 4.17). Therefore, all amino acid substitutions identified in Cockayne 
Syndrome patients as putative causative mutations are unable to correct the UV sensitivity 
of the mutant UV61 hamster cells. It can be concluded that they each result in the 
production of protein in which the DNA repair function has been completely inactivated. 
4.5 Discussion 
The analysis of eleven patients from different backgrounds has revealed a wide variety of 
mutations in the CSB gene. A considerable number of the mutations found in CS-B 
patients resulted in severely truncated products. Several patients possessed two alleles 
affected in this way and it is unlikely that any functional protein is produced. A similar 
result was also found in the patient CS 1 AN analysed by Troelstra et al., 1992. This 
confirms that CSB is not an essential gene, as also demonstrated for the S. cerevisiae 
homologue RAD26 (van Gool et al., 1994). The generation of a CS-B knockout mouse 
(van der Horst et al., 1997) gives further support to the non-essential nature of the gene 
with the mice demonstrating near normal development. 
The results of the analysis carried out on the CS-B patients are summarised in Table 4.2. 
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Of the 14 inactivating mutations identified, five were CG to TA transitions at CpG sites, 
presumably as a result of deamination of 5-methylcytosine. The proportion of such 
transitions is consistent with that found in other human genetic disorders. The other 
mutations present were a further two transitions, two transvcrsions, two occurrences of 
aberrant splicing, two frameshifts and an insertion of unknown origin. The frameshifts 
shown here all result from the deletion of a single nucleotide from within a run of several 
repeated bases. Such deletions are relatively common and generally occur as a result of 
replication slippage. 
The mutations identified did not reveal any regions within the gene that could be termed as 
hotspots. There is, however a tendency for the mutations to be located towards the 3' two 
thirds of the gene, indicated by the slight clustering of the mutations in this region. It can 
therefore be tentatively postulated that mutations occurring in the N-terminal part of the 
gene may have less pronounced effects on function. 
When studying the effects of mutation location on protein function, it is only relevant to 
look at mis-sense mutations. Nonsense mutations and frameshifts result in truncated 
protein and therefore location will only influence protein size. Many of the mis-sense 
mutations are located in or around the helicase/ATPase motifs (Figure 4.2) suggesting that 
these domains are functionally significant. It has been demonstrated that although CSB 
has no detectable helicase activity it does have a strong DNA-dependent ATPase activity 
(Selby and Sancar, 1997; van Gool et al., 1997). These ATPase motifs are present in all 
members of the SWI/SNF superfamily, with many possessing ATPase rather than helicase 
activity. In the case of CSB and other proteins in this family it is more appropriate to refer 
to these domains as ATPase consensus motifs. 
When the patient analysis was first begun, it was hoped that the location and nature of the 
mutations would show some correlation with the clinical features of the patient. Clinically, 
Cockayne Syndrome has been classified into two groups by Lowry, 1982. Patients with 
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type I CS appear normal at birth with symptoms appearing during the first few years. In 
contrast, type II patients exhibit severe symptoms at birth and show little or no physical or 
neurological development. Of the patients studied, nine are type I and two are type II CS. 
When considering the relationship between the nature of mutations and the clinical features 
it is interesting to look at the four patients 25627, CS 1 TAN, CS 1 MA and CS 1 AB R. All 
four patients possess termination codons in both alleles of CSB and are unlikely to produce 
any functional protein. Two of these, CSITAN and 25627 are type I CS and the others 
CS1MA and CSIABR are type H. Therefore, carrying mutations resulting in non- 
functional CSB protein can have a wide variety of symptoms and be classified as either 
form of CS. The variation of clinical symptoms exhibited by CS patients must be a result 
of some other environmental or developmental stimulus. 
The findings of this study have led to a number of hypotheses about important domains and 
regions of the CSB gene. The clustering of the mutations towards the 3' end and the high 
levels of conservation in the central part of the gene prompted a study into the functional 
significance of the N- and C-terminal ends of the protein (chapter 6). Also, the presence of 
a highly acidic region of amino acids and a stretch of glycine residues led us to study the 
effects of removing and replacing these regions (chapter 6). 
With CSB showing significant homology to the yeast SNF2 gene and possessing strong 
ATPase activity, it was thought that the seven helicase/ATPase motifs may prove crucial to 
protein function, particularly with the high number of mutations occurring within this 
region. To this end, a number of mutations were created in this region analagous to 
mutations created in SNF2 (Peterson et. al., 1997) and will be tested for functional 
complementation in UV61 and for activity in in vitro assays (see chapter 7 for greater 
detail). 
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CHAPTER 5 CS2GO AND CS3GO 
5.1 Introduction 
During the study of the mutations in the CS13 gene of Cockayne Syndrome patients, the 
siblings CS2G0 and CS3GO proved to be a more interesting and complex case than the 
other patients studied. They are a brother and sister of Scandinavian origin and are the 
offspring of unaffected parents who are not known to be related. 
Homozygous mutations result from the same affected allele being inherited from each 
parent, i. e. the alleles are of common ancestral origin. Therefore, when such mutations 
occur the parents of the affected patient are often related and the mutation has arisen in an 
earlier generation of the family to which they both belong. In contrast, compound 
heterozygous mutations are the result of inheriting a different affected allele from each 
parent. The two mutant alleles are likely to be from different origins arising as new 
mutations either in the patient or within earlier generations of each family. The parents of 
patients in these cases are often unrelated and have separate genealogy. 
The siblings studied here carry compound heterozygous changes and it was anticipated that 
the pattern of mutations identified in both the brother and sister would be identical. Since 
the parents are unaffected, presumably carrying only one affected allele each, to produce 
affected offspring the child must inherit the one affected allele from each parent. However, 
the siblings presented here do not show the expected pattern of mutations. 
5.2 Materials and methods 
For the main part of this study, the same techniques of RNA extraction, RT-PCR and direct 
sequencing were employed as outlined in chapter 4 (section 4.2). In addition to the 
standard techniques a PCR and cloning analysis was carried out. To determine the allelic 
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origin of mutations occurring at the C"terminal end of the gene PCR fragments V and VI 
were amplified in one piece and cloned into T vector. The resulting clones were sequenced 
by standard Sequenase sequencing of ssDNA to determine presence of mutations in the 
different alleles. PCR product I was also cloned and sequenced using the T vector system 
to confirm the presence of a possible mutation. 
5.3 Results 
The first of the siblings to be sequenced was the brother CS2GO, yielding five amino acid 
changes. Initially, two mis-sense mutations were identified, the first of which had been 
seen previously in the patient CS3TAN as described in chapter 4. The mutation is aT to A 
at nucleotide 2630 and is shown in figure 5.1, seen as heterozygous in this patient, 
compared to the wild-type sequence, and that of the homozygous CS3TAN. This results in 
the substitution of tryptophan 851 with an arginine and is located at the edge of helicase 
domain IV within 37 aas showing 76% identity to Rad26. 
The second mutation found in CS2GO was aC to T transition at nucleotide 213, the most 
N-terminal change seen to date in CSB. The mutation is heterozygous and was only just 
visible on the sequencing gel. To confirm this observation, PCR fragment I was cloned 
into T vector and subsequent clones were analysed for presence of the mutation. Both 
wild-type and mutant clones were observed and figure 5.2 shows the sequencing of one 
clone of each, confirming the presence and heterozygosity of C213T. This change results 
in a leucine to proline change at residue 45. Although the N-terminus of the protein is not 
particularly well conserved (appendix II), the introduction of a proline residue is likely to 
result in conformational changes in the protein. 
Previously when two potentially inactivating mutations have been found in a CS-B patient, 
further sequence analysis has not been carried out. However, because of the unusual 
extreme N-terminal position of the L45P mutation, it was decided that sequencing of the 
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Figure 5.1 Sequence of wild-type (panel a) and patient CS2GO around position 2630 
showing the presence of both the wild-type 'I' and mutant A nucleotides at the same 
position in panel b. 
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Figure 5.2 Sequence of a wild-type (panel h) and a mutant (panel a) clone around position 
213 showing both alleles from patient ('S260. The wild-type has aC and the mutant a 'I' at 
nucleotide 213. 
rest of the cDNA was necessary. This full sequence revealed three additional amino acid 
substitutions that occur in the C-terminal third of the gene. 
The first of the three new mutations was a heterozygous A to G change at nucleotide 3368, 
compared to the wild-type sequence from the same region (Figure 5.3). This change 
results in a valine residue instead of methionine at amino acid 1097, a conservative change 
situated within a relatively poorly conserved region of the protein. Figure 5.4 shows the 
second of the mutations which appears to be homozygous and is also an A to G change, 
this time at 4317. Again, the amino acid change is fairly conservative being a glutamine to 
arginine at residue 1413 and is within the less well conserved C-terminus. 
The final mutation observed in CS2G0 is an A to G at nucleotide 3716 and can be seen 
clearly as heterozygous on sequencing of this region when compared to the wild-type 
(Figure 5.5). The A3716G change results in the substitution of arginine 1213 with a 
glycine residue. Although the overall region in not exceptionally well conserved, the 
precise residue is retained between human and mouse, although not present in yeast, and 
the amino acid change is the most severe of the three observed. 
Because of the large number of mutations observed in CS2GO, it was decided to sequence 
the CSB cDNA in the sister of this patient, CS3GO. Initially the cDNA was checked for 
the presence of the first two mutations found in CS2GO, W851 R and L45P. However, it 
was surprisingly found that neither of these changes was apparent in the sister. The sister 
did possess the three mutations M1097V, R1213G and Q1413R, suggesting that these 
mutations are located on a single allele which is common to both siblings. It was also 
interesting to find that these three changes appeared to be homozygous in CS3GO (seen in 
Figures 5.3,5.4 and 5.5). 
The mutation in the second allele of CS3G0 is a C-terminal deletion. The deletion 
originates at nucleotide 3858 and stretches to 4563, which is beyond the end of the open 
reading frame. Figure 5.6 shows the sequence obtained from direct sequencing of fragment 
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Figure 5.3 Sequence of wild-type (panel a) and patients C'S2GO (panel h) and C'S3(ºO 
(panel c) around position 3368. CS3GO possesses a mutant G nucleotide in the place of 
the wild-type A, whilst panel b shows the presence of both mutant and wild-type alleles 
in CS2GO. 
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Figure 5.4 Sequence of wild-type (panel a) and mutant (panel h) around position 4317. 
Panel b shows patients CS2GO (lanes I) and ('S3G0 (lanes II) who possess aG in the 
place of the wild-type A nucleotide at 4317. 
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Figure 5.5 Sequence of wild-type (panel a) and patients CS2GO (panel h) and ('S3GO 
(panel c) around position 3716. Panel c shows CS3GO to have a mutant G nucleotide in 
place of the wild-type A, whilst panel b shows the presence of both the wild-type and 
mutant alleles in CS2GO. 
ACGT 
I 
a 
I 
+ ACTAAAAAAC 
TTTGCGAAAA 
b 
Figure 5.6 Sequence of wild-type (panel a) and patient ('S3(ßO (panel h) around position 
4561. The marked region in panel b shows the presence of both the wild-type and deleted 
alleles. The mutant sequence is that of nucleotide 3858 to the 5' end of' P('R fragment 
six(primer VIB-bio) reading 3' to 5'. 
ACGT 
VI using the reverse primer W4679 located at nucleotides 4696-4679. The start of the 
sequence is normal, then at 4653 an alternative sequence appears, which reads 3' to 5' from 
3858. The result of this is, in effect a frameshift with the normal termination codon 
removed along with the amino acids from residue 1290 downstream, causing 
the 
translation to terminate within the 3' un-translated region. 
It is interesting that nucleotide 3858 is also the 5' boundary of exon 18, making 
it possible 
that the deletion is the result of a splice abnormality originating at the 5' end of exon 
18: 
AAAAATCAGTTG GCGTGC... ........ AATGGAAGTTG 
G CTGACT 
Underlined are the boundaries, 3858 and 4653 of the deletion and bold indicates the repeated sequence. 
It is however more likely to be due to polymerase slippage with a repeat of six nucleotides 
occurring at each end of the deletion. Deleting such a large portion of CSB is very likely to 
result in a non-functional protein. 
It is important to note that observations of homo- and heterozygosity are based on direct 
sequencing of defined PCR fragments. However, the deletion at the C-terminus of one 
allele of CS3GO encompasses the antisense primer for fragment V(4253 to 4230), so 
amplification of this fragment includes only the undeleted allele. It cannot therefore be 
concluded that the apparent homozygosity of the changes A3368G and A3716G reflect the 
situation in the cDNA, they could be either homo- or heterozygous. In contrast, A4317G 
must be hemizygous, since this residue is contained within the deletion. 
To determine whether the mutations A3368G and A3716G are present in both alleles of 
each patient, the cDNA was amplified using the sense primer for fragment V and the 
antisense primer for fragment VI. This yields a fragment of approximately two kilobases, 
which was cloned into aT vector and subsequent clones sequenced to determine the 
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presence or absence of the two mutations. The sequencing revealed clones possessing 
either both the wild-type or both mutant sequences demonstrating that the second allele is 
wild-type at these positions, and that these mutations are in fact heterozygous. 
5.4 Functional Analysis 
With the large number of mutations present in these two patients it was important to 
determine which were the inactivating mutations in each allele. The alleles unique to each 
patient carry mutations that are very likely inactivating, the deletion in CS3GO and 
W851R in CS2GO, shown to be inactivating for CS3TAN in chapter 4. However in the 
case of the first allele of CS2GO one problem remains, the presence of L45P, which might 
be expected to result in inactive protein. To determine the effect of L45P and to discover 
the inactivating mutation in the common allele it was necessary to perform a functional 
analysis of these changes. 
The two mutations in allele one of CS2GO were created in pCDNA3 and transfected into 
UV61 as described in chapter 2. As noted before the wild-type gene carried on this vector 
is unable to fully correct the UV sensitivity of the hamster cells. Figure 5.7 shows the 
survival curves generated for wild-type, L45P and W851R cDNAs in clones of UV61. 
This clearly shows that L45P has no effect on the DNA repair function of CSB since the 
survival is similar to that of cells carrying wild-type eDNA. In contrast as seen previously, 
the W851R mutation destroys the ability of the eDNA to correct. 
The three mutations carried on the common allele were each create in pCI-neo and 
transfected into UV61 cells along with a wild-type. Clones generated from the transfection 
of eDNA with the Q1413R change produced the survival curve shown in figure 5.8. The 
wild-type transfectants correct the UV sensitive defect fully, as do the transfectants 
carrying cDNAs with the mutation Q1413R. The other two mutations demonstrate a far 
less clear cut result with neither eDNA able to correct the UV sensitivity of UV61 fully. 
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Figure 5.7 Graph illustrating the ability of CSB cDNAs with the mutations W851 R (+) or 
L45P (A) to correct the UV sensitivity of UV61. W851R fails to show any survival above 
that of untransfected UV61 cells (o), but L45P restore survival to the same level as wild- 
type cDNA (A).  = AA8. 
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Figure 5.8 Graph illustrating the ability of CSB cDNA carrying the mutation Q1413R (0) 
to correct the UV sensitivity of UV61 (0). The cDNA is able to restore UV resistance to 
the same levels as WT cDNA (A), back to that of the parental AA8 cells (a). 
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Figure 5.9 Graph illustrating the ability of CSB cDNA with the mutation R1213G to 
correct the UV sensitivity of UV61 (0). The mutant clones vary in their ability to correct, 
but both fail to correct to the same extent as WT cDNA (A).  = AA8, "= clone 2, 
Q= clone 10. 
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Figure 5.10 Graph illustrating the ability of CSB cDNA with the mutation M 1097V to 
correct the UV sensitivity of UV61 (o). The mutant clones vary in their ability to correct, 
but all fail to correct to the same extent as WT cDNA (A).  = AA8, "= clone 1, 
o= clone 4, f= clone 5. 
Two clones were analysed that carried the R1213G mutation, of which one showed no 
correction above UV61 levels, and the other was intermediate (Figure 5.9). Three clones 
carrying the mutation M1097V were also analysed for survival and both of these gave 
intermediate levels of correction (Figure 5.10). It is difficult to determine whether either or 
both mutations are responsible for the CSI3 phenotype of the patients CS2G0 and CS3GO. 
5.5 Discussion 
The siblings CS2GO and CS3GO have presented an interesting case, both through the 
spectrum of mutations observed and the presence of three different mutant alleles. The 
brother and sister possess one common allele, presumably inherited from the one parent. 
Therefore the other two alleles should be inherited from the second parent, who 
theoretically has mutations in both alleles. However, neither parent is known to be affected 
with CS, so it must be concluded that either one of the siblings inherited the normal allele 
from one parent and a new mutation that has occurred in that child. Alternatively, the two 
siblings might have different biological fathers. The most conclusive way to determine 
this would be to screen the parents for the mutations observed in the children, to determine 
their origin. A request for material from the parents has been made, but currently none is 
available. 
The patients CS2GO and CS3GO possess several different mutations, one deletion and five 
mis-sense mutations (shown in Figure 5.11). The mutations in the common allele 
M1097V, R1213G and Q1413R were tested for functional complementation in hamster 
cells to determine which of the three is responsible for the CS phenotype. The data 
obtained from the complementation analysis is inconclusive as to which mutation is 
phenotypically significant. It is clear that the Q1413R change does not affect protein 
function, as the cDNA with this mutation is able to restore the UV resistance of UV61 cells 
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back up to wild-type levels. However, neither of the other two mutations is clearly 
inactivating or able to correct. 
These three mutations occur together in two other patients, CS8BR and CS7TAN (analysed 
by our colleagues in Pavia), unrelated to each other and the patients studied here (Mallory 
et al., 1998). It is therefore possible that these mutations comprise a single haplotype or act 
additively. Alternatively it is possible that either mutation alone is inactivating and that the 
intermediate levels observed are a result of over-expression. Since the levels of expression 
of CSB in the transfected cells are likely to be higher than would occur in vivo, it is 
reasonable to suggest that the cDNAs might not correct if expressed at endogenous levels. 
Further analysis of these mutations is required to determine which of the above theories is 
most likely. Firstly, more clones from each transfection need to be analysed to check 
whether the intermediate survivals are reproducible. Western blots on cell extracts from 
these clones should then be used to determine the levels of CSB present and whether there 
is a correlation between the survival and protein levels. Secondly, both mutations need to 
be introduced into the same construct and transfected into cells. Clones derived from this 
transfection would then show whether the levels of survival from clones with both 
mutations differs from that of each mutation alone. 
The mutations demonstrated here have provided some insight into the functionally 
significant regions of the gene. During the earlier stages of the sequencing study it had 
been noted that mis-sense mutations clustered around the helicase/ATPase domains in the 
middle of the gene. It was postulated at this stage that the N- and C-terminal ends of the 
gene could be deleted without significantly affecting the protein function. The deletion 
seen in CS3GO which removes the C-terminal 233 amino acids is the only mutation in this 
allele and is therefore inactivating. This shows that removal of the C-terminus of CSB 
results in non-functional protein. The deletion seen here is quite large and would be 
expected to affect the protein, so smaller deletions are analysed for their effect on DNA 
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repair function in chapter 6. The next chapter also investigates the effects on N-tcnninal 
deletions on the DNA repair function of CSB. The change L45P gives us some insight as 
to what these effects might be, through its ability to correct the UV sensitivity of UV61. 
The introduction of a proline residue in the place of leucine might be expected to result in 
conformational changes in the protein because of the structural kink resulting from the 
introduction of this amino acid. This suggests that conformational changes in the N- 
terminus of CSB might not be significant for the DNA repair function, and that the region 
may not be essential. 
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CHAPTER 6 DELETION ANALYSIS 
6.1 Introduction 
Analysis of mutations in the CSB cDNA of patients with Cockayne Syndrome has provided 
information about the gene and important regions. Although a few sites were mutated in 
unrelated individuals and may therefore have arisen independently, there are no dramatic 
hotspots for mutation. In an attempt to discover further structure-function information, a 
series of deletions were created to determine whether certain regions of the gene were 
essential for function. 
The majority of inactivating mis-sense mutations were clustered in the central two thirds of 
the gene, which is also the location of the seven helicase/ATPase domains. It was thought 
that the N- and C- terminal ends of the gene may not be required for the production of 
active protein. Information has been gained from the sequence analysis study through the 
L45P mutation and the 3858-4653 deletion. The L45P change does not have any effect on 
the DNA repair function of CSB, which is surprising as proline residues often result in 
conformational changes. However the deletion that removes the C-terminal end of the 
cDNA downstream of the 5' junction of exon 18 results in inactive protein. In order to 
investigate the involvement of the termini in repair function, two deletions were created 
each at the C- and N-terminal ends of the gene. 
Two interesting domains were identified close to the N-terminus of the protein (Troelstra et 
al., 1992). Firstly, a stretch of six glycine residues and a glutamic acid residue at amino 
acids 440 to 446. Glycine residues are the smallest and uncharged amino acid residues 
and can often be spacer regions between highly charged or polar groups of residues. 
Secondly, at amino acids 356 to 395 is a region rich in acidic residues, which in particular 
contains seven consecutive glutamates (amino acids 378-384). Substantial concentration 
of negative charges might be expected to be important for protein function. To test 
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whether these domains really are important, they have been removed as part of this study 
and the deleted cDNAs checked for their ability to correct the UV sensitive phenotype of 
UV61 hamster cells. 
6.2 Construction of deleted cDNAs 
Six deletions were created in the CS13 eDNA to carry out a structure-function analysis, and 
positions and lengths of these deletion are illustrated in figure 6.1. The sequences of all the 
primers used to create these constructs by PCR and site-directed mutagenesis are shown in 
Appendix I. 
6.2.1 C-terminal deletions 
Two C-terminal deletions were created removing 111 and 26 amino acids respectively. 
The smaller of these was created by site-directed mutagenesis of nucleotide 4481, replacing 
the wild-type G with an A. Therefore, a stop codon is introduced at amino acid 1468 in the 
position of the wild-type glutamic acid residue, resulting in the truncated cDNA I shown in 
figure 6.1, in which the C-terminal 26 amino acids are missing. 
The larger C-terminal deletion was created by a restriction digestion method to give the 
deleted cDNA II in figure 6.1. The cDNA cloned into pcDNA3 was digested with the 
restriction enzyme Apal which cuts at nucleotide 4227 in CSB and in the multiple cloning 
site of pcDNA3,3' of the insert. This removes the C-terminal 111 amino acids including 
the stop codon and the 3' untranslated region. Termination therefore relies on the presence 
of a stop codon within the vector sequence, which occurs very close to the end of the CSB 
cDNA. 
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Figure 6.1 Diagrammatic representation of ('S13 showing, the putative tünctional domains 
The lines shown below the gene indicate the deleted cDNAs created and tested for 
functional complementation. 
6.2.2 N-terminal deletions 
Two N-terminal deletions were constructed using a PCR and cloning based method. PCR 
primers were designed to amplify the N-terminus of the cDNA, to create the deleted 
constructs III and IV of the lengths illustrated in figure 6.1, missing the first 28 and 137 
amino acids respectively. The forward primer for amplification of the larger clone III was 
designed to cover the methionine residue at amino acid 29, using this as a transcriptional 
start site. To create the larger deletion, the forward PCR primer was designed to 
encompass a base change corresponding to nucleotide 491 which changes the lcucine 
residue at 137 to a methionine, and therefore a start codon. 
The resulting PCR products were cloned into the Invitrogen TA vector and sequenced to 
check for PCR errors. Error-free clones were digested with Sphl at nucleotide 795 and 
Not!, in the polylinker 5' of the insert and cloned into Sphl/Notl digested pcBlsSE6 (Figure 
6.2). This replaces the full length wild-type N-terminal fragment with the newly created 
deletions. The new CSB eDNA constructs were tranferred as Notl/Wzol fragments into 
Notl/Sail digested pCI-neo (Figure 6.2). 
6.2.3 Internal deletions 
Two deletions were created, each removing seven amino acids from the N-terminal third of 
the protein, disrupting either the glycine domain or the acidic rich region. Both deletions 
were created by site-directed mutagenesis of the full length cDNA in the mammalian 
expression vector pCI-neo. The sequences of the primers used for the mutagenesis are 
shown in Appendix I. The first deletion is located within a region of 39 acidic residues 
removing 21 nucleotides from 1211 to 1231 and consequently deleting seven glutamic acid 
residues at 378 to 384. The amino acid sequence of the acidic domain is shown below in 
Figure 6.3. 
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Figure 6.2 The cloning strategy for the creation of N-terminal deletions of CSB cDNA. 
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Figure 6.3 The 39 amino acid sequence of the acidic domain of CSB. The residues 
underlined are the acidic glutamic acid or aspartic acid residues and those in bold are the 
seven glutamic acid residues deleted. 
The second deletion is also of 21 nucleotides this time from 1397 to 1417 removing seven 
glycine residues at amino acids 440-446. The mutageneised cDNAs were sequenced 
through the entire ORF to ensure that there were no polymerase errors. The length and 
position of both the internal deletions described are shown as constructs V and VI 
respectively in figure 6.1. 
All deletion constructs were transfected into the mutant hamster cell line UV61 as 
described in chapter 2. Antibiotic resistant clones were picked and expanded, then checked 
for the presence of the eDNA by PCR amplification in six fragments from total genomic 
DNA. Subsequently, a minimum of two clones from each transfection were analysed for 
UV survival by colony-forming assays. 
6.3 Results 
In total, six deletion constructs were analysed to determine whether removal of parts of the 
gene would affect the ability of the CSB cDNA to correct the UV sensitive phenotype of 
UV61. Initially mixed populations of antibiotic resistant transfected cells were subjected 
to UV-selection as described in chapter 4. Of these six constructs, three failed to show any 
resistance above that of the untransfected cells, whereas the other three appeared to be 
more resistant. 
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6.3.1 C-terminal deletions 
Two C-terminal deletions were created introducing stop codons at residues 1468 and 1383 
that result in truncations of 26 and 111 amino acids respectively. Figure 6.1 shows the 
length of the deleted cDNAs with respect to full length and the hclicasc /ATPase domains. 
Two clones from each deletion were analysed for survival to determine the effects of the 
truncation and to ensure that there was no excessive clonal variation. 
Figure 6.4 shows the survival curves generated for the clones carrying each of the deleted 
cDNAs. The survival curves in all cases are similar to that of the untransfected UV61 cells 
and considerably lower than the levels obtained after transfection with the wild-type. 
Therefore deletion of the C-terminus of the gene, even only 26 amino acids, destroys the 
DNA repair capacity of CSB. 
6.3.2 N-terminal deletions 
N-terminal deletions were created to produce cDNAs starting at amino acids 29 and 137, 
and the relative lengths of these cDNAs compared to the full length can be seen in figure 
6.1. Two clones for each deletion were analysed for survival in a colony forming assay, 
the results of which are shown in figure 6.5. For comparison, the survivals for UV61, the 
parental AA8 and the wild-type corrected cells are also shown. Survival curves for each of 
the clones carrying N-terminally deleted cDNAs show intermediate levels of correction. 
The clones show levels of survival significantly higher than that of the mutant UV61, yet 
do not reach the levels of correction seen with the full length CSB. It is also interesting 
that the larger 137 amino acid deleted cDNA appears to restore more UV resistance to the 
cells that the 28 amino acid deletion. 
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Figure 6.4 Survival curves for clones derived from transfection of UV sensitive UV61 
cells with C-terminally truncated CSB cDNA. Cells transfected with cDNA missing either 
the C-terminal 25 (0) or 110 (4) amino acids fail to show any survival above that of 
untransfected UV61 cells (0).  = AA8, A= WT corrected. 
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Figure 6.5 Survival curves for clones derived from transfection of UV sensitive UV61 
cells with N-terminally truncated CSB cDNA. Cells transfected with cDNA missing either 
the N-terminal 25 or 137 amino acids show survival levels above that of untransfected 
UV61 cells (0), but do not restore the survival to that of WT corrected (A) or parental 
AA8 cells (. ). 0= 25 (clone 1), f= 25 (clone 7), "= 137 (clone 2), o= 137 (clone 3). 
6.3.3 Glycine and acidic domain deletions 
Seven glycine residues and a glutamic acid residue positioned at amino acids 440 to 446, 
and seven glutamic acid residues at 378 to 384 were deleted from the cDNA. The position 
of these deletions relative to other domains within the gene can be seen in figure 6.1. The 
survival curves for the clones analysed from each transfection can be seen in Figures 6.6 
and 6.7 along with the curves for AA8, UV61 and a wild-type transfectant. Removal of the 
glycine domain appears to destroy the DNA repair capacity of CSB. This could either be 
because of the functional significance of these residues, or just through changes caused by 
removal of a portion of the gene. In contrast, the deletion of seven glutamic acid residues 
from the acidic rich region seems to have a varying effect on the ability of the CSB eDNA 
to correct the UV sensitivity of UV61. A rapid survival screen of a mixed population of 
transfected cells suggested that the 01211-1213 eDNA was able to correct the UV 
sensitivity. However, survival curves on clones derived from the transfection showed an 
intermediate and variable sensitivity (Figure 6.7). 
6.4 Discussion 
Deletion analysis of CSB has revealed several interesting features of the protein. 
Removing even 26 amino acids from the C-terminus destroys all ability of the CSB cDNA 
to correct the UV sensitive phenotype of UV61. 
The results are very different for the N-terminal end of the gene where substantial DNA 
repair activity is retained even when 137 amino acids are missing. This demonstrates that 
the N-terminal part of the protein is not essential for this activity of the CSB protein. Its 
necessity for other activities associated with CSB, transcription coupling or DNA 
dependent ATPase activity, is yet to be determined. Interestingly, the 137 amino acid 
deletion appears to correct better than the smaller 28 amino acid deletion. This may be due 
to the expression levels being higher in these clones. Alternatively, the structure may be 
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Figure 6.6 Survival curves for clones derived from transfection of UV sensitive UV61 
cells with CSB cDNA deleted for the seven glutamic acid residues 378-384. Two clones 
(0 and f) fail to restore survival levels above that of untransfected UV61 cells (o). The 
third clone (o) shows some increase in survival, but does not correct to the same extent as 
WTcDNA(A).  =AAS. 
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Figure 6.7 Survival curves for clones derived from transfection of UV sensitive UV61 
cells with CSB cDNA deleted for the glycine domain at residues 440-446. The two clones 
shown (0 and f) fail to restore survival levels above that of untransfected UV61 cells (0). 
 = AA8, A= WT corrected. 
such that the smaller deletion leaves exposed or free tails that result in steric hindrance of 
protein folding or interactions. 
The deletions of the glycine and acidic regions have given very surprising results. The 
removal of the glycine domain results in non-functional protein for the purposes of cell 
survival. Glycine is the smallest amino acid and has no side chains, often occurring in 
regions of flexibility. Therefore, removal of the seven consecutive residues could prevent 
the protein from adopting the correct conformation for activity or protein: protcin 
interactions. Alternatively, it may be that removal of seven amino acids from the gene has 
in itself destroyed the protein structure irrespective of the residues deleted. 
The removal of seven amino acids, in the case of glutamic acid residues from the acidic 
rich region, does not appear to have a particularly dramatic effect on the DNA repair 
function of CSB. The intermediate nature of the clones may be as a result of different 
expression levels. The variation between clones can be presumed to be a result of different 
protein levels, thus this may reflect an ability of the mutant protein to correct when over- 
expressed. Alternatively and less likely, this region may not be absolutely essential for the 
DNA repair activity of CSB and it is still able to carry out substantial repair. This is 
somewhat surprising as acidic regions are often involved in holding together protein 
structures, or are points of contact in protein: protein interactions. Furthermore removal of 
the seven residues will result in a drastic change in the overall charge of this part of the 
protein. Either the necessary interactions are being carried out by other means or domains, 
or sufficient acidic residues remain for the structure or complexes to hold together. 
There is clearly a need for further investigation into functional domains and residues. The 
helicase/ATPase domains are good candidates for essential regions and mutational analysis 
of these motifs will be discussed in chapter 7. 
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CHAPTER 7 GENERAL DISCUSSION 
Lowry et al., 1982 have classified CS into two groups. Type II is the more severe form of 
the disease with symptoms evident at birth and type I is milder with patients appearing 
normal at birth and symptoms becoming apparent during the first few years. 
The aim of this project was to try and identify mutations in the CSi3 gene of patients with 
Cockayne syndrome. It was hoped that the mutations would correlate with the severity of 
the disease, with mutations resulting in severely truncated protein occurring in type II 
patients. Furthermore, a series of deletions were created to determine whether the N- or C- 
terminus of the protein was essential for function. Also, putative functional domains were 
deleted to see whether these regions were indeed functionally significant. 
7.1 Mutational analysis 
The full mutation spectrum identified in CS-B patients is shown in figure 7.1 (see also 
(Mallery et al., 1998)). Mutations resulting in severely truncated product and therefore 
probably no protein, have been identified in both alleles of patients indicating that the gene 
is not essential for viability. This is also the case in mice (van der Horst et al., 1997) and 
the yeast Saccharomyces cerevisiae (Verhage et al., 1996) where knocking out the 
respective CSB homologues does not affect viability. Interestingly, in both cases the 
phenotype is particularly mild when compared to that of CS-B patients. CS-B patients 
exhibit a wide variety of symptoms including UV sensitivity and neurological degeneration 
(see chapter 1 for more detail), and the severity of the disease is such that patients rarely 
survive beyond their teens. In contrast, CSB mice appear almost normal with typical CS 
symptoms occurring only very mildly. 
There is no apparent correlation between the location or nature of the mutation and the 
clinical features, nor are there any particular mutational hotspots. Therefore the site and 
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type of mutation is not sufficient to explain the variation in clinical features. Cockayne 
syndrome is a DNA repair disorder and as such any residual non-repaired damage might 
have an influence on the health of the cells of CS patients. Cells from patients with CS arc 
deficient in the repair of actively transcribed DNA, and it is likely that damage will persist 
within the life-cycle of these cells leading to mutations in other genes. CS cells arc also 
known to have an enhanced mutation frequency in response to UV (Arlett and Harcourt, 
1983). Levels of repair are particularly significant when considering cell types such as 
neurones that are not generally renewed and have a long life span. Cell death as a result of 
non-repaired damage in these cells will have significant phenotypic consequences, 
although the neurological defect in CS patients is dismyclination of neurones rather than 
neurone death as is found in complementation groups A and D of XP. Consequently, 
greater exposure to DNA damaging agents may result in a more severe phenotype. 
A major difference between clinical features in CS patients is the time of onset of the 
disease and the speed of deterioration and there is also great variation in the types of 
symptoms observed. Under these circumstances it is reasonable to predict that the 
environment might influence the stage in development at which the disease becomes 
apparent. For example, the levels of nutrients reaching a foetus may have an effect, since a 
healthy foetus may be better able to tolerate a lack of or mutant CSB. Similarly, if there is 
substantial exposure to DNA damaging agents at an early stage of development, it might be 
expected that the symptoms would be more severe and evident at birth. Under both these 
circumstances, the health of the mother, either through the environment, nutrition or 
through smoking might affect the general health of the CS child and possibly influence the 
severity of the resulting disease. 
In addition to the environmental effects described above, the genetic background of the 
patient may affect the disease severity and symptoms. For example, the efficiency of 
global genome repair or alternative repair pathways may vary between individuals. 
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Therefore the levels of damage persisting is also likely to vary, thereby influencing the 
resulting phenotype. Other genetic factors may also enable or prevent the CS patients from 
tolerating or preventing damage. There may be genes not related to the repair pathways 
that will allow or prevent transcription and replication to bypass DNA lesions under certain 
conditions. Therefore, mutation of these genes might upset the balance of the cell and 
create a situation whereby there is too much or little damage remaining in the genome. 
Interestingly there are two siblings, GM10903 and GM10905 who present a classical XP 
phenotype, but have been shown to belong to the CS-B complementation group (Itoh et al., 
1996). The mutation present in these patients is the same as those found in the patients 
CS 1 TAN and in one allele of 25627 from this study (Figure 7.1) who have a classic CS 
type I phenotype (S. Colella, M. Stefanini, personal communication). An identical 
mutation can therefore result in a wide variety of clinical features, with effects extending 
beyond the severity of the CS symptoms. In this case it is very difficult to predict what has 
caused this improbable phenotype, since insufficient information is available about the 
exact function of CSB and the XP gene products during development. 
XP-G patients with XP alone and XP combined with CS have been studied with reference 
to their involvement in the transcription-coupled repair of oxidative damage (Cooper et al., 
1997). Only cells from patients exhibiting CS symptoms are defective in the TCR of 
thymine glycols. Therefore, a defect in preferential repair of oxidative damage correlates 
with the presence of the CS phenotype in XP-G patients. It is possible that persistence of 
un-repaired oxidative damage may result in some of the symptoms not related to a NCR 
defect. Further investigation into the cause of XP with CS rather than XP alone in patients, 
when the mutations occur in the same gene may also shed light on the genotype phenotype 
relationship of CS-B. 
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Although the mutation spectrum did not show any hotspots in the gene or any correlation 
with the clinical features, it did suggest a number of possibilities as to important domains, 
and regions that may not be absolutely necessary for function. 
The leucine to proline mutation at amino acid 45 does not affect the ability of the protein to 
correct the UV sensitive phenotype of UV61 CIIO cells. A leucine to prolinc change is 
likely to result in conformational changes due to the unique nature of the amino acid. For 
example if this region of the protein is a-helical in structure the disruption is likely to be 
greater since proline is the only amino acid whose side chain does not project out from the 
helix. Therefore, the ring structure of the prolinc side chain will cause stcric hindrance to 
the a-helical structure and will usually result in a significant bend in the helix. It can be 
predicted that the N-terminus of the protein can be disrupted at least to some extent without 
loss of function. In contrast, the 3' end of the gene appears to be essential, since the 
deletion of the C-terminal 233 amino acids in patient CS3GO results in a complete loss of 
function, as measured by its ability to complement the UV sensitivity of UV61. The 
majority of the mutations and more importantly the missense mutations are located in the 
C-terminal two-thirds of the gene, suggesting that this region and particularly the central 
region may be functionally the most important. This is also the region in which the 
putative functional ATPase, glycine, and acidic rich domains arc located. 
Such observations led to the work on deletion analysis of the gene to study the effects of 
deleting both the C- and N-termini of the protein, and two putative functional domains, an 
acidic rich region and a stretch of glycine residues. 
In agreement with the prediction from the C-terminal truncation in the patient CS3GO, 
deletion of the C-terminal 26 amino acids of CSB totally destroys the ability of the eDNA 
to complement UV61. Also, the data obtained from the deletion of the N-terminal end of 
CSB cDNA supports the idea that deleted eDNA are able to at least, partially complement 
the UV sensitivity of UV61 cells. Clones carrying an intact eDNA as judged by PCR 
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correct to some extent, but there is considerable variation between clones, with deletion of 
the 488 N-terminal residues resulting in greater levels of survival than clones missing the 
N-terminal 154 residues. There are a number of possible explanations both for the larger 
deletion correcting to a greater extent than the smaller, and for the clonal variation. 
Firstly, the structure of the CSB protein may be such that deletion of a smaller part of the 
N-terminus disrupts the protein structure. This disruption may result in a free tail that 
could cause steric hindrance to protein: protein or protein: DNA interactions. Since the 
ATPase activity of CSB is dependent on DNA (Citterio ct al., 1998; Selby and Sancar, 
1997) it is likely that a good interaction is necessary for enzymatic activity. Similarly, 
CSB resides within a large molecular weight complex (van Gool et al., 1997) and any 
disruption of interactions between proteins of the complex is likely to at least, partially, 
disrupt the activity of the complex in some or all of its functions. Therefore, if the deletion 
affects such interactions, this could explain why the larger deletion might correct more 
effectively, since the free tail would be missing or shorter. 
An alternative reason for the differences in levels of survival in the clones bearing N- 
terminal deletions may be differences in levels of protein expression. If the levels of CSB 
are regulated in some way, it is possible that this regulation might be facilitated by the N- 
terminus of the protein. Alternatively the expression levels obtained from this vector may 
be variable and the levels may be such that interactions or activities that occur may be 
dependent on the amount of protein present. 
With either of the above, it is possible that higher levels of expression might be able to 
counteract the effects of the deletions. The N-terminal deletions may be sub-optimal in 
their ability to form interactions, and therefore greater protein levels may increase the 
chances of such interactions occurring. 
Further mutational analysis has investigated the functional significance of the glycine and 
acid rich regions within the gene. The region of seven consecutive glycinc residues 
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appears necessary for function, since deletion of these residues results in a eDNA that 
is 
unable to complement the UV sensitivity of UV61 (Figure 6.6). However, several 
interpretations of these data are possible. For example, deletion of seven amino acids 
from 
the protein might result in the three dimensional structure of the protein being disrupted. 
Furthermore, glycine residues are the most flexible amino acids and allow unusual 
conformations through the lack of a side chain. It may therefore be possible that a change 
in these residues from the original glycine might alter the protein structure considerably. 
Hence, the deletion may well result in the disruption of a functional protein structure rather 
than of an activity, either through the loss of the glycine residues or seven amino acids. 
The same may be true for the deletion of seven glutamic acid residues from the acidic rich 
region, although the inactivating nature of this deletion is less clear (Figure 6.7). There 
appears to be some level of correction from the truncated protein, and this suggests that the 
secondary structure of the protein is not completely disrupted. The acidic domain stretches 
over thirty-nine amino acids, of which twenty-two arc either glutamic acid or aspartic acid 
residues (Figure 6.3). The functional activity partially remains with respect to correction 
of the UV sensitivity of UV61, suggesting that the remaining acidic residues are at least to 
some extent able to carry out the necessary role required for NER. Since acidic residues 
are commonly found in regions of interaction between proteins, it is feasible that a smaller 
acidic domain when over-expressed is capable of forming such interactions, albeit less 
efficiently. 
7.2 Western blots 
To determine the inactivating nature of base substitution mutations found in CS-B patients, 
the changes were created in an expression vector and transfcctcd into UV61 hamster cells 
as described in chapter 4. The presence of the transfcctcd cDNA in the genome of the 
recipient cell line was determined by PCR from genomic DNA. However, presence of the 
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DNA does not necessarily result in expression of the protein either because of 
rearrangement in the transfected vector or rapid degradation of protein produced, 
particularly if it is mutant. The results of several transfections with mutant cDNAs have 
shown considerable clonal variation in the ability to rescue the UV sensitivity of UV61. 
As discussed earlier there are several theories that may explain such variation, including 
differences in the levels of human CSB protein expressed. To determine whether this was 
the case and to confirm that transfected cDNAs were being expressed in the hamster cells, 
Western blots were carried out. 
Early attempts were carried out using a CSB antibody raised against a C-terminal peptide 
(van Gool et al., 1997) and detected using the ECL system. Later, an alkaline phosphatase 
conjugated secondary antibody was used for detection of CSB antibody bound to the filter. 
Efforts were also made to detect protein in cells transfected with HA tagged cDNA 
constructs using a monoclonal HA antibody. Several different methods have also been 
employed for preparation of extracts including cell fractionation, freeze-thawing, detergent 
lysis, sonication in PBS and boiling in SDS sample buffer. 
Early experiments failed to show any significant bands of around the correct size, and in 
the absence of a positive control, it was difficult to determine whether any bands seen were 
in fact CSB. A positive control was obtained through expression experiments in the 
baculovirus system, with a partially purified tagged recombinant protein giving a very 
strong signal on Western blots (see section 7.3.2). Decreasing amounts of protein could 
then be used to determine the sensitivity of the different antibodies and detection systems. 
With ECL detection, monoclonal HA antibodies (Figure 7.2a), either commercially 
obtained or purified from 12CA5 hybridomas (Figure 7.2b) were more sensitive than the 
CSB specific antibody. However, when using alkaline phosphatase detection, the 
sensitivity of CSB was equal to that of the HA (Figure 7.2c). Since many of the earlier 
transfections were performed using non-tagged constructs, it was decided to proceed with 
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Figure 7.2 Western blots of CSB positive control (obtained from expression of recombinant 
protein through baculovirus) to test the sensitivity of a commercially bought monoclonal I IA 
antibody (panel a), monoclonal HA purified from 12CA5 hybridomas (panel h) and polyclonal 
CSB antibody (panel c). All three antibodies produce a good signal with 5 microlitres of protein. 
the CSB antibody. Whole cell extracts of corrected hamster cell lines failed to produce a 
definite CSB band, with the extracts made either by sonication in PBS or freeze-thawing. 
In order to concentrate the CSB protein in proportion to other proteins in the cell, nuclear 
preparations and extracts were made. Again, these extracts failed to show CSI3 specific 
bands. 
Whole cell extracts were made in a buffer, routinely used as a first step in immuno- 
precipitations, containing a cocktail of protease inhibitors and detergent to lyse the cells 
and nuclei. This time there were bands, which were slightly smaller than the positive 
control in lanes for extracts from cells transfected with both wild-type and mutant cDNAs 
(Figure 7.3). However, when extracts were made by the same method for non-transfected 
UV61 cells, the resulting Western blot produced the same band as present in the 
transfected cells (Figure 7.4). Therefore, it is likely that the band seen in these extracts is 
either hamster CSB or a non-specific protein that is recognised by the antibody. 
To check whether the lack of detection of human CSB in the transfected UV61 cells was a 
detection or blotting problem, a blot containing human nuclear extracts was obtained to try 
and detect the human protein in human cells. Native levels of human CSB were easily 
visible with CSB antibody and alkaline phosphatase detection (Figure 7.5). This blotting 
and extraction procedure is highly reproducible, with CSB detectable in several 
independent extracts from a wild-type cell line. The reason for the lack of detection of 
human CSB over-expressed in hamster cells is not clear, but it severely hindered 
interpretations of some of the transfection experiments. 
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Figure 7.3 Western blot with varying amounts ol'cell extracts from cells transI'ectedI Mth a 
wild-type or mutant CSB cDNA. Detection was with polyclonal CSL3 antibody and alkaline 
phosphatase. 
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Figure 7.4 Western blot with varying amounts of cell extract from untransfkcted UV(I cells 
and cells transfected with a mutant CSB cDNA. 
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Figure 7.5 Western blot of cell fractionation of cells wild-tvlw and mutant tier (", ti'/t. 
demonstrating that CSB is detectable at native levels in transformed human fibroblasts. 
The lack of protein in the cells null for ('SB indicates that the hand present tier the wild-t 
cells is CSB. 
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7.3 Future Work 
7.3.1 Functional analysis of the acidic and glycine domains 
As discussed in section 7.1, deletion of a number of amino acids from a protein may result 
in loss of function, irrespective of the functional significance of the deleted fragment. 
Therefore, it is important to confirm whether the information gained from deletion of the 
acidic and glycine domains, is a result of loss of their specific function. For this reason it 
is proposed to repeat the experiments, this time replacing the residues rather than deleting 
them. In the case of the acidic rich region, this spans 39 amino acids and contains seven 
consecutive glutamic acid residues. These seven residues will be replaced by glutamine 
residues. This should not disrupt the overall protein structure of CSB through stcric 
hindrance, since the structure of glutamine is virtually identical to that of glutamic acid, 
with the acidic group being replaced by its amide. Therefore, replacement of glutamic acid 
with glutamine should only change the acidic nature of the seven residues. 
The glycine domain is a stretch of seven consecutive glycinc residues that may give a 
region of flexibility within the protein structure. The idea of future experiments is to 
replace alternate residues with serines. Serine is also a small amino acid and like glycine is 
un-charged, and as such is unlikely to cause any steric hindrance or disruption of structure. 
This will determine whether the presence of the glycine residues in this region is 
functionally significant. 
In both cases, the mutant cDNAs will be tested for functional complementation of the UV 
sensitive phenotype of the CHO mutant UV61. Furthermore, recombinant protein derived 
from the deletion constructs and the corresponding mutant constructs will be tested for 
ATPase and DNA binding activity through expression and purification from the 
baculovirus expression system (see below). 
98 
7.3.2 Expression and purification of recombinant proteins 
The baculovirus expression system allows the production of high levels of recombinant 
protein. The main advantages of this system over expression in E. coli or yeast is that 
mammalian proteins are more likely to be soluble and the insect cells in which the proteins 
are expressed are able to carry out a similar level of post-translational modification to that 
seen in mammalian cells. 
For the purposes of the CSB protein, the BAC-TO-BAC baculovirus expression system 
from GibcoBRL is being used with infection of Spodoptera frugiperda (Sf9) cells under 
serum-free conditions in suspension culture. The CSB eDNA is expressed in the pFastBac 
vector and possesses two fusion tags, a His tag at the 3' end and HA at the 5' end. The 
protein will be purified in three stages as determined by van Gool et. at., 1997. The first 
step of purification takes advantage of the DNA binding capacity of CSB by running cell 
extract through a heparin column to eliminate proteins that do not bind DNA from the 
sample. The fractions eluted from the heparin column are then purified on a nickel column 
that binds the His tag. The partially purified CSB is finally bound to monoclonal HA 
antibody and run down a protein G column. The protein G resin is able to bind 
immunoglobulins and will therefore bind the HA antibody now attached to CSB. Purified 
CSB can be eluted from the column with an HA peptide. Purified CSB will be analysed 
for DNA-dependent ATPase activity and DNA binding activity, in an attempt to identify 
regions of the protein required for these functions. 
7.3.3 SNF2-like mutations 
As described in chapter 1, CSB is a member of the SWI/SNF family of DNA-dependent 
ATPases, and as such possesses the seven characteristic domains. Peterson et. al. created a 
series of mutations around the ATPase domains of S cerevisiae SNF2, some resulting in 
loss of activity and others dominant negative activity (for more detail see Richmond and 
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Figure 7.6 Diagrammatic representation of CSB showing the position and nature of the 
SNF2-like mutations created for functional complementation studies and protein assays. 
03 = helicase domains 
Mutation in CSB Mutation in SNF2 Phenotype in SNF2 
K 538 A K 798 A + Dominant negative 
DE 646,7 AA DE 894,5 AA No activity 
R 745 A R 994 A ++ Dominant negative 
R 915 A R 1164 A Low activity 
R 945 K R 1196 K ++ Dominant negative 
Table 7.1 The nature of the mutations created in CSB and the analagous mutations in 
SNF2 from which they were derived. Also shown is the phenotype observed in the SNF2 
mutants in yeast. 
Figure 7.7 Survival curves showing the effect transfection of CSi3 mutant cDNAs has on 
the repair ability of wild-type AA8 cells. The cDNA deleted for seven glutamic acid residues 
has no effect (0) on AA8 survival, whereas the K538A mutation results in survival levels (o) 
just below those of AA8 ( ). 
Peterson, 1996). Analagous mutations have been created in the CS1i cDNA, the mutations 
and the respective SNF2 mutations are shown in Figure 7.6 and Table 7.1. The mutant 
cDNAs created will initially be transfected into UV61 and AA8 cells to determine their 
ability to correct or induce UV sensitivity in these cell lines. 
The mutations K538A and R745A have been transfcctcd into AA8 to determine potential 
dominant negative activity. Preliminary data indicates that K538A results in some 
dominant negative activity with the UV survival showing levels consistently below that of 
untransfected AA8 cells (figure 7.7). In contrast the second mutant transfcctcd, R745A has 
no effect on the ability of AA8 cells to withstand UV irradiation. A similar response for 
both mutations when in SNF2 is seen in S. ccrevisiae (Richmond and Peterson, 1996). 
Dominant negative activity is commonly seen in proteins that function as part of a 
complex, where the mutant protein competes with the wild-type to form the complex and 
any that possess the mutant will be non-functional. The dominant negative activity could 
also result from the complex or CSB alone blocking the access of the repair enzymes to a 
lesion, since it has been predicted that the ATPasc activity may help to move a stalled 
RNA Polymerase from the lesion site (see below). 
To further characterise the nature of the mutant protein and determine how the dominant 
negative effect might come about, the proteins will be purified and tested for ATPase and 
DNA binding activity. 
7.4 Models for the Role of CSB 
There are a number of different models proposed for the function of CS! ) in transcription- 
coupled repair. As discussed in chapter 1, human cells lacking functional CS! ) are unable 
to repair lesions in the transcribed strand of active genes. Therefore the protein is clearly 
required for functional TCR and as such is likely to have some involvement in 
transcription itself. 
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CSB has been linked with the movement or removal of a blocked 1tNA polymcrase 
molecule and the subsequent recruitment of the repair proteins (1lanawalt, 
1994). On 
encountering a lesion, RNAPII stalls (Hanawalt, 1994) and therefore may 
be required to 
retract or dissociate to allow repair enzymes access to the lesion (Donahue ct at., 
1994; 
Selby and Sancar, 1990). Transcription pause sites occur frequently and in E. coll, these 
result in backtracking of the polymerase molecule. This is accompanied by a shortening of 
the transcript, followed by resumption of RNA synthesis, in an attempt to bypass the pause 
site (Kassavetis and Geiduschek, 1993). It is possible that backtracking occurs 
in an 
attempt to bypass the stalling, with dissociation occurring only when this fails. Therefore 
it has been suggested that CSB could be involved in the backtracking or dissociation of 
RNAPII (Hanawalt, 1994; Troelstra et al., 1992; van Gool et al., 1997). however, it has 
been shown in vitro that neither recombinant CSB alone, nor with CSA, is able to prevent a 
stalled RNAPII molecule from resuming transcription, hence leading to the conclusion that 
these proteins cannot dissociate stalled RNAPII (Selby and Sancar, 1997). This may not 
disprove a lack of involvement of CSB in this process, since dissociation may be an 
indirect effect of the protein requiring other factors not present in this assay. Also, this 
experiment does not test for the ability of the CS proteins to induce backtracking of the 
polymerase, which may act as a signal for dissociation or ubiquitination (see below). 
The model initially accepted by most groups as to the role of CSB was proposed by 
comparisons with the transcription-coupled repair pathway and MFD in E. coll. The E, coll 
MFD protein is also known as the transcription-repair coupling factor, and as such 
facilitates the preferential repair of the transcribed strand of active genes. TRCF acts by 
removing a RNAP molecule stalled at a lesion and attracting the NCR proteins to the 
damage site (see chapter 1 for more detail). Whether CSB alone or along with CSA acts as 
a TRCF in mammalian cells is the subject of debate, although little data exists. Work with 
the S. cerevisiae CSB homologue Rad26 has suggested a function more like an uncoupling 
101 
factor, by allowing the basal transcription factor TFIII I to return to transcription mode after 
repair (van Gool et al., 1994). This has also been suggested for human 
CSB (van 
Oosterwijk et al., 1996). CS cells arc hypersensitive to the DNA damaging agent NA-AAF 
and are unable to recover RNA synthesis after exposure to this agent. The lesions caused 
by NA-AAF are repaired as efficiently in CS cells as in wild-type cells, and without strand 
bias. Therefore the recovery of RNA synthesis and repair of these lesions arc clearly not 
linked, suggesting that TFIIH is trapped in repair mode and that the CS gene products arc 
required for converting it back to transcription mode (van Oostcrwijk et al., 1996). 
CSB is a member of the SWI/SNF superfamily of ATPases and helicases, many of which 
are involved in chromatin remodelling (see chapter 1). Like many of the other family 
members CSB resides in a high molecular weight complex, in this case of over 700kDa 
(van Gool et al., 1997) and possesses a DNA-dependent ATP'ase activity that is 
preferentially stimulated by dsDNA, either naked or nuclcosomal (Cittcrio ct al., 1998). It 
has been suggested that members of the SWI/SNF family arc able to move along DNA, 
consequently destabilising bound proteins using energy derived from ATP hydrolysis 
(Pazin and Kadonaga, 1997). On the basis of such an activity, it was suggested that CSB 
may facilitate resumption of transcription after repair or pausing, through dissociation or 
destabilisation of associations between NER factors or nuclcosomcs and DNA (Cittcrio et 
al., 1998). This theory is not readily compatible with the observation that CS cells appear 
to possess a looser chromatin structure, in which chromatin-associated proteins arc not as 
tightly bound as in normal cells. The experiments that instigated this theory measured the 
percentage of proteins released from the DNA after treatment with detergent and the 
resulting rates of transcription of the extracts. (Balajcc et al., 1997). There was however no 
analysis of the additional proteins released in CS cells compared to normal cells, hence it is 
not clear whether these proteins are chromatin or transcription related. Also, the end-point 
of these experiments measured transcription rate and as described below there arc a number 
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of potential problems associated with such a measurement in CS cells. Therefore, it is not 
certain that the predicted "loose" chromatin structure is significant to the phenotype of CS 
cells. 
Furthermore, CSB has been shown to interact in vitro with RNAPII (Tantin ct al., 1997; 
van Gool et at., 1997) and the ATPase activity associated with CSB is important for this 
interaction (Tantin et al., 1997). Selby and Sancar have reported that CSB enhances 
RNAPII elongation in a mechanism similar to the elongation factors TFlIF and ELL (Selby 
and Sancar, 1997). On the basis of these data they have suggested a model for the role of 
CSB. They suggest that through stimulation of transcript elongation, CSI3 is able to speed 
up the rate at which RNAP moves and therefore it may encounter any lesions present 
sooner than in the absence of CSB. This will subsequently lead to an increased rate of 
repair. Furthermore, CSB may also be able to position and stabilisc RNAPII at a dimcr 
and hence counteract the TFIIS-induced transcript degradation, (although no effect on TCR 
has been observed in yeast TFIIS mutants, (Verhage et al., 1997)). 
This might go some way to explaining the faster rate of repair in the transcribed strand, but 
also suggests that CSB is involved in transcript elongation. As such, a slower rate of all 
RNAPII transcription might be expected in CS-B cells. Reduced rates of transcription 
have indeed been observed in CS cells (Balajee et al., 1997; Dianov ct al., 1997), but this 
does not take into account other characteristics of CS cells that may indirectly affect the 
rate of transcription. CS cells have a shorter life span (Thompson and Holliday, 1983) and 
in many cases a slower growth rate (Arlctt, Harcourt and Lehmann, unpublished 
observations). Therefore to obtain a true comparison of transcription rates, the number of 
cell divisions occurring over the course of the experiment must be taken into account. 
Furthermore, it has been suggested that TCR could allow gro%vlh to resume rapidly after 
genotoxic treatment in yeast (van Gool et al., 1994) which may result in an increase in the 
efficiency of RNAPII displacement and subsequently repair. Therefore CSB deficient cells 
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might have a slower recycling of RNAPII, which could result in a reduction in 
transcription rate. 
7.4.1 A model for the role of CSl3 
It has been shown that approximately 10-15% of RNAPII binds tightly to CSB (Citterio ct 
al., 1998) and this may be the proportion that is either stalled at a lesion or at a pause site. 
CSB may therefore preferentially bind to a stalled RNA polymcrasc molecule, thereby 
pinpointing the site of a lesion. Additionally, the binding of CSB to RNAPII may be a 
signal for ubiquitination of the large subunit of the C-terminal domain (Brcgman et al., 
1996), since CS cells are deficient in the damage induced ubiquitination of the large 
subunit of RNAPII. This will result in the degradation of the polymcrase, and the 
subsequent removal of the stalled RNAP molecule, as in E. colt. 
As discussed above, CSB may be able to translocate along the DNA using the energy 
derived from its ATPase activity and translocation may enable the protein to locate the site 
of a lesion or stalled polymerase (Tantin et al., 1997). This translocation activity and a 
possible ability to dissociate bound proteins could allow CSB to act as an uncoupling 
factor, as suggested for Rad26. CSB could move along the newly repaired DNA and 
dissociate the NER factors, allowing the resumption of transcription freeing TFI111 for 
participation in initiation. 
E. coli RNAP, on encountering a pause site, is able to backtrack reversibly in an attempt to 
bypass it (Nudler et al., 1997). This leads to the possibility that mammalian RNAPII could 
backtrack from a lesion site, possibly helped by the ATPasc activity of CSB, allowing the 
repair enzymes access to the site. However, the movement of RNAPII may not be 
required, since a stalled RNAPII molecule does not inhibit repair (Selby and Sancar, 1997). 
The assay, however was carried out using partially purified repair factors on an artificial 
substrate, and is not therefore able to detect a small retraction of RNAPII. 
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7.5 Concluding remarks 
There are a considerable number of theories (discussed above) as to the function of C5Il in 
both repair and transcription. This study has attempted to address some of these questions 
through a functional analysis of the gene. A number of regions, particularly the 
helicase/ATPase, glycine and acidic domains have been shown to be necessary for 
function. Further questions have also been raised, such as how the disruption of these 
regions results in loss of functional protein and whether any arc specifically required for 
either repair of UV damage or enzymatic activity. It is hoped that continuation of this 
work will address these and other points. 
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APPENDIX II 
Alignment of the sequences of the human and mouse CSB proteins and the yeast homolog 
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Black boxes indicate residues identical to the human CSB sequence. The mouse sequence is incomplete and 
X indicates sequence that is unavailable. 
ERCC6 (CSB) sequence (Troelstra et al. 1992). Mouse CSB (van der Horst, Mallcry unpublished data, EST 
accession no. AA675285). Rad26 (van Gool et al. 1994). 
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APPENDIX III 
The full nucleotide sequence and amino acid translation of CSB. 
TGGGTTCCAAGGCGGCTGGCGGCGGTAGCGTCTCTGTTTCCTTGTGGGCGCTCGCGCGGC 
-' 60 
CCTGGGTAGTCTGTAGAGAATGCCAAATGAGGGAATCCCCCACTCAAGTCAAACTCAGGA 
MPNEGIPHSSQTOE 
GCAAGACTGTTTACAGAGTCAACCTGTCAGTAATAATGAAGAAATGGCAATCAAGCAAGA 
120 
,ý'''' 180 
QDCLOSOPVSNNEEMAIKOE 
AAGTGGTGGTGATGGGGAGGTGGAGGAGTACCTGTCCTTTCGTTCTGTGGGTGACGGGCT 
240 
SGGDGEVEEYLSFRSVGDGL 
GTCCACCTCTGCTGTGGGGTGCGCATCAGCAGCTCCGAGGAGAGGGCCAGCCCTGCTGCA 
300 
STSAVGCASAAPRRGPALLH 
CATCGACCGACATCAGATCCAGGCAGTAGAGCCTAGCGCCCAGGCCCTTGAGCTGCAGGG 
a -------- a ---- - 
a-- 
-- ----- 
-1 360 
IDRHýIýAVEPSAOALELýG 
TTTGGGTGTGGACGTCTATGACCAGGACGTGCTGGAACAGGGAGTGCTTCAGCAGGTGGA 
t -- --I - -I -----1,420 
LGVDVYD0DVLE0GVL00V0 
CAATGCCATCCATGAGGCCAGCCGTGCCTCCCAGCTCGTTGACGTGGAGAAGGAGTATCG 
.I- I--- -a 480 
NAIHEASRAS0LVOVEKEYR 
GTCGGTCCTGGATGACCTCACGTCATGTACGACATCCCTAAGGCAAATCAATAAAATTAT 
--- - --- -- --a 540 
SVLDDLTSCTTSLR01NKII 
TGAACAGCTTAGCCCTCAAGCTGCCACCAGCAGAGACATCAACAGGAAACTAGATTCTGT 
EQLSPOAATSRO1NRKLDSV 
600 
AAAACGACAGAAGTATAATAAGGAACAACAGCTAAAAAAGATCACTGCAAAACAAAAGCA 
,, I -------- I-- -. . --- . 660 
KR0KYNKE00LKKITAK0KH 
TCTCCAGGCCATCCTTGGAGGAGCAGAGGTGAAAATTGAACTAGATCACGCCAGTCTGGA 
720 
LOAILGGAE VK IELDHASLE 
GGAGGATGCAGAGCCGGGGCCATCCAGTCTTGGCAGCATGCTCATGCCTGTCCAGGAGAC 
EDAEPGPSSLGSML MPVOET 
780 
TGCCTGGGAAGAGCTCATCCGCACTGGCCAGATGACACCTTTTGGTACCCAGATCCCTCA 
1-. ---I- -a -- 1 840 
AWEELIRTG0MTPFGT01P0 
GAAACAGGAGAAAAAGCCCAGAAAAATCATGCTTAATGAAGCATCAGGCTTCGAAAAGTA 
- --- - -- - -- --- -- 900 
K0EKKPRKIMLNEASGFEKY 
TTTGGCAGATCAAGCAAAACTGTCTTTTGAAAGGAAGAAGCAAGGTTGTAATAAAAGAGC 
, 960 
LAD0AKLSFERKK0GCNKRA 
AGCTAGAAAAGCTCCAGCCCCAGTCACGCCTCCAGCCCCAGTGCAAAATAAAAACAAACC 
I-1 
ýý 1020 
ARKAPAPVTPPAPVONKNKP 
AAACAAGAAAGCCAGAGTTCTGTCCAAAAAAGAGGAGCGTTTGAAAAAGCACATCAAGAA 
-- a --I - -1 - -- ---- 
' 
1080 
NKKARVLSKKEERLKKHIKK 
ACTCCAGAAGAGGGCTTTGCAGTTCCAGGGGAAAGTGGGATTGCCAAAGGCAAGGAGACC 
ýI -- ý -- -ý '- 1 140 
LOKRALQFQGKVGLPKARRP 
TTGGGAGTCAGACATGAGGCCAGAGGCAGAGGGAGACTCTGAGGGTGAAGAGTCTGAGTA 
WESDMRPEAEGDSEGEESEY 
TTTCCCCACAGAGGAGGAGGAAGAGGAGGAAGATGACGAGGTGGAGGGGGCAGAGGCGGA 
-- --- ---- --- 
FPTEEEEEEEDDEVEGAEAO 
CCTGTCTGGAGATGGTACTGACTATGAGCTGAAGCCTCTGCCCAAGGGCGGGAAACGGCA 
- -- -------LSGDGTDYELKPLPKGGKR0 
1200 
1260 
1320 
GAAGAAAGTGCCAGTGCAGGAGATTGATGATGACTTTTTCCCAAGTTCTGGGGAAGAAGC 
1380 
KKVPV0E1DDDFFPSSGEEA 
TGAAGCTGCTTCTGTAGGAGAAGGAGGAGGAGGAGGTCGGAAAGTGGGAAGATACCGAGA 
-- -- -I--- - 1440 
EAASVGEGGGGGRKVGRYRO 
TGATGGAGATGAAGATTATTATAAGCAGCGGTTAAGGAGATGGAATAAACTGAGACTGCA 
-----I------ -- aDGDEDYYK0RLRRWNKLRL0 
GGACAAAGAGAAACGTCTGAAGCTGGAGGACGATTCTGAGGAAAGTGATGCTGAATTTGA 
1500 
1560 
OK EKRLKLEDDSEESDAEF0 
CGAAGGTTTTAAAGTGCCAGGTTTTCTGTTCAAAAAGCTTTTTAAGTACCAGCAGACAGG 
E GE KVPGFLFKKLF KY OOTG 
I 
TGTTAGGTGGCT. GTGGGAATTGCACTGCCAGCAGGCAGGAGGAATTCTGGGAGATGAAAT 
- -t -a- - 
-1 
---- -i-I -- ---1 1680 
VRWLWELHC00AGGILGDEM 
GGGATTGGGCAAGACCATCCAGATAATTGCCTTCTTGGCAGGTCTGAGCTACAGCAAGAT 
- -- I 1740 
GLGKTI0IIAFLAGLSYSKI 
CAGGACTCGTGGTTCAAATTACAGGTTTGAGGGGTTGGGTCCAACTGTAATTGTCTGTCC 
-. --I 
RTRGSNYRFEGLGPTVIVCP 
AACAACAGTGATGCATCAGTGGGTGAAGGAATTTCACACGTGGTGGCCTCCGTTCAGAGT 
-- - ------ --- 
TTVMHQWVKEFHTWWPPFRV 
GGCAATTCTACATGAAACCGGTTCCTATACCCACAAAAAGGAGAAACTAATTCGAGATGT 
1 t 
AILHETGSYTHKKEKLIRDV 
TGCTCATTGTCATGGAATTTTGATCACATCTTACTCCTACATTCGATTGATGCAGGATGA 
AHCHG IL ITSYSYIRLM000 
CATTAGCAGGTATGACTGGCACTATGTGATCTTGGACGAAGGACACAAAATTCGAAATCC 
ISRYDWHYVILDEGHK1RNP 
AAATGCTGCTGTCACCCTTGCTTGCAAACAGTTTCGCACCCCTCATCGGATCATTCTGTC 
NAAV IL ACKOFRTPHRII LS 
TGGCTCACCGATGCAAAATAACCTCCGAGAGCTGTGGTCGCTCTTTGACTTCATCTTCCC 
r A 
GSPM ON 
ýý--ý--ý-- 
NLRELWSLFDF1 
1620 
1800 
1860 
1920 
1980 
2040 
2100 
-' 2160 
FP 
GGGAAAGTTAGGCACGTTGCCTGTGTTTATGGAGCAGTTCTCCGTCCCCATCACCATGGG 
,a, I-. -- a 2220 
GKLGTLPVFME0FSVP1TMG 
GGGATATTCAAATGCTTCCCCAGTACAGGTCAAAACTGCTTACAAGTGTGCATGTGTCTT 
GYSNASPV VKTAY 0 KCACVL 
ACGAGATACCATAAATCCATACCTACTGCGGAGAATGAAGTCAGATGTCAAGATGAGCCT 
2280 
2340 
RD TINPYLLRRMKSOVKMSL 
TTCTTTGCCAGATAAAAATGAACAGGTCTTATTTTGCCGTCTTACAGATGAGCAGCATAA 
-- ' -- - --' ý ýi -- 2400 
SLPDKNEOVLFCRLTDE ON K 
AGTCTACCAAAATTTCGTTGATTCCAAAGAAGTTTACAGGATTCTCAATGGAGAGATGCA 
__ý ý-`__. ý __. ýý_i L. 2460 
VYONEVOSKEVYR IL NGE MO 
GATTTTCTCCGGACTTATAGCCCTAAGAAAAATTTGCAACCACCCTGATCTCTTTTCTGG 
ý_ , '- 2520 
IFSGLIALRKICNHPOLFSG 
AGGTCCCAAGAATCTCAAAGGTCTTCCTGATGATGAACTAGAAGAAGATCAGTTTGGGTA 
.--. I- ---2 -' 2580 
GPKNLKGLPDDELEED0FGY 
CTGGAAACGTTCTGGGAAAATGATTGTTGTTGAGTCTTTGTTGAAAATATGGCACAAGCA - ' 2640 
WKRSGKMIVVESLLKIWHK0 
GGGTCAGCGAGTATTGCTGTTTTCTCAGTCAAGGCAGATGCTGGACATACTTGAAGTATT 
`I`--- - I. -- -- .. '- 2700 
G OR VLLFS OS R OM LDI LE VF 
CCTTAGAGCCCAAAAGTATACCTATCTCAAGATGGATGGTACCACTACAATAGCTTCAAG 
--2 -- ----I - -- I -- ----. 2760 
LRA0KYTYLKMDGTTTIASR 
ACAGCCACTGATTACGAGATACAATGAGGACACATCCATATTTGTGTTTCTTCTGACCAC 
PLITRYNEDTSIFVFLLTT 0 
GCGGGTGGGCGGCTTAGGTGTCAACCTGACGGGGGCAAACAGAGTTGTCATCTATGACCC 
2820 
L- 2880 
RVGGL CV NL TGANRVV IV OP 
AGACTGGAACCCAAGCACGGACACGCAGGCCCGGGAGCGAGCATGGAGAATAGGCCAGAA 
Iý---ýý---ý 
.. J- 2940 
OWNPST 01 OARERAWR IC OK 
GAAGCAAGTGACTGTGTACAGGCTCCTGACTGCGGGCACCATTGAAGAAAAGATCTACCA 
---- I- ----11-------K0VTVYRLLTAGTIEEKIYH 
CCGACAAATCTTCAAGCAGTTTTTGACAAATAGAGTGCTAAAAGACCCAAAACAAAGGCG 
-------I------ 
1- 
--.. 
R01FK0FLTNRVLKDPK0RR 
3000 
3060 
GTTTTTCAAATCCAATGATCTCTATGAGCTATTTACTCTGACTAGTCCTGATGCATCCCA 
-- -- - ---- " 3120 
FFKSNDLYELFTLTSPDAS0 
GAGCACTGAAACAAGTGCAATTTTTGCAGGAACTGGATCAGATGTTCAGACACCCAAATG 
-- -- -- -- 
STETSAIFAGTGSDV0TPKC 
CCATCTAAAAAGAAGGATTCAACCAGCCTTTGGAGCAGACCATGATGTTCCAAAACGCAA 
A 
3180 
A 3240 
HLK RR IQPAFGADHDVPKRK 
GAAGTTCCCTGCTTCTAACATATCTGTAAATGATGCCACATCATCTGAAGAGAAATCTGA 
ý--''----'--' ----- -ý--- a- 3300 
KFPASNISVNDATSSEEK SE 
GGCTAAAGGAGCTGAAGTAAATGCAGTAACTTCTAATCGAAGTGATCCTTTGAAAGATGA 
I I I--I--I 
AKGAEVNAVTSNRSDPLKDD 
CCCTCACATGAGTAGTAATGTAACTAGCAATGATAGGCTTGGAGAAGAGACAAATGCAGT 
. 
PHMSSNVTSNDRLGEETNAV 
ATCTGGACCAGAAGAGTTGTCAGTGATTAGTGGAAATGGGGAATGTTCAAATTCTTCAGG 
.. ". -. _ ---ý 1--- 
SGPEELSVISGNGECSNSSG 
AACAGGCAAAACTTCTATGCCATCTGGTGATGAAAGCATTGATGAAAAGTTAGGTCTTTC 
TGKTSMPSGDESIDEKLGLS 
TTACAAAAGAGAAAGACCCAGCCAGGCTCAAACAGAAGCTTTTTGGGAGAATAAACAAAT 
----------------------YKRERPS0A0TEAFWENKOM 
GGAAAATAATTTTTATAAGCACAAGTCAAAAACAAAACATCATAGTGTGGCAGAAGAAGA 
-- ----- - ---- -- 
ENNFYKHKSKTKH 'H SVAEEE 
GACCCTGGAGAAACATCTGAGACCAAAGCAAAAGCCTAAGAACTCTAAGCATTGCAGAGA 
3360 
3420 
3480 
3540 
3600 
3660 
3720 
IL EKNLRPKOKPKNSKNCR 0 
CGCCAAGTTTGAAGGAACTCGAATTCCACACCTGGTGAAGAAAAGGCGTTACCAGAACCA 
--- -- 
AKFEGTRIPHLVKKRRYOK0 
AGACAGTGAAAACAAGAGTGAGGCCAAGGAACAGAGCAATGACGATTATGTTTTGGAAAA 
-J. --l ----------- 
DSENKSEAKE0SNDDYVLEK 
GCTTTTCAAAAAATCAGTTGGCGTGCACAGTGTCATGAAGCACGATGCCATCATGGATGG 
- ----- -- -- --- -LFKKSVCVHSVMKHDAIMDG 
3780 
3840 
3900 
." AGCCAGCCCAGATTATGTACTGGTGGAGGCAGAAGCCAACCGAGTGGCCCAGGATGCCCT 
I11 
J- 3960 
ASPDYVLVEAEANRVAODAL 
GAAAGCACTGAGGCTCTCTCGTCAGCGGTGTCTGGGAGCAGTGTCTGGTGTTCCCACCTG 
I- 4020 
KALRLSR0RCLGAVSGVPTW 
GACTGGCCACAGGGGGATTTCTGGTGCACCAGCAGGAAAAAAGAGTAGATTTGGTAAGAA 
-----I----I----I"iý 
L 4080 
TGHRGISGAPAGKKSRFGKK 
AAGGAATTCTAACTTCTCTGTGCAGCATCCTTCATCAACATCTCCAACAGAGAAGTGCCA 
- 
--- 
-, 
' 
4140 
RNSNFSV0HPSSTSPTEKC0 
GGATGGCATCATGAAAAAGGAGGGAAAAGATAATGTCCCTGAGCATTTTAGTGGAAGAGC 
... .... ....... -. -JL- .-I L 4200 
DGIMKKEGKDNVPEH F' SGRA 
AGAAGATGCAGACTCTTCATCCGGGCCCCTCGCTTCCTCCTCACTCTTGGCTAAAATGAG 
4260 
EDADSSSGPLASSSLLAKMR 
AGCTAGAAACCACCTGATTCTGCCAGAGCGTTTAGAAAGTGAAAGCGGGCACCTGCAGGA 
4320 
ARNHLILPfRLESESGHLQE 
AGCTTCTGCCCTGCTGCCCACCACAGAACACGATGACCTTCTGGTGGAGATGAGAAACTT 
ASALLPTTEHDDLLVEMRNF 
CATCGCTTTCCAGGCCCACACTGATGGCCAGGCCAGCACCAGGGAGATACTGCAGGAGTT 
,,, 
IAF0AHTDG0ASTREIL0EF 
TGAATCCAAGTTATCTGCATCACAGTCTTGTGTCTTCCGAGAACTATTGAGAAATCTGTG 
ESKLSASQSCVFRELLRNLC 
CACTTTCCATAGAACTTCTGGTGGTGAAGGAATTTGGAAACTCAAGCCAGAATACTGCTA 
- -- -- ,,, 
TFHRTSGGEGIWKLKPEYC. 
AACAACATTGCTTCCTAAACTTTCAAGTCCCTTTTTCTAACGGGCATTTCTGATTATTAA 
4380 
4440 
4500 
4560 
4620 
TTTATTATTAATAATCATGTTTGTCAATGGAAGTTGGCTGCACTTGATGTTTGTTTGCAT 
ý''' 4680 
GATGTCTACCTCAGAATTAAAACTTTAAGGAAGG 
ý- --ý----ý----ý- ý---- 4714 
The location and nature of the putative functional domains in CS13 (all numbers are 
inclusive). 
Functional Domain Nucleotide position Amino acid position 
Acidic domain 1169-1261 363-394 
Glycine stretch 1397-1417 439-446 
Nuclear localisation signals 1475-1522 
3191-3244 
465-481 
1037-1055 
Casein kinase II phosphorylation site 1526-1549 
3281-3301 
482-490 
1067-1074 
Nucleotide binding site 3479-3493 1133-1138 
Helicase domain 1 1658-1711 526-544 
Helicase domain la 1784-1822 568-581 
Helicase domain II 1994-2026 638-649 
Helicase domain 111 2087-2143 669-688 
Helicase domain IV 2651-2686 857-869 
Helicase domain V 2789-2869 903-930 
Helicase domain VI 2888-2929 936-950 
The location and size of the twenty introns within the CSB genomic DNA. 
Intron Location Size (kilobases) 
1 65/66 6 
2 501/502 1.8 
3 622/623 2.1 
4 M532 4 
5 1476/1477 19 
6 1605/1606 5 
7 1764/1765 7.5 
8 1900/1901 9 
9 2071/2072 0.5 
10 2248/2249 3.5 
11 2365/2366 2 
12 2461/2462 2 
13 2677/2678 0.5 
14 2788/2789 0.4 
15 2908/2909 0.4 
16 3003/3004 1.1 
17 3149/3150 0.085 
18 3857/3858 8.5 
19 4062/4063 0.8 
20 4141/4142 1.2 
0 
Am. J. Flum. Genet. 6177-81,1998 
Molecular Analysis of Mutations in the CSß (ERCC6) Gene in Patients 
with Cockayne Syndrome 
Donna L. LMallery, ' Bianca Tanganelli, 2 Stefano Colella, 2 Herdis Steingrimsdottir, " 
Alain J. van Gool, 3, t Christine Troelstra, 3 Miria Stefanini, 2 and Alan R. Lehmann' 
'NMRC Cell Mutation Unit, Sussex University, Falmer, Brighton; 'Istituto di Genetica Biochimica ed Evoluzionistica CNR, Pavia, Italy; and 
'Department of Cell Biology and Genetics, Erasmus Lniversity, Rotterdam 
Summary 
Cockayne syndrome is a multisystem sun-sensitive ge- 
netic disorder associated with a specific defect in the 
ability to perform transcription-coupled repair of active 
genes after UV irradiation. Two complementation 
groups (CS-A and CS-B) have been identified, and 80% 
of patients have been assigned to the CS-B complemen- 
tation group. We have analyzed the sites of the mutations 
in the CSB gene in 16 patients, to determine the spectrum 
of mutations in this gene and to see whether the nature 
of the mutation correlates with the type and severity of 
the clinical symptoms. In nine of the patients, the mu- 
tations resulted in truncated products in both alleles, 
whereas, in the other seven, at least one allele contained 
a single amino acid change. The latter mutations were 
confined to the C-terminal two-thirds of the protein and 
were shown to be inactivating by their failure to restore UV irradiation resistance to hamster UV61 cells, which 
are known to be defective in the CSB gene. Neither the 
site nor the nature of the mutation correlated with the 
severity of the clinical features. Severe truncations were found in different patients with either classical or early- 
onset forms of the disease. 
Introduction 
The process of nucleotide excision repair (NER) protects 
cells from damage produced in cellular DNA by a wide 
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variety of carcinogens, including UV light. Three genetic 
disorders-xeroderma pigmentosum (XP), Cockayne 
syndrome (CS), and trichothiodystrophy (TTD)-are as- 
sociated with defects in NER (Lehmann 1995). Most 
patients with XP are deficient in NER and contain mu- 
tations in one of seven genes (XPA-XPG) whose prod- 
ucts are directly involved in NER. The recent discovery 
that the products of the XPB and XPD genes are com- 
ponents of the basal transcription factor TFIIH-which 
has a dual role, in transcription and as a component of 
NER-revealed an unexpected link between DNA repair 
and transcription (reviewed in Lehmann 1995; Hoeij- 
makers et al. 1996). 
The clinical features of XP-namely, multiple skin ab- 
normalities, including a greatly elevated skin-cancer in- 
cidence caused by exposure to sunlight-are consistent 
with predictions based on the hypersensitivity and hy- 
permutability of cultured XP cells to UV light. In con- 
trast, CS patients do not have an increased frequency of 
skin cancers. CS is a multisystem disorder characterized 
by severe physical and mental retardation, microcephaly, 
progressive neurological and retinal degeneration, skel- 
etal abnormalities, gait defects, and sun sensitivity but 
no increased frequency of cancer (Nance and Berry 
1992). Like XP, CS cells are hypersensitive to the lethal 
effects of UV light, but NER of the bulk of genomic 
DNA is unaffected. CS cells are, however, defective in a 
subpathway of NER, known as "transcription-coupled 
repair" (TCR), whereby damage in the transcribed 
strand of active genes is rapidly and preferentially re- 
paired. In CS cells, damage in active genes is repaired 
at the same relatively slow rate as the bulk DNA (van 
Hoffen et al. 1993). This correlates with earlier findings 
that RNA synthesis recovers rapidly after UV irradiation 
of normal cells, whereas this recovery does not occur in 
CS cells (Mayne and Lehmann 1982). Cell-fusion studies 
have assigned some 30 CS patients to two complemen- 
tation groups, CS-A and CS-B (Tanaka et al. 1981; Leh- 
mann 1982; S(efanini et al. 1996); 80% of them are in 
the CS-B group. In addition, there are a few rare cases 
of individuals with the clinical and cellular features of 
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Table 1 
Primers Used for Reverse Transcription and PCR 
Primer Sequence 
Am. /. Hum. Genort. 62: 71-8f, 199g 
Position' Annealing Temperature 
IF S'-TCTCTGTTTCCTTGTGGGCGCTCG"3' 31-54 
1R 5'-CTCTCGCCTCATGTCTCACTCCCA-3' 1142-1165 6S1C 
2F S'-CATGCTTAATGAAGCATCAGGCTTC-3' 868-892 
2R S'-TTCAACCACCAGTCCTGATCTTGC-3' 1734-1757 63'C 
3F S'-GCTCTTAGGT000TGTGCGAATT 3' 1619-1641 
3R S'-GGTATCTCGTAAGACACATCCACAC-3' 2266-2290 6TC 
4F 5'-CCTCATCGCATCATTCTCTCTGGC-3' 2081-2104 
4R S'-CATCATGGTCTGCTCCAAAGGCTCGTT 3' 3201-3227 67'C 
SF S'-ATTACCACATACAATGAGGACACATCC-3' 2771-2805 
SR 5'-TAGCC. kAGAGTGAGGAGCAAGCGA-3' 4237-4253 67C 
6F S'-GTGAAAACAACAGTGACGCCAAGG-3' 3786-3809 
6R S'-CCTTCCTTAAAGTTTTAATTCTCAGG-3' 4688-4714 60'C 
' The ORF starts at nucleotide 79 and ends at nucleotide 4518 (Troelstra et aL 1992). 
both CS and XP. The defects in these individuals have 
been assigned to the XP-B, XP-D, and XP-G groups 
(Hoeijmakers 1993). 
The genes defective in the CS-A (Henning er al. 1995) 
and CS-B (Troelstra et at. 1992) complementation 
groups have both been cloned recently. A gene desig- 
nated "ERCC6" was cloned by its ability to correct the 
UV sensitivity of a mutant hamster cell fine, UV61 
(Troelstra et al. 1990). When the ERCC6 cDNA was 
introduced into different human cell lines, it was able 
to correct the UV sensitivity and post-W irradiation 
RNA-synthesis defect in a CS-B cell line, CS1AN (Troel- 
stra et al. 1992), and this cell strain was found to contain 
mutations in the ERCC6 gene. ERCC6 was therefore 
subsequently renamed "CSB" (Lehmann et at. 1994). CSB encodes a 1,493-amino-acid protein, which con- 
tains seven domains characteristic of DNA helicases (Troelstra et al. 1992). However; the CSB protein is a 
member of the SWI2/SNF2 family of ATPases, and, like 
other members of this family, CSB does not appear to 
be a helicase (Selby and Sancar 1997). The function of 
the SWUSNF protein family is thought to involve re- 
modeling of protein-DNA interactions-such as chro- 
matin structure-in different circumstances (Peterson 
and Tamkun 1995; Cairns et al. 1996; Pazin and Ka- 
donaga 1997). The CSA gene has been cloned directly 
by its ability to correct the UV sensitivity of a CS-A cell 
line, CS3BE, and encodes a "WD-repeat" protein (Hen- 
ning et at. 1995). In order to gain more insight into 
genotype-phenotype relationships in CS, we have iden- 
tified mutations in the CSB gene in 16 CS patients whom 
we previously had assigned to this complementation 
group. 
Material and Methods 
Cell Culture 
All CS cells were primary fibroblast cultures derived 
from patients with CS. Cultures were grown in Eagle's 
minimal essential medium supplemented with 1S% FCS. 
The UV-sensitive Chinese hamster cell line UV61 was 
grown in Eagle's minimal essential medium with 10% 
FCS. 
cDNA Synthesis and PCR 
RNA was extracted from --10' cells, by use of lysis 
either (a) in NP40, by spinning out the nuclei and phenol 
extraction of the cytoplasmic fraction, followed by eth- 
anol precipitation, or (b) with guanidinium isothiocyan- 
ate, followed by phenol extraction and isopropanol pre- 
cipitation. cDNA synthesis was performed in three parts 
(A-C), by use of primers 2R, 4R, and 611 (see table 1). 
Reactions were performed by use of 1-S pg RNA and 
Moloney murine-leukemia-virus reverse transcriptase in 
a total volume of 20 pl. After incubation for I h, the 
mixture was diluted to 40µI, and 5 pl was used in PCR. 
Each of the cDNA samples was amplified in two parts, 
by the primers shown in table 1, so that the whole open 
reading frame (ORF) was amplified as six fragments. 
PCR mixtures contained S pI appropriate cDNA, 20 
pmol primers, and 0.125 m-M each dNTP, in a total 
volume of S0 pl. PCR conditions were 35 cycles at 94°C 
for 1 min, annealing (at temperatures indicated in table 
1) for 1.5 min, and elongation at 72°C for 3 min. The 
products were reamplified by means of the same 3' pri- 
mer and a nested biotinylated S' primer, under conditions 
identical to those described above. PCR products were 
captured on streptavidin-coated Dynabeads and were 
sequenced by means of the dideoxy termination proce- 
dure with T7 DNA polymerase and "S-dATP, as de- 
scribed elsewhere (Steingrimsdottir et al. 1993). 
In compound-heterozygote patients, in whom the mu- 
tations in the two alleles were different, the sequencing 
gel had both normal and mutant bands at the site of the 
mutation. In many of these cases, we confirmed the mu- 
tation by cloning the PCR products into a "T vector" 
and sequencing several clones. 
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Table 2 
Mutations in CS-B Patients 
Inactivating 
Cell Line Mutation(s)' 
CS2TAN G 1630A 
CSITAN C2282T 
CS8BR C2639T 
25627 C2282T 
CS4BR 
CS1BO 
C1436T 
C629T 
C208: T 
-G 1397 and C2918T 
G3363C 
C2087T 
-A 3613 
Deletion of exon 10 
C2081-T 
C3204T 
CS3TAN T2630A 
CS7TAN A3716G 
CSIIAF T2949G 
CSIMA Deletion of exon 10 
CS2BI 
CS10BR +26nc 3636 
CSIABR -G 2223 
CS10LO +T 1359 
CS2BE -T 3614 
CSiBE 
Amino Acid Change Location 
TrpS 17stop Exon 7 
Arg73Sstop Exon 11 
CIn8S4stop Exon 13 
Arg73Sstop Exon 11 
Arg4S3stop Exon S 
C1n184stop Exon 4 
Arg670Trp Exon 10 
Frameshih 506-+S42stop and Exon 6 and 16 
Arg947stop 
Pro109SArg Exon 18 
Arg670Trp Exon 10 
Frameshih 1179-1200stop Exon 18 
Frameshih 1203-123Sstop Exon 18 
Frameshift 71S-738stop Exon 10 
Frameshift 427-+43Sstop Exon S 
Frameshift 1179-1200stop Exon 18 
Deletion of 665-723 Exon 10 
Arg670Trp Exon 10 
Pro10421. eu Exon 18 
TrpBSlArg Exon 13 
Atg1213C1y Exon 18 
Va19S7GIy Exon 16 
Dc1665-723 Exon 10 
' Missense mutations shown to be inactivating by failure to restore UV resistance to UV61 cells. 
Functional Complementation 
Mutations were introduced into the CSB gene by 
means of two different procedures. PCR products con- 
taining the mutation of interest were cloned into aT 
vector and were sequenced to check for the absence of 
any PCR-induced spurious mutations. An appropriate 
restriction fragment containing the mutation was excised 
and used to replace the corresponding wild-type frag- 
ment in the intact CSB gene in BlueScript. Alternatively, 
the mutation was introduced directly into the gene by 
site-directed mutagenesis using the procedure of Kunkel 
et at. (1987). The entire ORF was checked for the ab- 
sence of spurious mutations. The CSB gene was then 
transferred as a BamHI fragment into the mammalian 
expression vectors pCDNA3 or pClneo (Invitrogen). For 
transfection experiments, Sx 10' UV61 cells were 
plated on 9-cm dishes. Two days later, 40 pl polybrene 
was added to the plates, followed by S pg DNA. After 
6 h, the cells were treated with 20% dimethyl sulfoxide 
in serum-free medium for 4 min. Two days later, the cells 
were trypsinized, split into three aliquots. and replated 
in the presence of 1 mg G418/mI. The cells on one dish 
were grown and frozen as a mass population, and the 
second dish was subjected to W irradiation selection 
with three doses of 4 Jm"' with 2-day intervals between; 
individual colonies were isolated from the third 
plate and were grown for UVirradiation-survival 
experiments. 
Results 
79 
The 16 patients whom we have analyzed all failed to 
restore RNA synthesis to normal levels after UV irra- 
diation, a phenotype that we regard as diagnostic for 
CS (Lehmann et al. 1993). Cell-fusion studies have as- 
signed these patients to the CS-B group Lehmann 1982; 
Stefanini et al. 1996). For molecular analysis, total cel- 
lular RNA was reverse transcribed by use of three CSB- 
specific primers. Each of the three eDNA samples was 
then amplified in two parts by PCR, so that the whole 
CSB cDNA was amplified in a total of six overlapping 
fragments of -1 kb each, which were then sequenced 
directly. Results of our analyses are summarized in table 
2 and figure 1. 
Nonsense Mutations 
Four cell strains contained nonsense mutations in both 
alleles, which resulted in truncation of >40% of the pro- 
tein. Two Turkish patients, CS2TAN and CSITAN, and 
one British patient of Asian origin, CSSBR, all the off- 
spring of consanguineous marriages. were homozygous 
for G1630A, C2282T, and C2639T, respectively, which 
convert TrpS17, Arg735, and G1nS54. respectively, to 
stop codons. In 1978 we reported on a sun-sensitive 
patient, designated "11961" (Arlen et al. 1978), who 
was subsequently diagnosed as having CS and who was 
assigned to group B (Lehmann 19321. We have deter- 
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Figure 1 Inactivating amino acid changes caused by mutations in the CSB gene. The CSB protein is shown with the seven Jom, arn% 
conserved in DNA helicases (hatched boxes) and with the putative nuclear-localization signals (gray-shaded boxes ".. tnuno acid changes resulting 
from mutations are shown boxed, with the change indicated by white letters on a black background. and the . e: l-line designations are shown 
below them. Subscripts "1" and "2" denote the different alleles. Mutations shown below the depicted procem result in protein truncations, 
whereas those above the depicted protein are all single-amino-acid changes. 
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mined the sites of the mutations in cells from his similarly 
affected brother, coded as "25627. " The patient is a 
compound heterozygote: one allele contains the 
Arg73Sopal mutation found in CS1TAN, and the other 
allele contains the mutation C1436T, resulting in 
Arg453opal. CS4BR, derived from a patient in the 
United Kingdom, is a compound heterozygote with the 
mutation C629T, resulting in Glnl84opal in one allele. CS1BO is a rare example of a black patient with CS. She is a compound heterozygote with C2918T in one 
allele, resulting in Arg947opal; this mutation is, how- 
ever, not relevant for the pathological phenotype, since it is 1,321 bases downstream of a frameshift mutation 
in the same allele (see below). 
Frameshifts and Insertions 
Single-base frameshifts, all resulting in stop codons 
7-35 amino acids downstream, were detected in six pa- 
tients and are shown in table 3. Three of these were 
single-base deletions or insertions in runs of five or six 
Table 3 
Frameshifts and Insertions 
identical bases, presumably the result of replication slip- 
page, which could also account for the loss of an A 
residue sandwiched between a run of S Ts and a single 
T in CS1BE. In CSIBO there was a loss of aG residue 
from the center of a 12 bp inverted repeat. In CSI0BR 
there was an insertion of 26 bases at position 3686, in 
the middle of exon 18. The origin of this insertion is 
not known. At the time of the writing of this report, this 
sequence was not present in any of the publicly available 
sequence databases. 
Missense Mutations 
A missense mutation, C2097T, causing an Arg-Trp 
change at amino acid 670, has been found in one allele 
of three unrelated patients, CS4BR and CS2BI from the 
United Kingdom and CS1BE (GM1629) from the United 
States. Arg670 is in helicase domain III and is part of a 
stretch of 34 amino acids that are 97°6 identical or con- 
served in CSB and the Sacchiromyces cerevisiae ho- 
mologue, Rad26 (van Gool et al. 1994). Two other mis- 
Cell Strain Status Mutation First Mutated Codon 
CSIOLO Homozygous +T 1355-1359 427 
CS I ABR Homozygous -G 2218-2223 715 
CS2BE Heterozygous -T 3610-3614 11 79 
CSIBE Heterozygous -A 3615 11'9 
CSI BO Heterozygous -G 159- 506 
CSIOBR Homozygous +26nt' 3686 1203 
Sue of Truncated Protein 
Sequence (amino acids) 
ACTT"I'iTCC 4 14 
ATGGGGGGAT 737 
A ATT'1TTAT 1,199 
TiTTTATAAGC 1.199 
AAAAAGCTI'ITIT 541 
ACCAA +26 nc' +AGCk-A 1,214 
' Insertion of GG GCT GGC TGC TTA AGG TCC ACC TTA. 
, \1allery cc al.: 
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sense homozygous mutations were present in highly 
conserved regions. Trp851Arg, found in CS3TAN from 
Turkey, is close to helicase domain IV in a run of 37 
amino acids that are 83% identical or conserved between 
CSB and Rad26, end Val957Gly in CS1L'F from Israel 
is in a run of 79 amino acids that are 97% conserved 
between yeast and man. The other missense mutations 
(Prol042Leu, heterozygous in CS2B1; Pro109SArg, het- 
erozygous in CS1BO; and Arg1213Gly, homozygous in 
CS7FAN) were in less-conserved regions of the protein, 
but Pro1042Leu is located in the putative nuclear-lo- 
calization sequence (Troelstra et at. 1992). 
It is of interest that all six of the missense mutations 
are in the C-terminal two-thirds of the protein. This 
could indicate that the N-terminal third of the protein 
is less important for the repair function of the CSB pro- 
tein and that this domain is involved in some other func- 
tion (for other possible roles of the CSB protein, see the 
Discussion section). Preliminary results from site-di- 
rected mutagenesis of the N-terminal part of the gene 
are consistent with this possibility. 
Splice Mutations 
In two patients the CSB mRNA was abnormally 
spliced. Exon 10 was absent from the cDNA of CS1MA, 
suggesting that the mutation in both alleles affected the 
splicing of this exon. This same exon was missing in one 
allele of CS2BE. We have sequenced the regions around 
the splice-donor site of intron 10 and the splice-acceptor 
site of intron 9, in genomic DNA of CSBMA, but this 
did not reveal the cause of the abnormal splicing. The 
loss of exon 10 results in an in-frame deletion of 59 
amino acids encompassing the whole of helicase domain 
III. 
Polymorphisms 
In addition to the inactivating mutations, we have 
detected the following changes in at least two pa- 
tients: G214C (Leu4S), C2830T (G1v917), G127SA 
(Gly399Asp), A3368G (Met1097Val), and A4317G 
(Gln1413Arg). We presume that Gly399Asp and 
Met1097Val are silent. Residue 399 is Glv in the human 
gene but is Asp in the mouse gene, and Mlet1097Va1 is 
a conservative change. We show below that Gln1413Arg 
is not inactivating. In patient CS- /TAN, we found three 
of the above-mentioned polymorphic changes, as well 
as Arg1213G1y, which we show to be inactivating (see 
below), and Lys2SSThr, all mutations being homozy. 
gous. Since Arg1213GIy is sufficient to account for the 
repair-deficient phenotype, we presume that Lys2SSThr 
does not contribute to the phenotype. 
Functional Studies 
Our mutation analyses have identified several different 
types of mutation in the CSB gene. The nonsense, frame- 
shift, and splice mutations have sufficiently severe effects 
on the protein structure for us to be confident that they 
are indeed the inactivating mutations. This contention 
is supported by our recent results (to be presented else- 
where) showing that deletion of only 25 amino acids 
from the C-terminus of the protein completely abolishes 
its repair function. In order to confirm that the missense 
mutations that we identified were causative, we have 
constructed intact CSB cDNAs containing these muta- 
tions in llluescript, either by subcloning fragments used 
in our sequence analysis or by site-directed mutagenesis. 
All cloned PCR products or mutated plasmids were se- 
quenced in their entirety, to ensure that the DNA con- 
tained only the desired mutations. The CSd cDNA was 
then transferred, as a I3amHl fragment, from ßluescript 
into one of the mammalian expression vectors pCDNA3 
or pClneo. Normal and mutant plasmids were trans- 
fected into the UV-sensitive CHO cell line UV61 (from 
the same complementation group as the CS-ß cells), and 
selection for the neoR gene was applied by use of 6418. 
Clones were picked and expanded, and the remaining 
clones in the dishes were trypsinized, respread, and sub- 
jected to UV irradiation selection with three doses, each 
of 4 Jm'=. This gave a crude measure of UV sensitivity 
of the transfectants. Whereas a confluent layer of cells 
resulted from the culture of UV61 cells that were trans- 
fected with the wild-type CSB gene and then UV irra- 
diated, very few cells survived after transfection with 
either empty vector or the CSB gene containing the mu- 
tations R670W, W8S1R, V9S7G, P10421., or R1213G. 
In contrast, when the cDNA contained mutation 
Q1413R, which we presumed to be a silent polymor- 
phism, the cells survived the UV irradiation selection, as 
did the wild-type transfectants. 
The clones that were picked and expanded without 
UV irradiation were examined by PCR, to ensure that 
the transfected human CSB cDNA was intact. For each 
transfection, two clones in which PCR indicated that the 
whole of the cDNA was present were examined quan- 
titatively for the effects that UV irradiation had on cell 
survival. Results are shown in figure 2. These results 
confirmed the findings seen with the batch cultures de- 
scribed above. In early experiments, in which the 
pCDNA3 expression vector was used, clones from cells 
transfected with the wild-type gene were much more 
resistant than were untransfeeted UV61 cells, although 
the survival did not reach that of the wild-type parental 
cell line AA8. In later experiments, with the pClneo vec- 
tor, the wild-type CSB gene restored the survival of 
UV61 cells up to the level of the parental AAS line. 
Irrespective of which vector was used, the survival of 
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Figure 2 UV irradiation survival of UV61 cells transfected with 
the CB gene containing different mutations. Transfectants are from 
CSB constructs made in pCDNA3 (a) or in pCineo (b). "AA$' denotes 
the normal parental hamster cell line from which UV61 was derived, 
and all other cell lines are UV61 cells transfected with GSB constructs 
containing the indicated mutations. 
UV61 cells transfected with DNA containing the mu- 
tations that we had identified as inactivating was indis- 
tinguishable from that of cells transfected with the empty 
vector. In contrast, the survival of transfectants with the 
Q1413R DNA approached that of the normal 
transfectant. 
Discussion 
We have identified the inactivating mutations in the 
CSB gene in 16 affected patients. The results are sum- 
marized in figure 1 and tables 2 and 4. A variety of 
different types and positions of mutations result in the 
CS phenotype. Of the 18 identified inactivating muta- 
tions, four were CG-TA transitions at CpG sites, re- 
suiting from deamination of S-methylcytosine, a pro- 
portion similar to that found in other human genetic 
disorders; and a further five were transitions at other 
sites, two were transversions, six were frameshifts, and 
one was an aberrant splicing. 
Twelve of the 18 mutations resulted in severely trun- 
cated products, because of either stop codons, frame- 
shifts, or splice abnormalities. In nine patients (table 4, 
top), both alleles were affected in this way, and it is 
Amt, /, 1hon. C"tf. 6141_'f, 19-is 
highly unlikely that the CSR protein in these individuals 
would have any functional ability. This was also found 
in the single patient analyzed by Ttoelstra et al. (1992). 
This demonstrates that CSI1 is not an essential gene, as 
also has been found for the yeast RAD26 homologue 
(van Cool et al. 1994) . Further evidence to support this 
comes from the generation of a CSU knockout mouse, 
which showed near-normal development (van der Ilotu 
et al. 1997). Of the six misscnse mutations, three were 
located in regions that were highly conserved not only 
in the mouse CSB protein but also in the homologous 
yeast Rad26 protein. These mutations lie either within 
or very close to the hclicase domains of the protein and 
are likely to abolish any function associated with these 
domains. Of the three other mutated sites, Atg1213 is 
conserved in the human and mouse proteins. Pro 1042, 
which is mutated to leucine in one allele of CS2BI, is 
not present in the mouse protein (C. T. J. van der I forst 
and J. H. J. Hoeijmakers, personal communication), but 
it is located in a putative nuclear-localization signal, and 
we have shown that this alteration, like the other amino 
acid changes indicated in figure 1, fails to restore UV 
irradiation resistance to UV61 cells. 
The CS patients studied come from a wide range of 
racial backgrounds, including Caucasian, Turkish, Indo- 
Pakistani, Israeli Jewish, and Black patients. The clinical 
features of CS are fairly heterogeneous, as can be seen 
in table 4, in our earlier clinical survey (Lehmann et al. 
1993), and in reviews in the literature (Nance and Berry 
1992). We previously had found that, in those patients 
in whom RNA synthesis failed to recover after UV ir- 
radiation (a feature that we use as a diagnostic marker 
for CS), the magnitude of this defect was broadly similag 
irrespective of the clinical features (Lehmann ct Al. 
1993). Similar observations have been trade in Japanese 
patients, by Sugita et al. (1991). Lowry (1982 (also see 
Nance and Berry 19921) has suggested that CS can be 
divided clinically into type I, with classical CS symptoms 
that become manifest within the first few years of life, 
and type II, with more-severe symptoms already mani" 
fest prenatally. Cellular defects in the response to UV 
irradiation appear to be similar for type I patients and 
type 11 patients (Sugita et Al. 1991). We do not have full 
clinical histories of all the patients in our study, but at 
least four of them-CSIMA, CS1ABR. CS8I3R, and 
CS1BO-had the more-severe, type 11 features. Three of 
these are homozygous for mutations resulting in severely 
truncated proteins, whereas CS1BO is a compound het- 
erozygote and has the ProIO9SArg change in one allele. 
However, six other patients also produced truncated 
products from both alleles but had classical, type I fca" 
lures. It thus seems unlikely that the assignment into one 
of the two clinical types can be based on the position 
or type of mutation; the clinical disparity is more likely 
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to result from other differences in genetic background 
or in the intrauterine environment. 
CS-B (and CS-A) cells are sensitive to the lethal effects 
of UV irradiation and of a variety of chemical carcin- 
ogens (Wa(e and Chu 1979). This is associated, in all 
cas'ts, with a failure of RNA synthesis to recover after 
DNA damage (Mayne and Lehmann 1982). Until re- 
cently this had been attributed to a deficiency in the 
ability of CS to perform TCR-that is, the rapid removal 
of damage from the transcribed strand of active genes 
(van Hoffen et al. 1993). These observations, in turn, 
have led to the suggestion that the function of the CS 
gene products is to recruit the NER machinery to actively 
transcribed regions of DNA, a role analogous to that of 
the transcription-repair coupling factor Mfd protein in 
Escherichia coli (Selby and Sancar 1993). Although this 
model has been widely accepted, it has recently been 
questioned by some of its original proponents, who 
found that, after damage to CS cells by the carcinogen 
N-acetoxy-acetylaminofluorene, TCR occurs at normal 
levels, although RNA synthesis fails to recover (van Oos- 
terwijk et al. 1996). Those authors proposed that, after 
UV irradiation, the dual-function transcription/repair factor TFIIH is converted into a form utilized in NER 
and that the function of the CS proteins is subsequently 
to revert TFIIH from repair mode to transcription mode, 
so that transcription can recommence. It has been pro- 
posed that, in CS patients, TFIIH is locked in the repair 
mode and transcription fails to recover (van Oosterwijk 
et al. 1996). In an alternative model, the features of CS have been suggested to result from defects in base ex- 
cision repair of oxidative base damage (Cooper et al. 
1997). 
Except for sun sensitivity, the clinical features of CS 
cannot be obviously attributed to defects in DNA repair. 
This is in contrast to xeroderma pigmentosum, in which 
most of the symptoms are readily explicable in terms of 
a repair deficiency. It has therefore been suggested that 
the CSB protein has a second function, possibly an in- 
volvement with transcription, as has been found to be 
the case with TFIIH (Bootsma and Hoeijmakers 1993; 
Friedberg 1996). Although this is an attractive hypoth- 
esis, CSB is not an essential gene, and therefore the CSB 
protein cannot be an integral part of the transcriptional 
machinery. Evidence in support of a role for the CS pro- 
teins in general transcription comes both from data sug- 
gesting that transcription rates are reduced in CS cells 
(Balajee et al. 1997) and from data showing that 
10%-1S% of RNA polymerase II is strongly associated 
with CSB protein in cell extracts (van Gool et al. 1997a). 
This has led to the suggestion that the role of CSB might 
be to release stalled transcription, by direct action on 
the RNA polymerise II (van Gool et al. 1997b). An 
alternative possibility is that CS genes are involved in 
tissue-specific transcription. A gene that has been des- 
i 
ignated "ATR-X " is another member of the S\VIJSNF 
superfamily. It is an X-linked gene that, when mutated, 
specifically down-regulates expression of several genes, including the a-globin gene on chromosome 16 (Gib- 
bons et al. 1995; Picketts et al. 1996). One can envisage 
that CSB might act in a similar manner on the expression 
of a set of tissue-specific genes involved in aspects of development that are abnormal in CS patients. 
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